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Preface 
 
This dissertation is divided into two different, but interactive aspects, the study of 
inflammatory mechanisms in systemic lupus erythematosus (SLE) and Alzheimer’s 
disease (AD). Thus, it will focus on the characterization of the immune response in 
autoimmune and neurodegenerative disorders. The premise is that understanding 
inflammation in the context of the disease may lead to a better understanding of 
immunopathogenesis and regulation. For the sake of clarity, the information contained 
in this work has been organized as follows:  
 
At the beginning a short summary provides the audience with the main findings of the 
present studies. The first chapter is intended to be an immunological framework 
conceptually useful to understand the key regulatory steps of inflammation and how 
misjudgement during this process can lead to autoimmunity. Chapter II will focus on the 
interaction within the immune system which leads to a loss of self-tolerance to SLE 
autoantigens (autoAg) that explains the onset and development of this prototype of 
systemic autoimmunity. Chapter III provides special information about cells of innate 
immunity and their role in chromatin-mediated pathogenesis in SLE. The accumulation 
of the self-peptide amyloid-beta (Aβ) plays a causal role in the neuropathology of AD. 
As the assembly of misfolded proteins is accompanied by inflammation, the fourth 
chapter gives attention to autoimmunity in the central nervous system (CNS). The 
intention of this general introduction is not to give a complete review of the different 
aspects but rather comprehensive background knowledge based on key publications.  
 
Chapters V to VII contain the main achievements of this dissertation based on already 
published results and submitted manuscripts as indicated. Every section is divided into 
an introduction, material and methods, results, discussion and references. This 
structure will enable the audience to find all relevant information within an accurate 
format for the presentation of scientific results which also guarantees this work to be 
comprehensible for international readers. These chapters represent the state-of-the-art 
when the respective project was prepared for publication and have been supplemented 
with the most relevant recent findings. Importantly in all sections that contain work from 
my colleagues, I have specified the extent of my contribution. Subsequently, the 
research results are recapitulated thoroughly followed by a final conclusion.  
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In addition, aspects of current research as well as future directions are mentioned, 
which should encourage other individuals to proceed with these experiments. I am 
looking forward to hearing from successes of the next generation of students towards 
realizing the full potential of these projects. I hope that the information contained within 
this dissertation will provide you with the knowledge to promote your investigations in a 
productive environment and friendly fashion. Abbreviations are listed at the end.  
 
The projects mentioned here include my research efforts under the guidance of Prof. 
Hans-Georg Rammensee from March 2008 till March 2010 at the Department of 
Immunology, Institute for Cell Biology, University of Tübingen. This work is my own 
intellectual property and has been written autonomously. Wherever further resources 
have been used, this has been indicated. Enjoy reading. 
 
Dennis Lindau 
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Summary 
 
Autoimmune inflammation potentially arises through aberrant reactions of innate or 
adaptive immunity. This results in cellular destruction and the failure to heal the 
inflamed tissue, complications which are seen in SLE and AD. The present study has 
as overarching theme the understanding of inflammatory mechanisms in both 
diseases. One major autoAg in SLE is the nucleosome. (1) We report here that 
nucleosomes from SLE patients’ plasmas induce the secretion of inflammatory 
mediators in neutrophils (PMN, polymorphonuclear leukocytes). Nucleosome-induced 
activation occurred independently of endotoxins, endosomal acidification, unmethylated 
cytosine-phosphate-guanosine (CpG)-motifs and Toll-like receptor (TLR) 9. Thus, the 
signaling pathway used is different from the classical pathway of unmethylated CpG- 
oligonucleotides (ODN). TLR9 might play different roles in nucleosome-induced innate 
immunity and anti-nucleosome autoimmunity. (2) We followed initial results by Viktoria 
Rönnefarth and report TLR9 expression at the cell surface of primary PMN. Cell 
surface TLR9 recognizes CpG-ODN and is functional, leading to PMN activation. Thus, 
we describe a novel pathway for DNA-recognition and PMN activation. The assembly 
of misfolded Aβ in AD is accompanied by microgliosis. (3) Close examination of 
infiltrating and CNS-resident immune cells lead to the identification of dendritic-like 
microglia. Characterization in transgenic (tg) AD mice as well as in human brain 
material, demonstrated that these microglia possess a high activity of phagocytosing 
Aβ ex vivo. However, this mechanism is highly regulated in vivo by the expression of 
several inhibitory signals. We were not able to restore the phagocytosing activity of 
dendritic-like microglia by simply ablating the gene for Programmed Death (PD)-1, 
which was highly and exclusively expressed on dendritic-like microglia. Our data 
solidify the interpretation that microglial activation is more complex than a simple all-or-
nothing process. Depending on the stimulus and biochemical environment, a wide 
range of qualitatively different immune responses may be elicited in vivo. The next 
important step is to develop a thorough understanding of how all these tightly regulated 
effector mechanisms of PMN and microglia can be modulated to produce qualitatively 
desired outcomes in SLE and AD. This knowledge is likely to advance our 
understanding of immune dysregulation and hyperactivation, which not only provides 
novel insight in pathomechanisms but also has implications for our current 
understanding of autoimmune inflammation. 
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Zusammenfassung 
 
Autoimmuninflammation kann durch einen Irrtum der angeborenen oder adaptiven 
Immunantwort entstehen. Daraus resultiert Zellzerstörung und der Verlust entzündetes 
Gewebe zu heilen. Diese Komplikationen sind im systemischen Lupus erythematodes 
(SLE) und in der Alzheimer-Krankheit (AK) anzutreffen. Ziel dieser Dissertation war es 
in beiden Krankheiten zu einem besseren Verständnis inflammatorischer Mechanismen 
beizutragen. Im SLE stellt das Nukleosom ein primäres Autoantigen dar. (1) Wir 
zeigen, dass Nukleosomen im Plasma von SLE-Patienten die Sekretion pro-
inflammatorischer Mediatoren in Neutrophilen (PMN, polymorphonukleäre Leukozyten) 
induzieren. Die Nukleosomen-induzierte Aktivierung war unabhängig von Endotoxinen, 
endosomaler Azidifizierung, unmethylierten Cytosin-phosphatidyl-Guanosin (CpG)-
Motiven und dem Toll-ähnlichen Rezeptor (TLR) 9. Der hier verwendete Signalweg 
scheint im Gegensatz zu nicht methylierter CpG-ODN Unterschiede aufzuweisen. 
Demnach spielt TLR9 bezüglich des Nukleosoms eine andere Rolle in der 
angeborenen Immunität oder vermittelten Autoimmunität. (2) Außerdem berichten wir 
die Expression des TLR9 auf der Zelloberfläche von primären PMN. Dieser TLR9 
erkennt CpG-Oligonukleotide (ODN), ist funktional und führt zur Aktivierung der PMN. 
Somit beschreiben wir einen neuen Signalweg für CpG-ODN und die Aktivierung von 
PMN. Im Morbus Alzheimer wird aggregiertes Aβ durch eine Mikrogliose begleitet. (3) 
Die Untersuchung von infiltrierenden und im Gehirn vorhandenen Immunzellen führte 
zur Identifizierung dendritisch-ähnlicher Mikroglia. Die Charakterisierung in transgenen 
(tg) Alzheimer Mausmodellen sowie in humanen Gehirnen, zeigte, dass diese Zellen 
über eine gesteigerte Aktivität zur Phagozytose von Aβ ex vivo verfügen. Diese 
Fähigkeit wird jedoch durch die Expression verschiedener inhibitorischer Signale in 
vivo reguliert. Es war nicht möglich das Potential zur Phagozytose in vivo durch die 
genetische Deletion von Programmed Death (PD)-1 in dendritisch-ähnlichen Mikroglia 
wiederherzustellen. Unsere Daten festigen die Annahme, dass die Aktivierung von 
Mikroglia komplexer ist als ein einfaches Alles-oder-Nichts Prinzip. Abhängig vom 
Stimulus und von der biochemischen Umgebung zeichnet sich eine Reihe von 
qualitativ unterschiedlichen Immunantworten in vivo ab, die die Möglichkeit zur 
therapeutischen Intervention signalisieren. Der nächste wichtige Schritt ist es, die 
Modulation der hoch regulierten Effektormechanismen von PMN und Mikroglia-Zellen 
besser zu verstehen, um qualitativ gewünschte Resultate im SLE und in der AK zu 
erzielen. Dadurch ergeben sich nicht nur neue Einblicke in Pathomechanismen 
sondern auch Konsequenzen für unser Wissen über die  Autoimmuninflammation. 
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Chapter I 
 
 
The origin and mediators of inflammation, 
autoimmunity and self-tolerance 
 
 
Inflammation 
 
Inflammation can be defined as the result of provocations by invading pathogens or 
even autologous components in the body, thus representing an immune response to 
these noxious stimuli. The hallmarks of inflammation (i.e. redness, heat, swelling and 
pain) were already described by the Roman encyclopedist Celsus around AD40. At 
present it is well known that they are initiated by the innate immune system. The latter 
has evolved under the constant selective pressure of microbial pathogens and uses a 
limited number of non-clonal receptors with fixed specificities to unmask them [1]. The 
benefit of this strategy is speed. The cost is that the system is critically dependent on 
the selection of appropriate microbial targets. If the target is easily mutated, then the 
immune response fails to hit the target. In response to the virtue of mutational and 
other alterations of pathogens, the adaptive immune response has developed. It 
recognizes pathogens which have escaped innate immunity by utilizing millions of 
clonally expressed receptors [2, 3]. Thus, this specific immune response is rather slow 
but has the unique ability to provide memory and protection against re-infection [4]. 
Despite these distinct properties, both arms of immunity are designed on the principle 
of distinguishing self from non-self and eliminating the foreign one.  
 
The ideal inflammatory response is rapid, yet specific and self-limiting [5]. However, if 
the target is not unique to pathogens, then the mediators of acute inflammation may 
attack the host, leading to maladaptive chronic inflammation. When this homeostatic 
imbalance in one or several physiological systems occurs they are not any more 
functionally related to host defense or tissue repair. The result is collateral damage 
seen in many autoimmune disorders. The emergence of autoimmunity is often 
connected with aging, and is suggested to be linked to activation of the innate immune 
system in individuals suffering from chronic infections. However, the mechanisms 
underlying the efficient activation of innate and adaptive immunity with prevention of 
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reactivity to autologous tissues remain elusive [6]. Thus, studying the balance between 
the immune system and the trigger of chronic inflammatory disorders will reveal the 
check points in self and non-self discrimination with fundamental implications for our 
understanding of autoimmunity. 
 
 
Inducers and sensors of inflammation – TLR sound the alarm 
 
The innate immune system comprises multiple cell types, receptors, signaling systems 
and soluble mediators equipped with germ line encoded pattern recognition receptors 
(PRR). TLR form one major group of PRR which recognize common pathogen-
associated molecular patterns (PAMP) on foreign organisms [1]. PAMP are nucleic 
acids, lipids, lipoproteins, carbohydrates or peptidoglycans from bacteria, fungi or 
protozoa. These microbial markers are recognized by a family of structurally related 
type I transmembrane (TM) receptors which received their name due to their similarity 
to the gene Toll originally discovered in Drosophila melanogaster [7, 8]. The 
mammalian homologues possess multiple copies of leucine at the extracellular            
N-terminus and a C-terminal intracellular Toll/interleukin (IL1)-1 receptor (TIR) domain 
[9]. TLR-dependent pathways of PAMP recognition play a central role in the innate 
immunity. To date the TLR family consists of at least 10 well characterized members in 
humans and 13 in mice [10]. TLR involved in the recognition of non-nucleic acids and 
components from bacteria and fungi (TLR1, TLR2, TLR4, TLR5 and TLR6) are located 
in the plasma membrane and can be recruited to phagosomes. By contrast, TLR which 
sense viral and bacterial nucleic acids (TLR3, TLR7/8 and TLR9) are normally found 
intracellularly. The ligands for TLR10, TLR12 and TLR13 remain elusive. TLR8 lacks 
functionality in mice and TLR10 is only expressed in human but not in murine tissue. 
TLR11, which mediates recognition of profilin, is together with TLR12 and TLR13 only 
found in mice but not in humans. TLR2 either builds a heterodimer with TLR1 or TLR6 
to distinguish between bacterial- and mycoplasma-derived peptidoglycans [11, 12]. 
Double stranded (ds) ribonucleic acid (RNA) produced during viral replication can be 
detected by TLR3 located in the endoplasmatic reticulum (ER) [13]. Lipopolysaccharide 
(LPS) is the ligand of TLR4 [14] and TLR5 recognizes bacterial flagellin [15]. Single 
stranded (ss) RNA and imidazoquinolines such as resiquimod (R848) are recognized in 
endosomes by TLR7/8 [16]. Most closely related to TLR7/8 is TLR9. Gene knockout 
(KO) experiments in mice suggested that this receptor binds to and signals in the 
presence of bacterial deoxyribonucleic acid (DNA) as well as synthetic ODN that 
contain unmethylated dinucleotides in a specific sequence context (CpG) [17, 18]. In 
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contrast, mammalian DNA contains only a small number of CpG. Cytosine of these 
dinucleotides is usually methylated at position 5 so that they lack immunostimulatory 
effects [19]. However, free circulating [20] and immune complex (IC)-associated [21] 
mammalian nucleic acids have been shown to stimulate PRR under particular 
conditions and they have been linked to the development of autoimmune diseases. 
Ligand binding results in TLR dimerisation and conformational changes of their extra- 
and intracellular TIR domains. TIR recruits specific adapter proteins which are shared 
by many TLR such as TRIF (TIR-domain-containing adapter-inducing IFN-β), TRAM 
(TIR-containing adaptor molecule), TIRAP (TIR domain containing adaptor protein) and 
myeloid differentiation primary response gene (MyD) 88 in order to propagate 
activation of downstream signaling events [1]. The signal itself is amplified by 
transcription factors including activator protein-1, NF-κB (nuclear factor kappa-light-
chain-enhancer of activated B cells), interferon regulatory factors (IRF) 3, 5 and 7 
which are required for the release of pro-inflammatory mediators. Despite TLR-
associated pathways, it is well known that TLR-independent routes exist, which 
effectively mediate recognition of PAMP. Viral RNA can also be detected by 
intracellular DExD/H box RNA helicases, referred to as retinoic acid inducible gene-I or 
melanoma differentiation associated antigen-5 [22, 23]. DNA-recognition does not 
seem to be only via TLR9 [24]. Recent studies identified intracellular AIM (absent in 
melanoma)-2 as a cytoplasmic DNA-sensor for the inflammasome [25]. Another 
putative DNA-sensor is ZBP (Z-DNA binding protein)-1, or DAI (DNA-dependent 
activator of IRF) [26]. Interestingly, it is now apparent that other receptors than TLR9 
might exist at the cell surface to recognize DNA, the mechanisms of action of which 
remain to be elucidated [27]. 
 
 
Mediators and effectors of inflammation 
 
Recruitment of immune cells to the site of inflammation 
 
Recognition of PAMP by TLR mediates the generation of numerous inflammatory 
mediators which in turn alter the functionality of many tissues and immune cells [28]. 
Activated through their PRR, tissue-resident macrophages (MΦ) start to produce a 
variety of inflammatory molecules including chemokines, products of proteolytic 
cascades and cytokines such as IL-1, 6, 8 and tumor necrosis factor (TNF). 
Perivascular mast cells release histamines, eicosanoids and tryptases causing 
vasodilatation (responsible for the heat and redness) and extravasation of fluid (the 
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cause of swelling) [29]. The main effect of these pro-inflammatory stimuli is to induce 
the formation of an exudate, in which leukocytes become tissue-migratory and gain 
access to the side of inflammation [5, 6]. These areas show massive infiltrations of 
PMN, the prototypic inflammatory immune cells. PMN form the most abundant group of 
leukocytes in the peripheral blood and play a central role in host defense [30]. They 
belong to the myeloid family and possess a range of surface membrane proteins [31], 
which commit adhesion, signal transduction and initiation of PMN effector function [32]. 
The cluster of differentiation (CD) 66b is expressed at the external plasma membrane, 
and represents a marker for the fully differentiated PMN [33]. Granulocytes in murine 
tissues lack CD66b expression but the Gr-1 epitope present on the two receptors Ly-
6G and Ly-6C has been useful in their identification [34]. However, it has been shown 
that Ly-6G is almost uniquely expressed by neutrophils [35]. PMN trafficking to sites of 
inflammation follows a defined temporal pattern in which endothelial-cell selectins and 
integrins and chemokine receptors mediate capture, tethering and rolling [36]. 
Interestingly, TLR9 signaling promotes adherence in this process [37] and IL-8 arrests 
moving on endothelium [38]. When PMN reach the afflicted tissue, either the 
recognition of antibody (Ab) secreted by B (plasma) cells, complement opsonized 
particles, heat shock proteins or the direct contact of bacterial products, triggers 
neutrophil effector functions [39, 40]. Activated PMN produce and release pro-
inflammatory cytokines like IL-6 and IL-8 which allow them to attract additional PMN. In 
addition, through cell-cell contact or secretion of macrophage-inflammatory proteins 
(MIP) and TNF, PMN can actively recruit players of adaptive immunity. Vice versa 
products of monocytes, T cells and dendritic cells (DC) can activate PMN in a 
bidirectional feedback loop [32]. PMN attempt to engulf microorganisms which are 
killed intracellularly when their antibacterial granules fuse with the phagosome [41]. 
They also degranulate thereby releasing antimicrobial factors into the extracellular 
space. However, incomplete closure of antibacterial granules or aberrant release of 
reactive oxidants species (ROS) [42] and proteases to the surrounding 
microenvironment may be responsible for organ damage and fungal sepsis, promoting 
their role as double-edged swords in autoimmune issues [43]. This example is fairly 
illustrated by the fact that TNF promotes the release of elastase, cathepsin-G and 
proteinase 3 even if PMN do not directly encounter any pathogen [32]. Thus, apoptotic 
PMN are normally removed by MΦ to prevent the release of ROS and other 
neutrophilic proteins [44]. Likewise, many autoimmune disorders such as SLE are 
linked to defective clearance mechanisms of apoptotic material and loss-of-function 
mutations of receptors can lead to spontaneous inflammation, as most clearly shown 
by complement component 1q (C1q) deficiency [45]. Migration, degranulation [46], 
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phagocytosis and respiratory burst [47] are provoked by ligation of CD11b/CD18 (Mac-
1). Although vital to normal homeostasis of PMN, Mac-1 has been implicated in the 
pathogenesis of inflammatory tissue damage. Elevated levels of CD11b and activation 
status correlate positively with indicators of disease severity [48, 49]. Increased PMN 
CD11b levels may also predict adverse outcomes and provide an early diagnostic 
marker for neonatal infection [50]. Recently, Zychlinsky and colleagues proposed an 
additional mechanism for extracellular killing of microorganisms. The authors 
demonstrated that activated PMN possess the ability to release granule proteins and 
chromatin which unite to form extracellular matrices. These structures were herein after 
referred to as neutrophil extracellular traps (NET). These web-like DNA matrices 
contain proteolytic activities, i.e. elastase, cathepsin-G, myeloperoxidase, lactoferrin, 
and gelatinase that are able to entrap pathogens and disarm their surface virulence 
factors [51]. However, all options for PMN end in the same eventual fate – their death 
by apoptosis and clearance by MΦ [5, 32]. 
 
 
Resolution of inflammation 
 
If the acute inflammatory response successfully leads to the elimination of the 
pathogen, then the overall response is shifted towards anti-inflammatory signals. In 
particular, lipopoxins, protectins and resolvins send anti-inflammatory signals that 
actively promote the resolution of inflammation and a phase of repair [5, 29]. These 
anti-inflammatory mediators are induced by MΦ that have engulfed apoptotic PMN [44]. 
Lipopoxins stop the accumulation of PMN into sites of infection or tissue injury, mediate 
the uptake of apoptotic cells by MΦ, and recruit additional monocytes to participate in 
the removal of dead cells and tissue debris [5, 29]. Additionally, several innate immune 
cells produce secretory leukocyte protease inhibitor (SLPI) [52]. SLPI inactivates the 
contents released from PMN granules and promotes the acute inflammatory response 
towards resolution [29, 53]. 
 
 
Persisting inflammation 
 
If the acute inflammatory response fails to eradicate the infectious agent or the 
autologous stimulus, inflammation persists and adopts new characteristics. PMN are 
replaced by professional antigen presenting cells (APC), mainly MΦ and DC. Both cell 
types sample their environment by virtue of their high endocytic activity. When these 
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cells detect pathogens with their various PRR, they become activated and undergo 
profound phenotypic changes. They start expressing high levels of major 
histocompatibility complexes (MHC), called human leukocyte antigen (HLA) in humans, 
and co-stimulatory molecules (CD40, CD80, CD86). Together they stimulate T cells in 
a process termed antigen (Ag)-presentation. Ag derived from endogenous sources (i.e. 
those synthesized by the cells themselves) are presented on their MHC class I 
molecules for the stimulation of CD8+ T cells (CTL, cytotoxic T cells) [54]. CTL are 
essential for the control of viral infections. They are armed with an arsenal of cellular 
weapons to destroy and lyse infected cells [55]. CTL produce cytokines such as 
interferon (IFN)-gamma (γ) and TNF, and kill their target either by releasing perforins or 
granzymes that create holes in the target cell membrane or by triggering Fas-induced 
apoptosis [56-58]. Peptides from exogenous sources (i.e. generated by an extracellular 
source) are presented on MHC class II molecules and recognized by CD4+ T cells (TH, 
T helper cells) [59]. However, substantial crosstalk between these two pathways has 
been observed (cross-presentation). As the synonym implies, TH predominantly 
possess helper activity supporting other cells of the innate and the adaptive immune 
response. Due to different cytokine patterns, TH can be further divided into TH1 and TH2 
cells [60]. TH1 cells produce cytokines such as IFN-γ, IL-2 or TNF which contribute to 
the activation of MΦ and CTL. In contrast, TH2 cells support the activation of Ab-
secreting plasma cells by generating mainly IL-4, IL-5 and IL-13. Each TH subset 
promotes its own development and inhibits the proliferation of the other cell type taking 
advantage of its unique cytokine spectrum [61]. The induction of one type of response 
suppresses the induction of the other [62]. TH17 cells represent the third group of TH 
cells and have been discovered upon studies on the IL-17 family [63]. The function of 
TH17 cells is currently receiving considerable attention and it seems that they are 
critical mediators in human autoimmune disorders, allergy and antimicrobial defense 
[64]. T cell reactions can also be inhibited or down regulated by another type of CD4+ 
lymphocytes, known as CD25high regulatory T cells (TREG) [65].  
 
 
Chronic inflammation 
 
If the combined efforts of these effectors are still insufficient, a chronic inflammatory 
state ensues. The characteristics of this inflammatory state can dramatically differ in 
the effector type of T cells, the magnitude of inflammatory mediators and the class of 
APC that are present. For example increasing quantities of type I IFN (alpha [α]/β) not 
only promote normal but also autoimmune responses by a multitude of effects. One 
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major effect is DC activation, leading to efficient self-Ag presentation to previously 
quiescent low-affinity autoreactive T cells. IFN-α activated DC further produce 
cytokines, which promote B cell survival, differentiation and isotype switching, 
characteristics which are connected to SLE [66]. The main producers of IFN-α are 
plasmacytoid DC (pDC) [67]. They are most likely playing an important role in 
recognizing viruses and their nucleic acids through TLR7/8 and TLR 9 [68]. Although 
pDC represent only 0.2-0.8 % of leukocytes in the peripheral blood, their tissue number 
increases under pathological conditions. They are present in psoriatic skin [69] and 
they are believed to be an important source of IFN-α in skin lesions of patients with SLE 
[70]. Moreover, IFN-α inhibits the generation of naïve B and T cells [71] thereby limiting 
the dilution of expanded autoreactive clones. Indeed, IFN-α has strong 
immunostimulatory effects illustrated at its best by inducing systemic autoimmunity with 
increased titers of autoantibodies (autoAb) and arthritis during the course of IFN-α 
therapy in patients with carcinoid tumors [72]. Subsequent studies have shown similar 
results and obviously raised the question whether IFN-α could be involved in the 
pathogenesis of SLE.  
 
In addition to persistent infection, chronic inflammation can result from other causes of 
tissue damage such as the persistence to autoAg or undegradable foreign bodies as 
seen in many neurodegenerative diseases such as AD, both leading to autoimmune 
issues. Unsuccessful attempts by MΦ to engulf and destroy undegradable foreign 
bodies can lead to the formation of granulomas. The latter is characterized as an 
organized collection of MΦ which wall off the autoAg [6], a clinical feature reported in 
SLE patients [73]. However, regardless of whether a foreign body is too large to be 
phagocytosed or disrupts the plasma membrane, when MΦ encounter foreign bodies, 
the NALP (NACHT-, LRR- and pyrin domain-containing protein) 3-inflammasome is 
activated [6]. The inflammasome is one of the first sensors of cell stress [74]. The 
danger signal theory proposes that in addition to foreign objects, the immune system 
senses and responds to damaged self [75]. Undegradable inclusion bodies and 
abnormally folded proteins may be endogenous signals derived from damaged or dead 
neurons in neurodegenerative disorders that are sensed by the NALP3-inflammasome. 
Indeed, granulomas and activation of the NALP3-inflammasome have been identified 
during the course of AD when studying microglia, described as the CNS-resident 
counterpart of MΦ, and the innate immune response to Aβ [76, 77]. To this end, 
several mechanisms, which are definitively not exclusive of one another, probably 
account for the loss of self-tolerance in different tissues. 
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Autoimmunity – the predisposition for self-destruction 
 
Inflammation may result in disharmony between the players of the immune system and 
non-affected tissue which results in collateral damage of the surroundings [78]. 
Therefore, in some cases the immune system can be directed towards self-tissue, 
causing inflammatory injury. This phenomenon is termed autoimmunity and was first 
described as horror autotoxicus by Paul Ehrlich in 1902 [79, 80]. Autoimmune diseases 
are complex processes, in which genetic susceptibility interacts with some triggers that 
sets the progress in motion [81]. In general, such disorders are classified by 
autoreactive lymphocytes directed against autoAg and/or autoAb [82]. Autoreactivity 
can be triggered by several identified mechanisms. Sequence similarity between 
exogenous and self-Ag (molecular mimicry) is thought to activate and enable cross-
reactive T cells to cause autoimmune diseases [83]. Tight association with infection 
and autoimmune diseases is reasonable and illustrated by several examples such as 
arthritis, multiple sclerosis (MS), diabetes, atherosclerosis and myocarditis [84-88]. The 
first confrontation between host and pathogen is mainly mediated by PRR. Therefore, 
after receptor-ligand interaction the subsequental signaling pathway can influence 
secretion of pro-inflammatory cytokines and chemokine expression by APC [89]. In this 
way the production of cytokines and chemokines depends strongly on the type of PRR, 
which results in an optimized pathogen-host balance but may also result in 
autoimmunity [90, 91]. Especially, excessive activation of TLR9 through recognition of 
IC-associated self-DNA can lead to chronic inflammation and amplify autoimmune 
disorders [92, 93]. Other scenarios which can break peripheral tolerance and initiate 
autoimmunity include spreading of epitopes, excessive autoAg, modified autoAb or 
bystander activation [94-96]. APC activated by pro-inflammatory stimuli can induce T 
cell responses to self-Ag through co-stimulatory signaling [97-99]. Consequently, a 
substantial number of clones from mature self-reactive T cells can specifically 
proliferate in response to their cognate self-Ag, and differentiate into effector cells in 
the context of inflammatory stimuli [100-102]. Most prominent examples are SLE [103] 
and rheumatoid arthritis [104]. Both of them belong to the group of systemic 
autoimmune diseases, because especially in the case of SLE virtually every organ can 
be affected, e.g. skin, joints, hematopoietic system, kidney, CNS and heart. By 
contrast, in organ-specific autoimmune diseases like MS and its rodent model, 
experimental autoimmune encephalitis (EAE), T cells reactive to the myelin basic 
protein contribute to CNS pathology [105]. AD is rather defined as a neurodegenerative 
than an autoimmune disorder, but there is evidence that effectors of immunity directed 
against the self-Ag Aβ play a considerable role during the course of the disease [106]. 
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Self-tolerance 
 
The immune system has developed a set of control mechanisms which contribute to 
the maintenance of self tolerance. Several strategies are used to provide central and 
peripheral tolerance. Central tolerance takes place during B and T cell development, 
e.g. through deletion or receptor editing [107]. This selective mechanism ensures that 
potentially self-reactive lymphocytes are eliminated. However this process is 
incomplete. Recently, it has been illustrated that nearly 40 % of autoreactive T cells 
can escape negative selection, even in the presence of the tolerance-inducing ligand in 
the thymus [108]. The repertoire of mature lymphocytes is strongly biased towards self-
reactivity [109]. This indicates that the selection process rather shapes the peripheral 
lymphocyte repertoire and not simply deletes potentially destructive self-reactive cells 
[110]. This phenomenon is known as the immunological homunculus [111]. To deal 
with pathogenic autoreactive lymphocytes which have escaped the cellular checkpoints 
regulating self-reactive receptors, the organism provides additionally peripheral 
tolerance [112]. These mechanisms include intrinsic as well as extrinsic features, e.g. 
anergy, biochemical tuning or regulation of self-reactive receptors. It is well 
documented that B and T cells with the ability to recognize self-Ag can become 
impaired by over-stimulation (anergy) [113]. Permanent confrontation with the autoAg 
can cause a progressive loss of function. This might begin with the inability to produce 
certain cytokines and ends in apoptosis (AICD, Ag-induced cell death) [114]. Self-
reactivity may be prevented because of abortive receptor signals for self-Ag, lack of T 
cell co-stimulation from APC or even by simple anatomical seclusion of autoreactive 
lymphocytes from their target autoAg [76, 115]. Despite these passive mechanisms, 
regulatory DC, B and T cells can also actively suppress the activation and proliferation 
of self-reactive lymphocytes [65, 116, 117]. Additionally, it has been proposed that 
PMN participate in the preservation of peripheral tolerance. The production of several 
pro-inflammatory cytokines [32], the possibility of Ag-presentation and the expression 
of the co-stimulatory molecules CD80 and CD86 [118, 119] provides strong evidence 
for communications and interactions between PMN and T cells. Moreover, PMN may 
not only have an impact on the induction but also on the quality of T cell responses. 
PMN are equipped with effector systems that can mediate T cell suppression. The two 
L-arginine metabolizing enzymes arginase and nitric oxide synthase, as well as the 
phagocytosis-associated oxidases that generate ROS can inhibit T cell activation [120]. 
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Chapter II 
 
 
Systemic lupus erythematosus – the prototype of 
systemic autoimmunity 
 
 
The origin of the name lupus 
 
SLE was first recognized and described as ‘wolf bite’ because of the redness across 
the cheeks in the 13th century. However, the term lupus érythémateux was first coined 
by the French physician Pierre Cazénave in 1851 to differentiate the non-infectious 
forms of lupus from cutaneous tuberculosis (lupus vulgaris) [1]. Lupus erythematosus 
derives from the Latin meaning of wolf and the Greek word of redness (ἐρυθήμα, 
erythema). Further investigations into the heterogeneous manifestations of lupus 
erythematosus by Moritz Kaposi recognized the relationship between discoid lupus 
erythematosus and SLE manifestations. To this end he extensively described the facial 
cutaneous signs of SLE also known as the butterfly erythema (Fig. 1). 
 
In 1872, M. Kaposi (1837-1902) described SLE as an acute febrile eruption with 
pronounced painful joint involvement and a characteristic facial erythema that he 
termed erysipelas persistans faciei. At the end of the 19th century, reports by 
Hutchinson, Goeckerman and Osler further emphasized the different expressions and 
variations of this disorder with respect to cutaneous and systemic manifestations. Thus, 
the heterogeneity of SLE was first characterized and evaluated by its cutaneous 
manifestations before the analysis and study of its systemic manifestations established 
the multifactorial nature of SLE (as reviewed in [2]). 
 
 
 
 
 
 
 
 
General introduction 
28 
 
 
 
Figure 1. Historical illustrations of SLE. This classical drawing shows a woman with the 
characteristic butterfly-like rash over the cheeks and further skin manifestations on the 
hands (Picture is adapted from [3]). 
 
 
SLE is an autoimmune disorder with multifactorial pathology 
 
SLE is a chronic relapsing-remitting autoimmune disorder of unknown etiology and 
characterized by widespread organ involvement (Fig. 2). Although it is believed that 
susceptibility to SLE is largely dependent on genetic predisposition [4], a multifactorial 
combining effect of genetic, environmental and hormonal factors is most likely. The 
prevalence in European countries is 25 in 100,000 individuals [5]. SLE primarily affects 
women during their childbearing age (women/men ratio of 8/1 among affected 
individuals). Furthermore it is more prevalent in the non-Caucasian than Caucasian 
populations. SLE is characterized as an IC-mediated (also referred to as type III 
hypersensitivity) systemic autoimmune disorder which becomes manifested in the 
central and peripheral nervous system (Fig. 2A, B), skin (Fig. 2C, D), by inflamed joins 
leading to arthritis (Fig. 2E) as well as kidney dysfunctions (Fig. 2F). The latter is 
known as glomerulonephritis (GN) and characterized, as the other manifestations, by 
the widespread of autoAb, causing inflammation and tissue destruction upon deposition 
of IC.  
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Figure 2. SLE is a highly heterogeneous, multiorgan disorder. (A) The solid arrow 
indicates a previous hemorrhage in the right frontal lobe of the brain from an individual 
suffering from SLE, supported by a high-signal change within the periventricular white 
matter which could resemble cerebral vasculitis. (B) The classical finding in lupus 
retinopathy is the cotton-wool-spot (indicated by the arrow), leading to complete blindness. 
The spot shows often deposits of IC with the complement factors C1q and C3. (C, D) 
Patients are suffering from discoid lupus erythematosus. (E) Inflamed joints leading to 
arthritis. (F) Depicted is a glomerulus of the kidney which shows severe thrombosis, 
swelling of the endothelial cell layer, necrosis and the massive infiltration of PMN indicated 
as black dots (Pictures are adapted from [6-11]). 
 
 
To diagnose SLE at least four of the following criteria are serially or simultaneously 
required: facial and/or skin rash, sensitivity to sun light, mouth aphtha, fluid reposition 
around the lungs, heart and joints, immunological disorders, low white blood cell and/or 
platelet counts, anemia, arthritis, CNS and/or kidney malfunctions as well as the 
presence of anti-nuclear autoAb (ANA) [12]. Circulating autoAb that are specific for 
autoAg such as DNA and nuclear proteins are the hallmark of SLE and will be further 
discussed below. 
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Circulating nucleosomes in systemic lupus erythematosus: not 
only passive targets for autoantibodies 
 
 
The following text is derived from an article by Viktoria Rönnefarth, Annika Erbacher, 
Dennis Lindau and Patrice Decker (in preparation). The author of this thesis classified 
the knowledge about TLR and the pathogenesis of circulating nucleosomes in SLE, 
designed figure 3 and was instrumental in correcting the manuscript. 
 
 
The production of huge amounts of circulating autoAb directed against nuclear and 
cytoplasmic autoAg is characteristic for lupus. SLE is typified by the presence of ANA 
and in particular, autoAb directed against the nucleosome and its individual 
components, dsDNA and histones [13]. Among these autoAg, the nucleosome is a 
main autoAg in SLE. It is the fundamental packing unit of DNA in chromatin within the 
nucleus and is composed of 180 base pairs (bp) of dsDNA and histones. Two copies of 
each histone protein H2A, H2B, H3 and H4 are organized into an octamer which has 
146 bp of DNA wrapped around it to form the nucleosome core. This structure is 
stabilized by the linker histone H1. A nucleosome has a molecular weight of 262 kD 
with a histone/DNA ratio of 1. The X-ray crystal structure of the nucleosome core 
particle was resolved at high resolution [14]. Circulating (oligo)-nucleosomes are found 
in the blood of SLE patients and lupus mice [15]. The levels of these circulating 
nucleosomes are raised in SLE patients with renal and CNS manifestations [16]. 
Originally, it has been thought that circulating DNA and not nucleosomes plays a role in 
tissue damage in SLE through the formation and deposition of DNA-anti-DNA-IC [17]. 
Since naked DNA is poorly immunogenic and because the DNA detected in the 
circulation of SLE patients is complexed in nucleosomes, nucleosomes are probably 
the triggering Ag for anti-dsDNA, anti-histone and anti-nucleosome Ab. Although, anti-
dsDNA Ab are a hallmark of SLE [18, 19], nucleosome-restricted autoAb have been 
described in SLE patients [20]. Importantly, anti-nucleosomal autoAb are present in 
patients with active and inactive SLE and their level positively correlates with disease 
activity suggesting that anti-nucleosome Ab reactivity may be a more sensitive marker 
than anti-dsDNA [21, 22]. Particularly, increased immunoglobulin (Ig) G3 anti-
nucleosome levels were shown to be associated with active nephritis [23]. Besides, it 
was demonstrated in several lupus-prone mice that anti-nucleosome Ab emerge early 
in life and are potentially pathogenic [24, 25]. It is thought that the nucleosomes are 
also a major Ag for the pathogenic autoAb-inducing TH cells which arise spontaneously 
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in SLE [26]. Thus the presence of nucleosome-specific TH cells in lupus-prone mice is 
necessary for the production of pathogenic autoAb and the development or 
acceleration of nephritis. Likewise, nucleosome-specific TH cells have been detected 
and characterized in SLE patients [27]. In addition, it was demonstrated that a single 
lupus nucleosome-specific TH clone can provide help to dsDNA-, histone- or 
nucleosome-specific B lymphocytes [26]. These nucleosome-restricted Ab only react 
with the whole nucleosome complex but not with its individual components (dsDNA and 
histones), and anti-dsDNA and anti-histone Ab are only minor components of the IgG 
anti-nucleosome response. It is believed that nucleosomes that are complexed with 
anti-nucleosome Ab are involved in the development of GN. Thus it was demonstrated 
that nucleosome-specific monoclonal Ab (mAb) complexed to nucleosomes bind to rat 
glomerular basement membrane in vivo, partly via the heparan sulfate, and activate the 
complement, whereas nucleosome-specific Ab alone do not [28]. Anti-nucleosome Ab 
are also associated with haematuria, malar rash, arthritis and oral ulcers [29].  
 
 
Dysfunctional removal of autoantigens in SLE patients 
 
To avoid an immune response to nuclear contents like nucleosomes, such components 
rarely appear in the circulation of healthy organisms. Very efficient removal strategies 
avoid their presence into the surrounding tissues. Single nucleosome fragments are a 
product of the programmed cell death called apoptosis. Within hours (h) the cell 
morphology changes drastically and during this process a caspase cascade is initiated 
which results in the activation of the caspase activatable DNase (deoxyribonuclease) 
[30]. This DNase is responsible for the characteristic cleavage of the DNA, degrading 
the chromatin in its basic units, the nucleosome. An early event during apoptosis is the 
relocation of the phospholipid phoshatidylserine from the inner to the outer leaflet of the 
plasma membrane without loosing the membrane integrity. The exposed 
phoshatidylserine is then recognized by phagocytes via a variety of receptors, for 
example the phosphtidylserine receptor [31] and opsonins like the milk fat globule 
EGF-factor 8 (MFGE8) [32]. The so identified apoptotic cells are internalized and 
cleared before any release of immunogenic molecules can take place. The elimination 
of cells undergoing apoptosis is therefore believed to be an anti-inflammatory process 
due to the involved receptors on monocytes and MΦ, and their secreted 
immunosuppressive cytokines like IL-10 and the transforming growth factor (TGF)-β 
[33]. Apoptotic cells are also characterized by cell shrinkage and bleb formation on the 
cell surface. These blebs accumulate cytoplasmic and nuclear material, which are 
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known to serve as autoAg in SLE [34]. Late apoptotic cells can also become cleared 
via backup mechanisms that involve opsonins like C1q [35] or the short pentraxins C-
reactive protein (CRP) [36] and serum amyloid P (SAP) [37]. The highlighted cells are 
then recognized by a set of phagocyte receptors like MFGE8 that differ from the former 
by rather binding to the opsonins than directly to the cells. When apoptotic cells escape 
these clearance systems they undergo secondary necrosis in the circulation, in which 
they loose their membrane integrity and release their noxious contents. Unlike 
apoptosis, secondary necrosis is able to evoke immune reactions involving pro-
inflammatory cytokines like TNF, IL-1β and IL-12 [38]. The efficiency of the removal 
mechanisms are demonstrated specifically in tissues with high cell turnover like the 
thymus [39]. Indeed, due to the failed positive or negative selection of lymphocytes 
more than 95 % of them undergo apoptosis. Accumulation of apoptotic bodies at the 
site of immune development like the thymus (but also in lymph nodes, bone marrow 
(BM) and the spleen) might lead to a rapid development of immune reactions against 
released intracellular contents. Human SLE is associated with an impaired clearance of 
apoptotic cells and moreover with an augmented apoptosis rate [40, 41]. Monocyte-
derived as well as tingible body MΦ of SLE patients are affected in their phagocytic 
function [40, 42]. High amounts of non-ingested apoptotic cells were observed in 
germinal centers and cell culture supernatants, and additionally only few MΦ contained 
engulfed cell debris in these experiments. The impaired phagocytosis of apoptotic cells 
by MΦ is thought to be partly associated with the membrane tyrosine kinase c-mer. 
Mice lacking the intracellular domain of c-mer show a delayed clearance of apoptotic 
cells, and develop additionally lupus-like manifestations [43]. Those results are striking 
due to the fact that MΦ are the most potent phagocytes for apoptotic and necrotic 
material. Their disability allows other phagocytes, for example DC which are 
specialized APC, to engulf apoptotic bodies or free material and present autoAg to 
developing lymphocytes. Other groups published studies in which immune cells of SLE 
patients, like lymphocytes and PMN, seem to be more susceptible to apoptosis in vitro 
compared to cells from healthy controls or patients with other chronic inflammatory 
diseases [41, 44]. Unfortunately the experiments could not determine if the high 
amount of circulating apoptotic cells in vivo results from impaired clearance 
mechanisms or increased apoptosis rates. Contrasting effects were reported 
concerning the clearance and frequency of apoptotic keratinocytes in patients with 
lupus compared to controls. About 30 % to 50 % of the patients are photosensitive and 
ultraviolet (UV) B light irradiation is known to induce the typical skin lesions. Moreover, 
UVB is a very effective inducer of apoptosis. But neither an increased apoptosis rate 
nor severe clearance defects have been observed in the skin of SLE patients after UVB 
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irradiation [45]. However, these findings do not exclude each other. They rather place 
emphasis on the theory. The presence of circulating nucleosomes in sera of SLE 
patients is thought to be a result of the enhanced rate and inefficient clearance of 
apoptotic cells, which results in the generation and release of nucleosomes in the 
circulation. It was shown in vitro that nucleosomes release from dying cells occurs 
about 24 to 48 h after apoptosis induction in the absence of phagocytes [46]. This 
indicates that removal of apoptotic cells from the circulation takes approximately 12 
hours. Mouse in vivo experiments reported equal results. Serum nucleosome levels 
peaked 24 to 48 h after induction of apoptosis in MΦ of healthy mice [47]. In addition, 
the same study showed that MΦ play a major role in the generation of circulating 
nucleosomes from apoptotic and necrotic cells in vivo and the lack of nucleosomes in 
their absence. There are several effector molecules suggested to be involved in the 
clearance of chromatin, once it is released into the circulation. Amongst them is the 
DNase1, an endonuclease present in body fluids like serum and urine. It is known that 
its activity is decreased during the active disease in SLE patients [48]. DNase1-
deficient mice display lupus-like symptoms, including ANA-production [49]. 
Interestingly, only mice with a lupus-prone background, for example mice with a mixed 
(129xC57BL/6)F2 genetic background, show symptoms of SLE, illustrating that 
DNase1 deficiency is not the only triggering factor for developing lupus but amplifies 
the severity of the disease. DNase1, in combination with plasminogen degrades the 
DNA of necrotic cells in an internucleosomal manner [50]. It has also been shown that 
the ability of DNase1 to degrade chromatin from necrotic cells is facilitated and 
increased in the presence of C1q [51]. As mentioned above, C1q is known to promote 
the clearance of apoptotic cells by binding to the surface blebs of apoptotic cells [35, 
52]. A deficiency of C1q predisposes to the development of SLE, shown by the fact that 
over 90 % of the reported individuals with a complete absence of this recognition 
molecule develop SLE [53, 54]. Besides this, the level of circulating C1q is decreased 
in SLE patients with active disease, probably due to an enhanced consumption of 
complement components by anti-C1q autoAb [55]. C1q-deficient mice only develop 
symptoms on a lupus prone genetic background, accentuating once more the 
multifactorial origin of the disease. Interestingly, the binding of C1q to DNA was also 
reported [56], suggesting a role of C1q in the clearance of free chromatin. The 
recognition molecule of the lectin pathway of the complement system, the mannose-
binding-lectin (MBL), shares functional and structural similarities with C1q. It binds, like 
C1q, to apoptotic cells and facilitates their uptake by MΦ [57]. Likewise, a binding to 
DNA is also observed indicating its possible involvement in chromatin removal [58]. 
But, compared to DNase1- and C1q-KO mouse models, MBL null mice do not develop 
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spontaneous autoimmunity, even on a lupus-prone background [59]. Another group of 
serum opsonins, which share functional and structural similarities to MBL and C1q, are 
Ficolins. Two members of this family, Ficolin-2 and Ficolin-3 (also known as Hakata 
Ag) are known to bind to dying cells. Ficolin-3 contributes to the uptake of late 
apoptotic cells by phagocytes via receptors like the Calreticulin-CD91 complex [60]. 
Ficolin-2, in contrast to Ficolin-3, is additionally known to bind DNA [61]. However, it is 
not known if their activity is decreased in SLE patients. Pentraxins are serum proteins 
of the acute phase response and serve additionally as opsonins for apoptotic cells and 
are known to enhance their phagocytosis [36, 37, 62, 63]. CRP and SAP are also 
thought to bind to circulating chromatin and considered to be involved in its clearance 
[64, 65]. SAP-KO mice spontaneously develop autoimmunity and GN. Nevertheless, it 
was recently reported that SAP levels are not decreased in SLE patients [66]. But a 
study by Sørensen et al. [67] could show a negative correlation between the ability of 
SAP to form complexes with DNA and high anti-DNA titers in SLE patients. Likewise, a 
low acute phase CRP response has been observed in SLE patients during the active 
phase of the disease and this deficit is now known to be associated with a 
polymorphism in the CRP locus [68]. The Pentraxin 3 (PTX 3) shares structural 
homology with CRP and SAP, and is also known to bind to dying cells [69]. But unlike 
these proteins, the binding of PTX 3 rather inhibits the uptake of apoptotic cells by DC. 
By this, PTX 3 regulates the maturation of the DC and thus restrains the activation of 
autoreactive lymphocytes [70].  
 
 
The role of nucleic acid-sensing TLR in SLE 
 
Recent studies strongly suggest that microbial and even endogenous nucleic acids can 
induce systemic autoimmune disease as well as subsequent clinical flares via the 
engagement of TLR7/8 and TLR9 [71]. These sensors and their molecular signaling 
pathways are sequestered intracellularly which normally excludes recognition of 
extracellular host-derived nucleic acids [72]. Furthermore, methylation of DNA motifs 
[73] and the subsequent degradation of nucleic acids by nucleases are thought to 
prevent autoimmunity. However, the immunostimulatory CpG-motifs in SLE autoAg 
reveal higher contents of unmethylated sequences [74]. Additionally SLE-patients show 
defects in DNA methylation [75] and degradation [54]. Defects in mechanisms of 
clearing apoptotic cells or IC, such as complement, Fc-receptor (FcR) or phagocytotic 
defects, serve to elevate the absolute concentration of available autoAg. In humans 
TLR9 maps to chromosome 3p21.3 and some polymorphisms predispose to SLE in 
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Japanese [76, 77]. Furthermore, variants of the transcription factor IRF5 downstream of 
TLR7/8 and TLR9 have been identified as an important susceptibility factor in humans 
[78, 79]. TLR can sense circulating autoAg released from apoptotic cells and such self-
recognition may be crucial in the induction and perpetuation of SLE (Fig. 3). The 
accessibility to TLR in the endolysosomal compartments by self-nucleic acids is 
thought to be mediated by the complexing of these sensors with SLE-associated 
autoAb with corresponding specificities. These IC activate autoreactive B cells and 
pDC through a mechanism dependent on dual engagement of TLR9 and the B cell 
receptor (BCR) or FcRγIIa (CD32), respectively [80-82]. Moreover, free DNA activates 
DNA-specific lymphocytes via the BCR and TLR9 [81]. CD32 mediates uptake by pDC 
of apoptotic material complexed with serum IgG autoAb, leading to the secretion of 
IFN-α, the major pro-inflammatory cytokine found in SLE [83]. Interestingly, 
predisposing autoreactive B cells to IFN-α lowers the BCR activation threshold and 
relaxes the selectivity for SLE-autoAg [84]. Likewise, in vitro activation of B cells by 
RNA-containing IC depends on TLR7 [85, 86]. It is thought that fragments of apoptotic 
DNA have a greater stimulatory capacity than genomic DNA, which may be due to the 
release of proteins such as high motility group box (HMGB)-1 from necrotic cells. 
HMGB-1 was identified as a CpG-binding protein which accelerates CpG-TLR9-
complex formation and enhances TLR9-dependent cytokine response such as IL-6,    
IL-12 and TNF [87]. Recent studies have shown that aberrant expression of TLR7 and 
TLR9 is a key player in the production of pathogenic autoAb and/or in development of 
clinical features in mouse models of SLE [88]. Rheumatoid factor B cells from lupus-
prone MRL (Murphy Roths Large) lpr/lpr mice are activated by CpG through cross-
linking of BCR by IgG2a-IC [89]. Thus, TLR9 expression has a specific requirement in 
promoting autoAb formation in vivo, although the results highly depend on the genetic 
background of the mouse models. MRL lpr/lpr mice deficient in TLR9 show an inhibition 
of anti-dsDNA and anti-chromatin autoAb, although no clinical effect was seen. By 
contrast, the ablation of TLR3 did not inhibit the formation of autoAb to dsRNA- or 
dsDNA-containing Ag [90]. Similarly, C57BL/6 mice deficient in TLR9 show significantly 
smaller autoAb IC deposits in the glomeruli and survive longer than their TLR9-
sufficient litter mates. In this case, B cells do not undergo IgG class switching to the 
pathogenic isotypes IgG2a and b [91]. TLR7 deficiency can also influence autoAb 
production. TLR7-deficient MRL lpr/lpr mice do not produce autoAb that react with 
RNA-associated autoAg and do not have exacerbated clinical disease. Therefore, 
either TLR7 or TLR9 deficiency in MRL lpr/lpr mice indicated that TLR9 is required for 
the secretion of anti-DNA Ab but not for the development of nephritis whereas TLR7 
promotes the disease [92]. Furthermore, TLR7 gene duplication in mice induces SLE 
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[93]. These observations led to the ideal to eliminate TLR3, TLR7, and TLR9 in lupus-
prone mice at once by inactivating the Unc93b1 gene essential for transporting these 
TLR to the endolysosome to function. Compared to lupus-prone mice with a functional 
Unc93b1 gene, the mice with the Unc93b1 mutation produced fewer ANA and had 
fewer and less severe symptoms of SLE. This result suggests that the three endosomal 
TLR, or UNC-93B itself, might be good targets for therapy [94]. 
 
 
 
 
Figure 3. AutoAg trigger chronic inflammation in SLE. Host-derived autoAg are 
released from apoptotic cells. Clearance checkpoints to get rid of autoAg such as 
nucleosomes are indicated, but may fail under certain circumstances leading to the uptake 
of autoAg by DC, B cells and neutrophils. The exact mechanism for internalizing free 
nucleosomes by PMN is unknown. However, nucleosome-induced PMN activation is 
independent of TLR2/4 and TLR9, and results in the release of pro-inflammatory cytokines.  
Neutrophils are discussed to interact with DC and T cells. FcR-captured nucleosomal IC 
lead to TLR signaling in pDC, in which IRF5 serves as transcription factor. In genetically 
predisposed individuals, IRF5 is expressed at higher levels and/or functionally more potent 
in pDC, leading to the up-regulated secretion of IFN-α. The latter induces a IFN-α signature 
(grey arrows) in various immune cells and has pleiotropic effects, such as enhanced 
survival and proliferation, cross-presentation, up-regulation of MHC molecules and isotype 
switching. One key principle of IFN-α is the rapid induction and amplification of the 
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signaling pathway, which generates a feed-forward loop of IFN-α production. Although such 
feed-forward pathways are highly adaptive when it comes to rapid and effective eradication 
of intruders, this amplification can be maladaptive in immune responses directed against 
host tissues. Monocytes mature in the presence of apoptotic blebs and IFN-α into APC 
which present autoAg and activate autoreactive T cells. CD4+ T cells help autoreactive B 
cells to produce autoAb, which lead to IC formation. In total, these events accumulate and 
contribute to tissue collateral damage. IC formation and nucleosomes from damaged 
tissue, in turn, may work on immune effectors to accelerate autoreactive process or the 
attraction of other immune cells to the site of inflammation. Thus, systemic inflammation 
leads to the creation of autoamplification feedback loops and chronicity of these 
syndromes. 
 
 
Pathogenicity of free circulating nucleosomes 
 
The immunogenic effect of IC-associated nuclear autoAg has been demonstrated 
several times in SLE but the role of free circulating autoAg such as the nucleosome is 
still a field of extensive research. Nucleosomes are detected at higher concentrations in 
the blood of SLE patients. Circulating nucleosomes directly bind [95] and act on diverse 
cell types [96]. They bind to the surface of mesangial cells [97], a specialized cell type 
organizing the glomerular capillaries in the kidneys, and enhance their proliferation 
which may contribute to GN. Natural killer (NK) cells prevent autoimmunity, but 
nucleosomes have been shown to inhibit the lysis of target cells by NK cells [98]. 
Although the direct effect of nucleosomes on the activation of NK cells remains elusive, 
enhancing NK cell activity in SLE may be an attractive therapeutic intervention. 
Nucleosome-indcued activation of DC [99] and PMN [100] leads to the secretion of 
several pro-inflammatory mediators (Fig. 3) which may result in further recruitment of 
cells to the site of inflammation but also to collateral damage of the surrounding tissue. 
Interestingly, free circulating nucleosomes activate PMN in a pathway independent of 
TLR2/4 [100] and TLR9 (present work, see chapter V). Highly purified nucleosomes 
from calf thymus induce necrosis-like cell death of lymphocytes [101]. Nucleosomes 
further inhibit the removal of apoptotic cells by MΦ [102], stimulate B cells [103] and 
induce IL-6 secretion in splenocytes [96]. Thus, in combination with the dysfunctional 
removal of apoptotic blebs the nucleosome promotes its own generation and release 
into the circulation. In summary the nucleosome-induced activation of the innate 
immunity network may partly explain why the peripheral tolerance is broken in SLE. 
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Chapter III 
 
 
Neutrophils, dendritic cells and chromatin-
mediated pathogenesis in systemic lupus 
erythematosus 
 
 
This chapter is derived from an article published in Autoimmunity 2009; 42(4): 254-256 
by Dennis Lindau and Patrice Decker. Both authors participated equally in writing the 
manuscript. 
 
 
Abstract 
 
Nucleosomes are key lupus autoAg and have been shown to activate several types of 
immune cells as well as the complement system, resulting in inflammation. The 
elevated concentrations and the immunostimulatory capacities of circulating 
nucleosomes may favor the break of peripheral tolerance in genetically predisposed 
individuals. Nevertheless, in most cases the signaling pathways involved are not 
elucidated yet, although Tir8/Sigirr (single Ig IL-1R-related molecule) deficiency has 
been recently shown to enhance cell activation upon exposure to nucleosome-
containing immune IC [1]. 
 
 
Introduction 
 
Persisting inflammation may result in disharmony between cells of the immune system 
and the surrounding healthy tissue which results in collateral damage of the latter. SLE 
is a rheumatic autoimmune disease characterized by the loss of tolerance against 
ubiquitous autoAg leading to serious tissue injury. SLE is a multifactorial and 
inflammatory disorder classified as an immune IC-mediated disease. The continuous 
production of autoAb against autoAg results in IC deposition in multiple organs, e.g. the 
kidneys.  
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Nucleosomes and defective clearance of apoptotic cells in SLE  
 
The autoimmune pathogenesis in SLE is associated with increased serum levels of IgG 
autoAb against self-components. Among these, the nucleosome and its constituents 
(histones and dsDNA) seem to play a central role as pathogenic mediators [2]. In the 
eukaryotic cell nucleus, DNA is associated with a set of specialized proteins (histones), 
resulting in a structure called chromatin. The fundamental repeating unit of chromatin 
fibers is the nucleosome. The core particle consists of 8 core histone proteins               
(2 molecules of each of H2A, H2B, H3 and H4) around which 146 bp of DNA is 
wrapped [3]. In addition, histone H1 binds to DNA outside the core particle to form the 
mononucleosome, which contains 180 bp of DNA. In higher-order chromatin structures, 
nucleosomes are connected through varying lengths of linker DNA. Although, under 
normal conditions these constituents are not released from the inner cell mass, patients 
with SLE show increased serum levels of circulating nucleosomes [4]. The latter are 
most likely released upon increased apoptosis in combination with impaired uptake of 
apoptotic cells [5], leading to secondary necrosis. Indeed, apoptotic cells represent a 
source of lupus autoAg. Thus, defects in the clearance of apoptotic cells or apoptotic 
cell-derived material may favor development of SLE. For example, it has been shown 
that the specific deletion of the genes encoding DNase 1 [6], SAP [7] or C1q [8] leads 
to the development of anti-nuclear Ab and a lupus-like disease in mice. 
 
 
The nucleosome is a major lupus autoantigen 
 
Autoreactive B and TH lymphocytes specific for nucleosome autoepitopes are detected 
in patients with SLE. The latter help nucleosome-specific B cells to produce potentially 
pathogenic chromatin-reactive autoAb [9]. Thus, the amounts of circulating anti-histone 
H1, ANA and anti-dsDNA autoAb correlate with disease activity, and the latter are used 
as a disease marker. Particularly, nucleosome-restricted autoAb, i.e. Ab that recognize 
the whole nucleosome particle but not its individual components have been reported 
[10]. ANA are detected before anti-dsDNA and are potentially nephritogenic in lupus 
mice. Importantly, ANA of the IgG3 isotype are not only increased in SLE patients but 
also correlate with disease activity [11]. 
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Polymorphonuclear leukocytes and dendritic cells in SLE 
 
DC play an important role in the regulation of immune responses. SLE DC have been 
shown to express higher levels of activation markers and to secrete higher amounts of 
the pro-inflammatory cytokine IL-8 [12], a phenotype characterizing activated DC and 
thus favoring T cell activation. We observed that DC derived from patients with SLE 
spontaneously overexpress CD86, another DC activation marker [13]. PMN are the first 
cells recruited at sites of inflammation where they are activated. Neutrophils from 
patients with SLE with more active disease express higher levels of activation markers 
and expression levels correlated with disease activity [14]. Thus, both PMN and DC 
have altered functions or phenotypes in SLE. Importantly, PMN have been suggested 
to link innate and adaptive immunity, e.g. by attracting DC, pointing at a potentially 
interesting crosstalk in the pathogenesis of SLE. 
 
 
Nucleosomes and inflammation 
 
Several reports have shown that extracellular chromatin fragments may influence cell 
behavior. Whereas, most studies focused on the effects of chromatin containing IC in 
the context of SLE, showing that they activate rheumatoid factor-positive B cells as well 
as DC, some groups investigated the direct effects of free nucleosomes. Thus, 
chromatin activates directly chromatin-reactive B cells [15]. Likewise, nucleosomes 
induce IL-6 secretion by mouse spleen cells [16]. Consistently, we have shown that 
circulating nucleosomes activate DC [17] and PMN [18] resulting in high cytokine 
secretion, especially IL-8. Thus, upon endocytosis of nucleosomes, DC are activated 
and then potentially process and present HLA associated nucleosome-derived peptides 
to autoreactive T cells. During activation DC secrete IL-8, leading to PMN recruitment. 
Likewise, nucleosome-activated PMN secrete IL-8, amplifying PMN recruitment, and 
activate and recruit other cells. Those mechanisms support the inflammation and tissue 
damages observed in SLE patients. Moreover, we have observed that circulating 
nucleosomes directly activate the complement system upon binding to C1q, leading to 
an increased C3a generation (Erbacher AE, in preparation). Interestingly, C1q is 
secreted by DC whereas the anaphylatoxin C3a stimulates PMN. Furthermore, C3a 
has been recently shown to interact with DC and naive TH cells, favoring DC maturation 
and T cell activation [19]. 
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Nucleosome-mediated pathogenicity 
 
As explained above, SLE is an IC-mediated inflammatory disease. IC deposit into 
tissues and activate the complement system, causing inflammation and tissue 
damages in the form of a type III hypersensitivity reaction. Renal disease is a major 
complication in SLE. Particularly, the deposition of nucleosome/anti-nucleosome IC in 
the glomerular basement membrane in the kidney is believed to be involved in the 
development of GN. Free nucleosomes have also been suggested to be directly 
pathogenic by affecting mesangial cells [20]. Our findings on the C1q-nucleosome 
interaction suggest that tissue-deposited nucleosomes may participate locally in 
complement activation and C3a production, e.g. in the kidney where the C3a receptor 
is highly expressed in SLE patients with GN. During the inflammatory process, PMN 
and MΦ are recruited and release their granule contents and reactive oxygen species, 
the latter being involved in tissue damage but also in the alteration of autoAg, prone to 
modify their immunogenicity. Consistently, we have observed that nucleosome-induced 
activation enhances oxidative burst in PMN (unpublished). Finally, nucleosomal Ag 
have also been found in the epidermal basement membrane of non-lesional skin in 
patients with SLE and GN, suggesting that nucleosome-mediated binding of autoAb 
may occur at sites other than the glomerulus [21]. 
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Chapter IV 
 
 
Alzheimer’s disease  
 
 
Historical background 
 
In 1901 Auguste Deter was admitted to the state asylum in Frankfurt (Fig. 1A). She 
was suffering from progressive dementia, characterized by memory loss and 
disordered cognitive functions. In the hospital she was examined by the medical doctor 
Alois Alzheimer (1864-1915, Fig. 1B). In 1903 Alzheimer joined Emil Kraepelin’s group 
in München. Three years later Auguste Deter died and her brain was analyzed by Alois 
Alzheimer with then newly identified histological methods. For the first time, Alois 
Alzheimer described extracellular miliary foci and intracellular dense bundle of fibrils as 
pathological characteristics of this disease [1]. In 1906 A. Alzheimer presented his 
observations at a psychiatry meeting in Tübingen. The results of this study were 
published in 1907 [2]. In 1910 Emil Kraepelin honored the study of A. Alzheimer by 
naming the disease after him. Until now both findings remain still the diagnostic 
hallmarks of AD post mortem (Fig. 1C). They are now referred to as senile plaques and 
neurofibrillary tangles (NFT). However, the composition of the plaques remained 
unknown until 1985, when the components were identified as Aβ [3]. 
 
 
 
 
Figure 1. Historical aspects of AD. Pictures show the first documented AD patient 
Auguste Deter (A) by the German psychiatrist Alois Alzheimer (B). (C) NFT drawn by Alois 
Alzheimer (adapted from [4]). 
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Neuropathology 
 
The most widely accepted criteria for the clinical definition of AD have been introduced 
by studies of the National Institute for Neurological and Communicative Disorders and 
Stroke and the Alzheimer’s disease and Related Disorders Association [5]. Definite AD 
requires the clinical finding of dementia as determined by the Mini-Mental Status Exam 
or other standardized neuropsychological testings to specify cognitive changes over 
time, and imaging studies. The exam must demonstrate deficits in two or more areas of 
cognition with progressive memory loss in the absence of delirium. Probable AD is 
supported by the findings of impaired activities of daily living, loss of specific cognitive 
functions such as language and motor skills, and a familial history. However, a 
definitive diagnosis can only be established at autopsy. Over time the brain shrinks 
(Fig. 2A) and the histological findings that Alois Alzheimer reported nearly 100 years 
ago become manifested: extracellular Aβ plaques and intracellular NFT composed of 
the hyperphosphorylated microtubule-associated tau-protein (Fig. 2B and C).  
 
Figure 2. Imaging atrophy and 
aggregates in AD. (A) Decreased brain 
volume of an AD patient (left) as 
compared to a healthy control person 
(right), visualized by positron emission 
tomography imaging [Courtesy of Alfred 
Pasieka, Science Photo Library, Photo 
Researchers, Inc.] (B) Stainings of Aβ 
plaques in the cortex of an AD patient 
(left). At higher magnification the plaque 
core appeared built-up by amyloid fibrils 
and accompanied by dystrophic neurons 
(right). (C) Within the cell body of 
dystrophic neurons, NFT are visualized 
with silver-staining (left). Pictures taken 
by electron microscopy (EM) reveal that 
NFT are composed of tau-protein that is 
assembled into paired helical filaments 
(right, pictures are adapted from [6]).  
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Small cleavage products of the amyloid precursor protein (APP) are the main 
components of Aβ plaques. However, neuropathologcial lesions that involve the extra- 
or intracellular cytoplasmic deposition of abnormally folded proteins are not restricted to 
AD. They are shared by most neurodegenerative diseases, e.g. Parkinson disease 
(PD) or Huntington’s disease [7]. These diseases are therefore summarized as 
proteopathies. Controlled aggregation of protein species may serve as cytoprotective 
functions, such as isolating misfolded forms [8] and it may also promote their clearance 
[9]. Therefore, imbalances in the build-up and clearance of Aβ aggregates in the CNS 
are linked to the initiation of AD. This observation led to the amyloid cascade theory 
[10]. The prevailing view is that excessive generation of Aβ is the primary cause of 
neuronal dysfunction. An initiating factor occurs when Aβ monomers undergo a 
conformational change and transform into oligomers, protofibrils or fibrils. Indeed, Aβ 
oligomers block hippocampal long-term potentiation and spatial memory in an AD 
mouse model [11, 12]. The accumulation of multimeric Aβ is concentration-dependent 
and confers toxicity. Metabolism of Aβ by normal physiology is poorly understood. 
Interestingly, a recent study identified the cellular prion protein (PrPC) but not the 
infectious PrPSc conformation as a possible high-affinity cell-surface receptor for Aβ on 
neurons [13]. Thus, the following chapter will focus on the molecular pathways leading 
to Aβ production. 
 
 
APP and the molecular pathways to the self-peptide Aβ 
 
APP is ubiquitously expressed, suggesting a fundamental requirement for its signaling 
in many tissues [14]. Even though its exact function could not be identified yet, APP 
plays a role in blood clotting, transmembrane signal transduction, calcium regulation,
 
neurite outgrowth, cell proliferation as well as cell adhesion [15-19]. Furthermore, APP 
may be involved in the migration of newly differentiated neurons into the developing 
cortex [20]. Recently, APP was identified as a ligand for death receptor 6 which triggers 
neuronal death through caspase 6 [21]. APP belongs to a family of type I membrane 
proteins containing a larger extracellular region, a TM domain and a shorter 
cytoplasmatic tail (Fig. 3). After synthesis in the ER, the glycoprotein is transported to 
the cell surface through the secretory pathway. At this point, the interaction of three 
different secretases leads to either an amyloidogenic (Fig. 3, lower part) or a non-
amyloidogenic processing (Fig. 3, upper part).  
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Figure 3. Proteolytic processing and resulting fragments of APP. Schematic structure 
of APP is shown. The region encoding Aβ is highlighted in red. The main part of APP is 
processed in the non-amyloidogenic pathway (upper part). Note that α-secretase cleaves 
APP within the Aβ domain which precludes the formation of Aβ plaques. In contrast the 
amyloidogenic pathway (lower part) results mainly in the generation of Aβ40 or Aβ42. Both 
tend to aggregate and deposit as senile plaques. Cleavage sides of secretases are 
indicated by straight black arrows. 
 
 
In the Golgi compartment as well as during reinternalization into endosomes, APP       
(amino acids [aa] 1-770) is cleaved by β-secretase (BACE1, β-site cleaving secretase). 
This cleavage results in the release of APPsβ (N-terminus) and in the membrane 
bound C99 (C-terminus) [22-24]. The latter is subsequently cleaved by the protein 
complex γ-secretase, liberating Aβ fragments into the extracellular space [25]. The 
tetrameric enzyme complex γ-secretase is composed of the presenilins (PS) 1 and 2, 
anterior pharynx-defective phenotype-1 and nicastrin [26]. Several available 
therapeutic strategies aim to target γ-secretase activity with to some extent detrimental 
side effects [27]. New achievements identified G protein-coupled receptor 3 as 
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potential target because its expression levels regulate the localization of γ-secretase, 
thereby affecting the regulated intramembrane proteolysis (RIP) of APP [28]. RIP of 
APP results in the generation of different Aβ species, e.g. Aβ40 (aa711), Aβ42 (aa713), 
Aβ43 (aa714) and Aβ49 (aa720). Aβ40 and Aβ42 are the most common forms. Aβ40 has 
been found to be less neurotoxic as the slightly longer Aβ42 fragment and is by itself not 
able to form senile plaques [29]. By contrast, Aβ42 is more prone to aggregate and most 
probably forms the seed of senile plaque formation [30, 31]. Due to its fibrilization 
properties Aβ42 is the dominant species in amyloid-β plaques [32, 33]. The non-
amyloidogenic pathway is committed by α-secretase, which is active in late Golgi, 
transport vesicles and at the cell surface [34-36]. Although α- and β-secretase compete 
for the APP substrate [37], α-secretase generally cleaves APP earlier in cell 
compartments than β-secretase [35]. The α-secretase (ADAM, a disentegrin and 
metalloproteinase 10) cleaves APP into the ectodomain N-terminal APPsα and the 
membrane-associated C83 [38]. Thereby, the sequence of Aβ is destroyed [39]. C83 is 
further processed by γ-secretase, which results in the release of the small p3 peptide. 
The p3 fragment is non-amyloidogenic, due to its smaller size than the larger Aβ 
fragment starting at position 17 of Aβ42. 
 
 
Epidemiology and genetics 
 
The social impact and economic burden of AD is growing rapidly due to increasing 
lifespan and a decreasing ratio of working to retired population in the western societies 
[40]. Indeed, the prevalence is partially due to the fact that aging represents a 
significant risk factor for developing AD [41]. Thus, there is a compelling need for 
treatment and prevention of AD, although a cure is realistically not within sight due to 
the multi-factorial nature of the disease. Despite the normal aging process it is well 
established that genetic risk factors play a major role in the pathogenesis of AD. Two 
different forms of AD are distinguished based on their genetic cause [42]. The first form 
is sporadic AD (SAD) which probably results from the synergistic interactions of 
disease-related genes with an individuals’ lifestyle and additional environmental 
factors. Up to now the apoE4 (apolipoprotein E4) allele is the only identified genetic 
risk-factor for developing SAD [43]. This protein is encoded on chromosome 19 and 
has functional properties in the lipid metabolism [44]. It has been shown that several 
copies of the apoE4 allele exist in SAD patients and may possibly affect Aβ deposition 
and NFT formation [45]. Mutations in three genes that are inherited in an autosomal 
General introduction 
54 
dominant fashion have been linked to the second, rare familial form of AD (FAD). 
These genes include the information encoding APP (chromosome 21), PS1 
(chromosome 14) and PS2 (chromosome 1). Variability of their expression contributes 
to the risk of developing AD before 60 years of age (early-onset AD). Several missense 
mutations have been discovered in APP (Fig. 4) which affect the β- and γ-secretase 
cleavage. However, less than 3 % of these mutations account for early-onset forms of 
AD [46]. The majority of FAD mutations are found in the genes encoding PS1 and PS2. 
More than 175 mutations have been identified. Mutations in PS1 account for 70 % and 
PS2 mutations for 20 % of all FAD cases [47-49]. Individuals with mutations in PS1 
have been shown to develop the most severe forms of AD with a mean age of onset 
that varies between 30-60 years [50]. There are no pathological and clinical symptoms 
that distinguish SAD from FAD [51]. In summary, all of the genetic risk factors of SAD 
and the autosomal dominant mutations of FAD ultimately lead to an overproduction of 
Aβ and its deposition in the CNS. To date the multifactorial etiology of AD makes it 
impossible to predict the disease onset or the severity of dementia. 
 
 
 
 
Figure 4. FAD-linked mutations in APP. Schematic drawing of APP (grey) and Aβ (red). 
The aa sequence of Aβ (straight line divides Aβ40 and Aβ42) is indicated and expanded to its 
flanking sides. The arrows represent cleavage sides of α-, β- and γ-secretase. The TM 
domain is depicted with grey lines (lower part). Several mutations cluster close to the 
cleavage sides of the secretases and the most important aa substitutions are indicated. 
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APP-transgenic mice are only partial models of AD 
 
The rationale for studying AD in a model system is mainly based on the discovery of 
FAD-linked mutations seen in APP, PS1 and PS2. These mutations subsequently 
opened the door for the design of tg mice. Most of them are generated in agreement 
with the amyloid cascade theory. Thus, the overproduction of Aβ triggers a cascade 
which eventually results in neuronal loss, dystrophic neuritis, inflammatory responses, 
learning impairments and deficits of synaptic interactions [10]. The strength of rodent 
models is that they develop AD-like pathology sharing many similarities with humans 
[52, 53]. However, it also points out some weaknesses. Rodent models show only 
features of rare, early-onset FAD and do not resemble the more common late-onset 
form of SAD. Moreover, there are notable differences in the AD pathology seen in 
humans and APP-tg mouse models. Human AD brains exhibit further processing of Aβ 
plaques into a more insoluble state [54, 55] and reveal a higher degree of inflammation 
which is mainly related to the role of the complement system [56]. Since mouse C1q 
poorly recognizes human Aβ deposits, complement activation in tg mice is minimal 
[57]. In human AD, there is full activation of the complement system resulting in 
neuronal destruction by the membrane attack complex [58]. None of the APP-tg strains 
do show neuronal loss and most of them do not exhibit NFT as seen in human AD 
brains. Tg mouse models of tauopathies exist but also mimic only parts of AD 
neurodegeneration [59]. Despite the fact that a large number of AD models have 
independently produced similar data, technical criticisms announce the possibility of 
artifacts due to the overexpresssion of APP with physiologically CNS-irrelevant 
promoters, the possibility of multifaceted transgene silencing and the use of cDNA 
rather than genomic DNA in these mice [60]. Thus, each mouse model has its own 
specific strengths and weaknesses for studying different aspects of neurodegeneration. 
In 1995 the first APP-tg strain was developed by Games and colleagues. This model 
shows extracellular Aβ deposits due to V717F mutated APP expression under control 
of a platelet derived growth factor-promoter [61]. Deficits in memory and learning have 
not yet been reported for this model. In Tg2576 mice AD-like pathology is triggered by 
expressing high amounts of K670N/M671L mutated APP in many cell types using the 
hamster prion protein promoter [62]. Besides Congo red positive Aβ plaques which are 
characteristic of amyloid structures [63], aging Tg2576 mice also develop correlative 
cognitive deficits [64]. APP23 and APPPS1 mice develop amyloidosis due to the same 
APP mutation as used in Tg2576 mice but in both models the expression is under 
control of a neuron-specific Thy 1 promoter element [65, 66]. APPPS1 mice show an 
earlier onset of disease in comparison to the APP23 model due to the coexpression of 
General introduction 
56 
L166P mutated PS1. The latter provokes first cognitive deficits at the age of 24 years in 
humans [67]. Despite the age-related accumulation of Aβ and gliosis, both models also 
show cerebral amyloid angiopathy (CAA). It develops from soluble Aβ that drains from 
the CNS along the cerebral and leptomeningeal microvasculature predisposing blood 
vessels to failure, thus increasing the risk of a hemorrhagic stroke [68]. Recent studies 
even presented models with multiple genetic manipulations. For example, the Tg-SwDI 
triple tg mice express low levels of double Swedish mutations (KM670/671NL), the 
Dutch (E693Q), and the Iowa (D694N) mutations in neurons and therefore shows 
vasculotropic mutant Aβ peptides and microvascular deposits [69]. Even the generation 
of a triple-tg model of AD by introducing KM670/671NL mutated APP and P301L 
mutated tau into the germline of the mutant PS1 knock-in mouse does not recapitulate 
all features of human AD [70]. In summary, AD mice develop pathogenesis to a varying 
degree, depending on the mutation used, the promoter element, the expression levels 
and gender differences. In addition, the integration site or even the murine genetic 
background may influence neuropathology. These differences should be taken into 
account when using mice as preclinical models of human AD. To study the effect of 
immune effector molecules on amyloid-β pathology several immune transgenes or 
immune gene knock-outs were generated in APP-tg mice [71]. It seems that the lack of 
CD4+ T cells retards amyloidosis, whereas the lack of autoAb-producing B cells has no 
effect on the extent of Aβ deposition [71, Lindau et al. unpublished]. Following these 
results some studies addressed the role of IL-12 family members in AD, because these 
cytokines are known to control T cell differentiation and activation. This family of 
cytokines compromises several heterodimeric proteins with pleiotropic activities 
including IL-12 (p35 + p40) and IL-23 (p19 + p40). IL-12 is produced by APC and has 
been shown to play a major role in TH1 differentiation. Interestingly, a decrease in TH1 
immunity caused by ablation of IL-12 seems to affect pathology in AD mice, which is 
currently investigated in detail [Burkhard Becher, University of Zurich, personal 
communication]. Indeed, a detrimental role for TH1 cells was already claimed in AD 
immunotherapy [71]. These results argue for T cell involvement and against a role of 
autoAb in the development of cerebral amyloidosis, but it also suggests caution in 
interpreting results obtained from immunodeficient APP-tg mice. The immune and the 
nervous system utilize many of the same molecules during development (MHCI and its 
subunits, CD3Zeta (ζ), Transporter associated with Ag-processing 1), communication 
(TLR3, TLR7), and genomic organization (recombination activating gene 1). Thus, both 
systems share similar principles of action to achieve specific functions such as 
signaling, migration and homeostasis (as highlighted by a special co-issue from 
Immunity and Neuron [72]). 
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Inflammation in Alzheimer’s disease 
 
Critically, the dialogue between the immune system and the CNS during the course of 
AD is poorly understood. It is well established, that soluble mediators of immunity such 
as chemokines or complement proteins are up-regulated both peripherally and in the 
brain of AD patients [71]. The generation of a pro-inflammatory cytokine milieu at sites 
of Aβ aggregates potentially suppresses neurogenesis thus favoring the cognitive 
decline seen in AD patients [56]. The CNS shows only limited expression of MHC on 
neurons and microglia [73] and is shielded from Ab by the blood-brain barrier (BBB) 
[74]. The capillaries of the CNS form a permeability barrier and are structurally different 
from other tissues. They are lined with a special layer of endothelial cells that lack 
fenestrations and are sealed with tight junctions. This architecture results in a very high 
transendothelial electrical resistance of 1500-2000 Ω x cm2 in the CNS compared with 
3-33 Ω x cm2 in other tissues. Furthermore, astrocyte foot processes surround the 
capillaries, forming a second barrier of the BBB. Thus, only lipophilic molecules that 
can freely diffuse through the capillary endothelial membrane may passively cross the 
BBB. This barrier makes the CNS practically inaccessible to lipophobic, small polar 
molecules or any larger protein. Consequently, a specialized local innate immune 
response has developed to effectively fight infectious agents [75]. In vivo imaging, in 
vitro and post mortem studies have shown that microglia and astrocytes are activated 
in the presence of misfolded proteins [76-78]. Furthermore, the BBB is easily 
penetrated by activated T cells and MΦ. To this end, inflammation is definitively 
present in AD, but little is known about its pathological relevance. 
 
 
Star shaped astrocytes 
 
Under normal conditions astrocytes contribute to CNS homeostasis and provide 
neurons with energy and substrates for neurotransmission. They act as physical 
barriers between the synaptic connections of neighboring neurons, and remove excess 
neurotransmitter molecules from the extracellular space, allowing discrete and precise 
encoding of synaptic signals and neurotransmission. Even more exiting, they seem to 
be involved in the formation of synapses and in modulating synaptic function through 
bidirectional communication with neurons [79]. Surprisingly, they are largely ignored by 
the scientific AD community in contrast to the intensively studied microglia. Not much is 
known about their role during the course of neurodegeneration which is remarkable 
because astrocytes are one of the most numerous cell types in the CNS [80]. 
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Histologically, astrocytes are characterized by expressing glial fibrillary acidic protein 
(GFAP) and, similar to microglia, they are located at sites of Aβ aggregates. Astrocytes 
secrete a set of chemokines such as monocyte chemoattractant protein-1 thus 
contributing to neuronal damage by recruiting phagocytes to Aβ deposits with the 
concomitant release of neurotoxins [81]. Furthermore some studies have shown that 
astrocytes can also degrade amyloid-β plaques [82]. Caspase activity has also been 
seen in astrocytes which leads to cellular degeneration in vitro and may indirectly play 
a role in AD progression [83].  
 
 
Microglia 
 
Microglia cells have been implicated in the pathogenesis of AD and generally are 
regarded as key players during several different proteopathies [84]. These immune 
cells represent 10 % of the cells in the adult CNS [71] and are most commonly 
characterized by the ionized calcium binding adaptor molecule (Iba)-1 which is 
unfortunately not directly related to function and phenotype [85]. Their differentiation 
and activation into different phenotypes is mainly seen by their morphological 
appearance [86]. Parenchymal microglia cells have been classified as BM-derived 
myeloid progenitors which enter the CNS from the peripheral blood circulation early 
during development and become resident APC [87]. These resident phagocytes survey 
the brain for damage and infection, engulfing apoptotic cells and debris [88]. Therefore, 
Aβ may be recognized as Ag which needs to be cleared and thus provokes activation 
of microglia [89]. If microglia fail to clear the Ag, their activation status becomes chronic 
and toxic. This concept is also known as the microglia dysfunction hypothesis [90]. 
Using gene expression profiling from microglia at different time points, it has been 
shown that these cells may fight against the build-up of Aβ plaques at the beginning of 
AD pathogenesis [91]. However, they lose their phagocytotic activity during the course 
of the disease and instead show increased expression of pro-inflammatory cytokines. 
These cytokines compromise IL-1, IL-6, IFN-γ and TNF which have been shown to 
mediate neurotoxicity in vitro [92-94]. In addition, microglia cells are able to secrete 
neurotoxic substances such as ROS and proteases [95]. Thus, the possibility is given 
that microglia may even participate in CAA and neuronal loss. Indeed, EM studies 
actually suggest that early microglial activation is one key factor in promoting 
progression of CAA [96]. Despite, these detrimental properties several studies also 
addressed beneficial functions of microglia. They have been implicated in synaptic 
remodeling during the development of the CNS, removing inappropriate synaptic 
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connections through the process of phagocytosis [97]. It has been shown that microglia 
can express neurotrophic factors like nerve growth factor and brain-derived 
neurotrophic factor. Both of which have been shown to promote neurogenesis in rodent 
and primate models of AD [98]. There is also evidence that even the above mentioned 
pro-inflammatory cytokines possess beneficial brain repairing properties [97]. These 
two opposing functions of microglia dominate lively discussions whether these cells 
may be therapeutically utilized to fight AD. Although, in vitro experiments showed an 
uptake of aggregated Aβ species [99] the histopathology of human brains does not 
support a role for microglia in Aβ clearance [96]. Moreover, evidence that microglia in 
brains of AD mouse model [100] as well as human patients [101] are able to degrade 
and harbor Aβ in their endolysosomal compartments is still missing. To this end, 
intensive research in AD mouse models has been focused on the peripheral 
counterparts of microglia, namely monocytes and CNS-exogenous MΦ. Peripheral 
myelopoesis is faster and more efficient as compared to the generation of brain 
endogenous microglia [102, 103]. Even more interestingly, it has been reported that 
CNS-exogenous MΦ are competent Aβ phagocytes [104]. Blood-derived monocytes 
are able to pass the BBB, settle close to cerebral vessels and Aβ deposits. Genetic 
ablation of these cells increases parenchymal Aβ plaque load in mouse models of AD 
[105, 106]. Furthermore, it has been shown that ablation of TGF-β signaling in CD11c+ 
cells results in accumulation of MΦ in cerebral vessels, CNS penetration of these cells, 
and clearance of Aβ deposits in mice [107]. Data from different proteopathies highlights 
the fact that monocytic phagocytes undergo profound changes in protein synthesis 
permanently, including surface receptors and pro-inflammatory cytokines, especially 
when activated under conditions of acute injury. Thus, microglial activation may be 
understood as a set of responses ranging from a productive (pro-phagocytic and anti-
inflammatory) to a deleterious (anti-phagocytic and pro-inflammatory) phenotype [108]. 
Further support of beneficial microglial phenotypes comes from a study which showed 
that immunization of an AD rodent model with glatiramer acetate (GA, Copaxone) 
induced Aβ clearance, neurogenesis, improved memory and learning [109]. The 
investigators found in GA-treated mice microglia expressing the DC markers MHCII 
and CD11c which produced neuroregenerative insulin-like growth factor-1. This 
revealed a phenotypic shift in contrast to the activated CD11b+ microglia present in the 
PBS-injected control animals. The MHCII+CD11c+ phenotype suggests the ability of 
Ag-presentation and indeed significantly more T cells were associated with Aβ deposits 
and microglia in GA-injected mice than in the untreated state. 
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Aβ-peptide autoimmunity – the role of T cells in AD 
 
The role of lymphocytes, which is observed by autoAg-specific T cells in the CNS 
pathology of MS is not present in AD. However, several studies demonstrate T cell 
entry into the brain of APP-tg mice [109, 110]. Interestingly, T cell surveillance of the 
CNS has been described in the elderly and in AD patients [111, 112]. This is line with 
early reports of T cell brain-tissue entry irrespective of their Ag-specificity [113], but 
only T cells capable of reacting with a CNS-derived Ag seem to remain there [114, 
115]. Within the brain microglia or MΦ may under some conditions react with 
lymphocytes because they are able to present HLA-associated Ag [116] and 
continuously survey the CNS [77]. In addition considerable data exist supporting the 
ability of DC to enter and leave the brain, presenting CNS-derived Ag to prime T cells 
in the periphery [117, 118]. These observations collectively demonstrate that the CNS 
does not escape immune surveillance but induces a tight and selective communication 
with adaptive immunity, being accessible to small numbers of T lymphocytes on a 
continuing basis [119]. During a pathological insult such as neurodegeneration or 
neuroinflammation the data exchange between both systems may be disturbed. The 
overall permeability of the BBB is increased and traffic signals for cell migration are 
altered [120]. Additionally, the expression of adhesion molecules and set of chemokine 
receptors permit the enhanced invasion of lymphocytes in the brain parenchyma [121]. 
Recent results suggested that intracerebral Aβ interacts with RAGE (Receptor for 
advanced glycation endproducts) at the BBB thus up-regulating endothelial expression 
of the chemokine receptor CCR5, thereby causing increased T cell infiltration [122]. In 
general, RAGE is expressed at increased levels in brains of patients with AD. Although 
a pathogenic role for Aβ-specific T cells has not been established in humans or mice, 
the invasion of T cells with unknown specificity in AN1792 (synthetic Aβ42)-immunized 
AD patients illustrates potential consequences [123, 124 and see below]. Analysis of 
brain-infiltrating T cells as well as the peripheral repertoire resembles the memory 
phenotype in vitro and in vivo [125, 126]. Generally memory T cells predominate at 
inflammation sites and respond briskly to recall Ag [127, 128]. Interestingly, individuals 
with AD show an increased expression of the co-stimulatory receptor CD28 in the total 
T cell population [129, Lindau et al. unpublished]. Signaling via CD28 and the T cell 
receptor results mainly in cytokine production to facilitate proliferation and survival but 
also in the prevention of anergy induction [130]. In vitro Aβ-specific T cell responses 
are present in virtually all individuals. The frequency of circulating Aβ-specific TH cells is 
increased in the elderly and individuals with AD and the allele HLA-DRB1*1501 seems 
to play a highly immunogenic role [131, 132]. This is in contrast to studies that 
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generally showed reduced T cell reactivity upon aging [133]. Whether this phenomenon 
has an etiological contribution to the disease or is simply a marker of the CNS damage 
present in AD remains elusive. Recently, it was suggested that homozygosity but not 
heterozygosity for HLA-A2*0201 is associated with an increased risk of SAD 
development [134]. One post mortem case report even demonstrated an increased 
presence of CTL in the brain [135] and was interestingly typed HLA-A2*0201+ [Lindau 
et al. unpublished]. The increased amount of CTL in the brain of AD patients is also 
commonly seen in other CNS-inflammatory diseases [136-138]. Aβ-derived CTL 
epitopes were identified and human Aβ-specific CTL visualized ex vivo showed 
neurotoxicity in vitro [Lindau et al. unpublished]. However, detrimental properties of 
autoreactive Aβ-specific T cells might be silenced in vivo due to an increased activity of 
TREG observed in AD patients [139]. It has been shown that neurons possess immune-
regulatory properties by mediating T cell apoptosis [140] or even activate TREG in 
response to inflammation to suppress autoreactive T lymphocytes which mediate 
neurodegeneration [141]. In addition, one has to take into account that reactions may 
change over time and switch from damaging properties to a mode that promotes tissue 
repair [142-144]. T cells can play a role in neuroregeneration [145]. Studies using 
models of optic nerve or spinal cord crush have shown that CNS-Ag-specific T cells are 
involved in reorganization and regeneration after CNS trauma [146]. Furthermore, T 
cells are known to produce neurotrophic factors that could prevent CNS tissue from 
secondary degeneration [147]. Whether a comparable regenerative potential also holds 
true for AD is unknown. However, first studies suggested a possible beneficial role for 
CNS-infiltrating T cells because nasal Aβ-peptide and GA-administration into APP-tg 
mice prevented Aβ deposition [148].  
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Immunotherapeutical strategies in AD 
 
Studies in APP-tg mouse models have placed attention on the clearance effect 
associated with Aβ vaccination as being a possible disease-modifying strategy. 
Immunization has been shown to reduce amyloid burden in AD mouse models both 
actively and passively, using synthetic Aβ42 or small fragments of it and through the 
peripheral administration of anti-Aβ Ab, respectively [149, 150]. Some data also 
suggest that stimulation of innate immunity using CpG-ODN is highly effective at 
reducing the Aβ plaque burden [151]. However, it has been shown that microglia 
expressing TLR9 and responding to CpG-motifs in vitro mediate neuronal injury [152]. 
Thus, the amyloid clearing effect associated with this strategy has been confirmed by 
several experiments, but the exact mechanism remains speculative. Three 
mechanisms have been postulated to explain how Aβ deposits are reduced in the CNS: 
(1) One hypothesis suggests that the Ab may bind directly to Aβ. This effect could lead 
to FcR-mediated phagocytosis of Aβ by microglia. However, successful reduction of Aβ 
in APP-tg mice deficient in FcR argues that other mechanisms besides FcR-mediated 
phagocytosis exist. (2) In this regard, some scientists favor the idea that Ab themselves 
react as Aβ disaggregating agents by preventing the formation of plaques. Consistent 
with these thoughts, directly injected Ab into the CNS decrease Aβ deposits. (3) In the 
last scenario, Ab are thought more directly to initiate a peripheral sequestration of Aβ 
into the plasma (peripheral sink hypothesis). These proposed mechanisms are not 
mutually exclusive; the Aβ clearance is likely to involve a combination of processes 
[153-155]. The finding that active Aβ immunization markedly reduced the amyloid 
plaque load in an animal model without any obvious side effects led to a randomized 
placebo-controlled double-blinded Phase II clinical trial [156]. In 2002 Elan 
Pharmaceuticals, Inc. halted the AN1792 trial prematurely because 6 % of the treated 
subjects developed encephalitis (Fig. 5A). The cause of inflammation remains 
controversial but was most likely induced by the massive infiltration of T cells into the 
CNS (Fig. 5B-D) [123, 135]. Although the trail was interrupted, cognitive analyses and 
biomarker testing revealed that Aβ immunotherapy had a positive clinical impact on AD 
[124]. Post mortem analysis revealed a reduction in the amyloid plaque load associated 
with gliosis, which might be connected to clearing mechanisms, but the NFT remained 
unchanged [123]. Investigations into the cause of the meningoencephalitis support the 
view that the full-length Aβ42 that was used in the trial induced the generation of a T cell 
response. However, it has also been suggested that the increased Ab levels, found in 
immunized subjects, induced damage to the microvasculature and consequently led to 
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the massive T cell influx from the periphery [157]. In support of this, Ab administration 
can lead to an autoAb response. This could facilitate the formation of serum IC which 
generates vasculitis and microhemorrhage upon deposition at the blood vessel wall as 
observed in other chronic disorders such as SLE. Nevertheless, the anti-Aβ vaccination 
trial seems to have promise at clearing Aβ and behavioral stabilization [123, 124]. To 
circumvent possible side-effects alternative immunization strategies using the 
immunomodulatory drug GA (Teva Pharmaceutical Industries Ltd.) are currently being 
investigated [148]. But how and whether immunization will influence the functions of 
already destroyed neuronal circuits remains to be elucidated. The most optimistic view 
is that it will stop disease progression, and that brain plasticity mechanisms will allow 
some recovery over time. 
 
 
 
 
Figure 5. Post mortem analysis of encephalitis in AN1792 treated AD patients. (A) 
Meningoencephalitis is indicated by the black arrow in the white matter. (B) T cell infiltrates 
showed a mixed population of CD4+ and CD8+ T cells in one subject, whereas (C) a 
different patient revealed mainly CTL infiltrates into the brain. (D) CTL surrounding a 
protein aggregate within the CNS (Pictures are adapted from [122] and [135]). 
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Abstract 
 
The nucleosome is a major autoAg known to activate PMN in SLE. TLR9 recognizes 
bacterial and even mammalian DNA under certain circumstances. Nevertheless, the 
role of TLR9 in SLE development is still unclear. Since nucleosomes are partly 
composed of DNA, we investigated whether TLR9 is required for nucleosome-induced 
PMN activation. Neutrophils were isolated from human blood and mouse BM. Cells 
were cultured with purified nucleosomes, lupus plasmas and other stimuli in the 
presence/absence of various inhibitors. Cell activation was estimated by flow cytometry 
and ELISA. TLR9 expression and nucleosome endocytosis were measured by flow 
cytometry and confocal microscopy. We found that nucleosomes circulating in lupus 
plasmas induce the secretion of pro-inflammatory cytokines by PMN. Nucleosomes 
activate human PMN independently of the presence of unmethylated CpG sequences 
in nucleosomal DNA, leading to IL-8, IL-6 and TNF secretion and CD11b up-regulation. 
Nucleosomes accumulate in the cytoplasm of PMN upon endocytosis but do not reach 
the nucleus. Nucleosome-induced activation was not inhibited by polymyxin B (PB), 
chloroquine (CQ), ammonium chloride (AC) or a TLR9 antagonist. Moreover, both PMN 
isolated from wild-type (WT) and TLR9-deficient mice were activated by nucleosomes, 
as detected by MIP-2 secretion and CD11b up-regulation. Activation occurred thus 
independently of endotoxins, endosomal acidification and TLR9. Although TLR9 is not 
required for nucleosome-mediated PMN activation, nucleosomes induced the up-
regulation of TLR9 in part of the donors. TLR9 may thus be differently required in the 
triggering of nucleosome-induced innate immunity and anti-nucleosome B-cell 
autoimmunity. 
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Introduction 
 
SLE is a rheumatic autoimmune disease. It is a systemic inflammatory disease 
characterized by the production of numerous autoAb. Upon binding to their target 
autoAg, the resulting IC deposit into tissues causing inflammation and damages. 
Nevertheless, the etiology of the disease is still unknown. The nucleosome is a major 
lupus autoAg composed of 180 bp DNA, one molecule of histone H1 and two copies of 
histones H2A, H2B, H3 and H4. Circulating nucleosomes are present in the blood of 
lupus patients [1] and increased concentrations are associated with the development of 
nervous and renal manifestations [2]. Nucleosome-restricted autoAb [3] and 
nucleosome-specific autoreactive TH lymphocytes [4] are also observed in SLE patients 
and the former strongly correlate with disease activity scores [5]. It is therefore believed 
that circulating nucleosomes trigger the production of anti-nucleosome, anti-histone 
and anti-dsDNA autoAb (a disease marker in SLE). Nucleosomes are thus a key lupus 
autoAg, although the exact mechanisms leading to anti-nucleosome autoimmunity are 
not completely elucidated. PMN are the first cells recruited at inflammation sites. Upon 
inappropriate activation, PMN-derived reactive species may induce tissue damages 
and may alter self-Ag, transforming a harmless self-Ag in a potent autoAg. PMN are 
activated in SLE patients [6, 7], especially during active disease, and secrete IL-8, the 
concentration of which correlates to disease activity [8]. Importantly, PMN have been 
suggested to link the innate and adaptive immunity by influencing e.g. DC [9-11]. PMN 
activation may thus favor adaptive immunity. Beside the expected activation of 
nucleosome-specific autoreactive B cells via BCR engagement, free nucleosomes 
induce IL-6 secretion by mouse spleen cells [12], affect glomerular mesangial cell 
function [13], induce necrosis-like cell death in lymphocytes [14] and trigger DC 
activation [15]. Those results suggest that circulating nucleosomes are not only passive 
targets for autoAb but might be pathogenic. Nevertheless, the impact of TLR 9 in those 
situations is not known. TLR9 is activated in endosomal/lysosomal compartments by 
unmethylated CpG motifs present in pathogen-derived DNA [16]. Nevertheless, 
vertebrate DNA can also trigger TLR9 under certain circumstances although TLR9-
independent pathways are triggered in addition [17]. Moreover, natural phosphodiester 
ODN lacking CpG motifs activate TLR9 upon enforced endosomal translocation [18]. 
Thus, intracellular localization of TLR9 is important to prevent activation by host-
derived DNA [19]. Nevertheless, it is unknown whether TLR9 recognizes free 
nucleosomes and whether nucleosome-induced cell activation requires TLR9. The role 
played by TLR9 during SLE development is still not elucidated. TLR9 is required for 
anti-nucleosome autoAb production whereas titers of autoAb against dsDNA are 
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increased in TLR9-deficient animals [20]. Moreover, TLR9 is necessary for the class 
switching to pathogenic autoAb isotypes in lupus mouse models [21]. On the contrary, 
disease induction was enhanced in different TLR9-deficient mouse models and TLR9 
was suggested to protect against lupus [22-24]. DNA-reactive B cells are stimulated by 
CpG-rich DNA fragments and the stimulation is abolished by inhibitors of the TLR9 
signaling pathway, whereas non-DNA-reactive autoimmune B cells are not activated by 
those fragments [25]. The data indicate that both TLR9 and the BCR are required and 
this mechanism might apply to B lymphocytes specific for DNA-binding proteins. 
However, the recognition of free nucleosomes by TLR9 has not been investigated in 
detail. On the contrary, some groups focused on nucleosome-containing IC but did not 
analyze PMN. In contrast, we analyzed the direct effects of free nucleosomes and 
found that nucleosomes activate DC in a partly MyD88-independent manner [15], 
suggesting the existence of a TLR9-independent pathway without excluding a second 
TLR9-dependent pathway. Interestingly, the accumulation of endogenous apoptotic 
DNA escaping lysosomal degradation activates a TLR9-independent innate immune 
response in vivo [26]. Although the contribution of TLR9 in SLE development has been 
investigated, the impact of TLR9 triggering in PMN in the context of SLE is unknown. 
PMN express TLR9 and respond to TLR9 ligands [27] but not to mammalian DNA [28]. 
We have shown that circulating nucleosomes activate and recruit PMN in vitro/in vivo in 
a HMGB1-independent manner in the absence of anti-chromatin Ab [29]. Since 
nucleosomes are partly composed of DNA and because TLR9 is able to recognize 
mammalian DNA and even self-DNA when DNA has access to TLR9 [19], we 
investigated whether TLR9 is required for chromatin-induced PMN activation in SLE. 
Indeed, TLR9 recognition of DNA in nucleosomes may differ from that of isolated DNA. 
Likewise, TLR9 might be differentially required for nucleosome-induced activation in B 
lymphocytes and PMN. We show here that nucleosomes activate PMN independently 
of TLR9 and endosomal acidification. Our results highlight the importance of the innate 
immune system and TLR9-independent pathways in SLE development. 
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Materials and Methods 
 
Mice. C57BL/6 mice were purchased from Charles River. C57BL/6-TLR9-KO mice 
(described in [16]) were obtained from Prof. H. Wagner (Munich, Germany). 
Experiments were approved by the local animal ethics committee 
(Regierungspräsidium Tübingen, § 4 Abs. 3). 
 
Human samples. Heparin-blood from random, healthy individuals and SLE patients 
were used. Lupus blood was kindly provided by Prof. I. Kötter (Tübingen, Germany) 
after receiving the informed consent of the donors. Patients fulfilled the American 
College of Rheumatology criteria. The patient characteristics are presented in Table I. 
Human experiments were approved by the local ethics committee (reference 
146/2001V). 
 
Nucleosome purification. Mononucleosomes were purified from calf thymus under 
sterile conditions by ultracentrifugation onto sucrose gradients as described previously 
[30]. As a control, an empty gradient (not loaded with chromatin) was prepared. DNA 
and protein contents were verified. We could previously demonstrate that purified 
nucleosomes do not contain detectable amounts of HMGB1 and that nucleosome-
induced PMN activation occurs in a HMGB1-independent manner [29]. For cell surface 
binding/endocytosis analysis, nucleosomes were dialyzed against phosphate buffered 
saline (PBS) and conjugated to fluorescein isothiocyanate (FITC) as previously 
described [14]. Importantly, histones are among the most conserved proteins. For 
instance, there is no difference in protein sequence between histone H4 from calf, 
human and mouse. The level of endotoxins was low (10-50 IU/mg nucleosomes) as 
determined using a Limulus Amebocyte Lysate assay (BioWhittaker). The same 
endotoxin concentration (in IU/ml) was measured in purified nucleosomes and in the 
purification buffer (empty gradient, Gdt) which was used as a negative control. 
Moreover, nucleosome preparations were always first tested using PMN cultured with 
and without the LPS inhibitor PB and only preparations which activate PMN without 
being inhibited by PB were used. 
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Cell isolation and culture. Human PMN were isolated from heparinized peripheral 
blood by density centrifugation as described previously [29]. Mouse neutrophils were 
isolated from BM cells obtained from adult WT and TLR9-KO mice. Neutrophils were 
enriched by positive selection for Ly-6G+ cells using magnetic beads (Miltenyi Biotec). 
Purity of the cell preparations was analyzed by flow cytometry. Human (defined as 
CD3-, CD19-, CD56-, CD11b+, CD66b+ cells, purity > 85 %) and mouse PMN (defined 
as SSChigh, F4/80-, CD3-, B220-, CD11b+, Ly-6Ghigh cells, purity > 90 %) were cultured 
in RPMI (Roswell Park Memorial Institute) 1640 medium (BioWhittaker) supplemented 
with 10 % fetal calf serum (FCS, from PAA), 100 U/ml penicillin, 100 mg/ml 
streptomycin (both from Gibco) and 50 µM (β-mercaptoethanol (Roth). Granulocyte 
colony-stimulating factor (50 ng/ml, ImmunoTools) was added to mouse PMN. Cells   
(1-1.5 x 106 cells/ml) were incubated in medium alone or activated with purified 
nucleosomes, the purification buffer as negative control (Gdt), R848 (Alexis), LPS (from 
Salmonella typhimurium or Escherichia coli, Sigma), CpG-motif-containing ODN (CpG-
ODN, 2006 or 1826, Metabion) and GpC-ODN (2006, Metabion). Human PMN were 
pre-incubated in the presence/absence of PB (25 µg/ml, Fluka), CQ (5 µg/ml, Sigma), 
AC (10 mM, Roth) or a TLR9 antagonist (an ODN containing a G5 motif (G-ODN),        
4 µM, Metabion). After 16 h, cell culture supernatants were harvested and cells were 
analyzed by flow cytometry. In some experiments, human PMN were cultured in the 
presence of 25 % plasma. In parallel, the experiment was performed in the absence of 
PMN. In a second set of experiments, human plasmas were first depleted from 
nucleosomes. Thus, cell culture plates were coated with 5 µg/ml of a nucleosome-
binding mAb (Chemicon) or a mouse IgG1 or PBS only overnight at 4 °C (in 100 
µl/well). Plates were then washed three times with PBS and incubated with 50 µl/well 
undiluted plasma for 4 h at room temperature (RT, plate 1). Freshly isolated PMN were 
cultured in another cell culture plate in 150 µl/well medium and the 50 µl plasma from 
plate 1 were transferred and added to PMN to reach a medium containing 25 % 
plasma. After 16 h, cell activation was estimated by measuring IL-8 secretion. 
Peripheral blood mononuclear cells (PBMC) were prepared from buffy-coats (blood 
bank, Tübingen, Germany) by density centrifugation through Ficoll (PAA). Human 
monocyte-derived DC were obtained from plastic-adherent PBMC cultured in the 
presence of granulocyte/macrophage colony-stimulating factor (Sandoz) and IL-4 
(R&D) for 7 days as described previously [31]. 
 
Results and discussion 
77 
Flow cytometry. PMN were first incubated with PBS/5 % heat-inactivated human 
serum or PBS/2 % heat-inactivated mouse serum and then stained with specific mAb 
or the corresponding isotype controls. mAb used were anti-human Peridinin Chlorophyll 
Protein Complex (PercP)-conjugated CD3, Phycoerythrin (PE)-conjugated CD11b, 
Allophycocyanin (APC)-conjugated CD19, CD56-PE and CD66b-FITC (all from BD 
Pharmingen) and anti-mouse Ly-6G-FITC, CD11b-PE, B220-PE (all from BD 
Pharmingen), F4/80-APC (eBioscience) and CD3-FITC (SouthernBiotech). Dead cells 
were excluded by 7-amino-actinomycin D (Pharmingen) staining. For intracellular TLR9 
staining, PMN were first stained for surface markers, permeabilized with 
Cytofix/Cytoperm (BD Pharmingen) and incubated with anti-TLR9-FITC (Abcam) and 
then anti-FITC-Alexa Fluor 488 (Invitrogen) in saponin-buffer (0.1 %, Sigma). Cells 
were finally fixed (1 % paraformaldehyde) and analyzed on a FACSCalibur apparatus 
with CELLQuest software (Becton Dickinson). To analyze nucleosome cell surface 
binding and endocytosis, 106 cells/ml were incubated with or without 10 µM FITC-
conjugated nucleosomes (FITC-nucleosomes) on ice (to detect cell surface binding) or 
at 37 °C (to measure binding and endocytosis) in 10 % FCS-containing PBS for 30 
minutes (min). Cells were then washed, incubated in the presence/absence of 0.1 % 
(PMN) or 0.4 % trypan blue to quench the extracellular FITC fluorescence or propidium 
iodide to exclude dead cells and immediately analyzed by flow cytometry. To confirm 
the inhibition of extracellular fluorescence, cells were stained with an anti-CD66b-FITC 
(PMN) or an anti-HLA-DR-FITC (BD Pharmingen) mAb. Monocytes were gated upon 
staining with an anti-CD14-PE mAb (BD Pharmingen). 
 
Confocal microscopy. To analyze nucleosome endocytosis, 200,000 cells were 
incubated with 30 µM FITC-nucleosomes together with another fluorophore-labelled 
reagent. Cells were incubated at RT and live cell imaging was performed immediately 
using an inverted LSM510 confocal laser scanning microscope (Carl Zeiss) fitted with a 
Plan-Apochromat 63x/1.4 OIL DIC objective. The pinhole was set to scan layers of 1 
µm. To study macropinocytosis, 10 µM Alexa Fluor 647-conjugated dextran (Molecular 
Probes) was used as a marker. Phagocytosis was estimated using crimson red 
fluorescent carboxylate-modified microspheres (1/2,500,000, 0.02 µm in diameter, 
Molecular Probes). To stain the nucleus, cells were first incubated with FITC-
nucleosomes and then fixed, permeabilized and incubated with TO-PRO-3 (1/1,000, 
Molecular Probes) for 15 minutes (min) at RT. For the simultaneous detection of FITC-
nucleosomes and fluorophore-conjugated markers, the 488 nm line of an argon ion 
laser and the light of a 633 nm helium neon laser were used. The fluorescence was 
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detected using a BP505-530 band pass filter for the FITC detection and LP650 long 
pass filter for the detection of fluorescent markers. 
 
ELISA. Cytokine secretion by PMN was analyzed by sandwich ELISA using mAb pairs 
and streptavidin-peroxidase conjugate from BD Pharmingen or R&D Systems according 
to the manufacturer’s instructions. Cytokine concentrations in supernatants are 
depicted as mean ± standard deviation of triplicates. 
 
Statistical analysis. The mean IL-8 concentrations induced in PMN by either SLE or 
normal plasmas were compared using a Mann-Whitney rank sum test. Correlations 
between the capacity of SLE plasmas to induce IL-8 secretion in normal PMN and the 
doses of therapeutic agents received by lupus patients were determined using 
Spearman correlation test. The Spearman correlation coefficient (R) and the probability 
(p) are reported. The SigmaStat software was used in all cases. P values < 0.05 were 
considered significant. 
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Results 
 
 
Plasmas from SLE patients activate PMN in a nucleosome-dependent 
manner 
 
We have previously shown that purified nucleosomes activate human PMN, leading to 
IL-8 secretion and CD11b up-regulation [29]. Activation occurs independently of 
HMGB1 and independently of autoAb, indicating that HMGB1-nucleosome complexes 
or nucleosome-containing immune complexes are not required. Sera from SLE patients 
with active disease have been shown to activate PMN [32]. To support a role of 
nucleosomes in neutrophil activation in patients, PMN isolated from healthy individuals 
were cultured in the presence/absence of plasmas prepared from healthy individuals or 
SLE patients. IL-8 secretion was measured by ELISA in order to screen for lupus 
plasmas having a PMN stimulatory activity. Among the eleven lupus plasmas tested, 
nine significantly stimulated PMN (Fig. 1A) whereas autologous plasmas or plasmas 
from unrelated healthy donors did not (mean IL-8 concentration = 0.46 ng/ml [SLE 
plasmas] and 0.04 ng/ml [normal plasmas]; p = 0.005). LPS was used as a positive 
control for PMN activation. Importantly, IL-8 was specifically secreted upon incubation 
of PMN with SLE plasmas as IL-8 was not detected when plasmas were incubated in 
the absence of PMN. To prove that PMN activation was mediated by circulating 
nucleosomes, we next measured PMN activation by SLE plasmas which were first 
depleted from circulating nucleosomes using a nucleosome-specific mAb or the 
corresponding isotype control bound onto a solid phase. Using the most potent 
stimulatory plasmas, IL-8 induction was not affected when plasmas were first treated 
with mouse IgG1 (Fig. 1B). On the contrary, upon depletion of nucleosomes from SLE 
plasmas IL-8 induction was completely inhibited in three samples and partially inhibited 
in two samples. Those results indicate that nucleosomes in SLE plasmas were involved 
in PMN activation in all the strong stimulatory samples tested. Circulating nucleosomes 
were either the main stimulatory activity in some patients or one of the IL-8 inducers 
among others. No IL-8 secretion was detected with autologous plasma, the mAb alone 
or the isotype control alone. Interestingly, a statistically significant negative correlation 
was observed in lupus patients between the capacity of SLE plasmas to induce IL-8 
secretion in normal PMN and the doses of therapeutic agents received by those 
patients (Fig. S1). All those results suggest that circulating nucleosomes activate PMN 
in vivo in patients and that untreated patients display a high stimulatory capacity which 
is down-regulated by the therapy. 
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Figure 1. Nucleosomes in SLE plasmas induce the secretion of pro-inflammatory 
cytokines by human neutrophils. (A) Normal PMN were cultured in the presence of 
plasma (autologous or prepared from healthy donors (HC, n = 5) or SLE patients (n = 11)). 
Each number represents an independent blood donor. IL-8 concentrations were determined 
by ELISA. To exclude that the IL-8 detected comes from the plasmas and not from PMN 
activated in the cell culture, the experiment was performed in the absence of PMN (without 
cells). (B) Lupus plasmas were first depleted from circulating nucleosomes using a 
nucleosome-binding mAb or mouse IgG1 as a control, and then used to activate PMN as 
described in A. The absence of side effects from the mAb or the corresponding isotype 
control in the absence of plasma was also verified. (C) PMN were cultured in the presence 
of purified nucleosomes or TLR ligands and the concentrations of IL-6, IL-8, TNF and IFN-γ 
in the cell culture supernatants were measured. The data are from three independent 
experiments using PMN isolated from three independent donors. Med, medium; Gdt, buffer 
used during the nucleosome purification; Nuc, nucleosomes. LPS was from Salmonella 
typhimurium. The CpG-ODN 2006 was used. Standard deviations are shown. 
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Nucleosomes stimulate PMN to secrete IL-8, IL-6 and TNF 
 
We have previously described that PMN isolated from healthy donors as well as SLE 
patients are activated by nucleosomes [29]. We then extended those results and 
analyzed the cytokine secretion profile of human PMN activated by nucleosomes in 
more detail. Nucleosomes not only induce IL-8 secretion by PMN but also IL-6 and 
TNF secretion (Fig. 1C), although to a lesser extent. Nucleosome-induced PMN 
activation did not lead to IFN-γ secretion and the lack of IFN-γ secretion upon activation 
was observed in response to all stimuli tested. Interestingly, IL-6 and TNF secretion 
was usually stronger upon stimulation with nucleosomes than with CpG-ODN. Thus, 
nucleosomes induced the secretion of several pro-inflammatory cytokines known to be 
present at higher concentrations in patient sera as compared to healthy individuals. 
 
 
Nucleosome-induced PMN activation is not inhibited by a TLR9 antagonist 
 
To determine whether TLR9 was required in human PMN for nucleosome-induced 
activation, we first measured the level of PMN activation in the presence/absence of a 
TLR9 antagonist or PB as a control to exclude the presence of endotoxins (Fig. 2A and 
B). Nucleosomes induced a clear concentration-dependent CD11b up-regulation 
starting at 2.5 µg/ml nucleosomes (PMN cultured in medium only) which was not 
inhibited by PB or G-ODN. No activation was observed with the nucleosome 
purification buffer alone. As expected, LPS-induced CD11b up-regulation was inhibited 
by PB but not G-ODN, excluding the presence of endotoxins in the nucleosome 
preparation. As a control, activation with the TLR7/8 ligand R848 was not inhibited by 
PB or G-ODN. Importantly, CpG-ODN induced PMN activation, which was completely 
inhibited in the presence of G-ODN but not PB. Moreover, the same ODN with GpC 
motifs instead of CpG was unable to activate PMN. Our results indicate that CD11b up-
regulation by ODN 2006 is CpG-motif-dependent and probably requires TLR9. On the 
contrary, those results indicate that the presence of CpG motifs in nucleosomes is not 
necessary for PMN activation and suggest that nucleosome-induced activation occurs 
in a TLR9-independent manner. Staining with the isotype control was not modified 
upon cell activation, excluding unspecific binding of the mAb. PMN activation was 
confirmed by measuring IL-8 secretion. Again, nucleosome-induced IL-8 secretion was 
not inhibited by PB or G-ODN whereas CpG-ODN-induced activation was completely 
inhibited by G-ODN and GpC-ODN did not activate PMN (Fig. 2C), supporting the 
involvement of a CpG-independent, TLR9-independent pathway in nucleosome-
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induced PMN activation. Similar results were obtained when IL-6 and TNF secretion 
was measured (Fig. 2D), although higher concentrations of nucleosomes were usually 
required to stimulate the production of those cytokines. Moreover, nucleosomes were 
often a more potent inducer of those two cytokines compared to CpG-ODN, which 
suggests that nucleosomes and CpG-ODN are recognized by different mechanisms. 
 
 
 
 
Figure 2. Nucleosome-induced PMN activation is not inhibited by a TLR9 antagonist. 
Freshly isolated PMN were pre-incubated in the absence (medium) or presence of 
polymyxin B (PB) or a TLR9 antagonist (G-ODN) and were then cultured for 16 h with 
purified nucleosomes or other stimuli. Cell culture supernatants were harvested and cells 
were analyzed by flow cytometry for CD11b expression (A, B). (A) Representative flow 
cytometry histograms showing CD11b expression and isotype control staining are depicted. 
(B) CD11b expression and unspecific staining for all the stimuli tested are presented. Cell 
activation was also estimated by measuring the secretion of IL-8 (C) as well as IL-6 or TNF 
(D) by ELISA. Med, medium; Gdt, buffer used during the nucleosome purification; Nuc, 
nucleosomes; MFI, mean fluorescence intensity. Data presented are representative of at 
least five independent experiments. 
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Nucleosome-induced PMN activation occurs independently of endosomal 
acidification 
 
To support a TLR9-independent pathway in PMN activation, we then investigated 
whether endosomal acidification was required during activation with nucleosomes. 
PMN were cultured in the presence/absence of PB, AC, CQ, or both PB and AC or PB 
and CQ and cell activation was determined. AC and CQ (another anti-malarial drug 
used in SLE therapy) are indeed known to inhibit endosomal acidification, which is 
required to trigger TLR9.  
 
 
 
 
Figure 3. Nucleosome-induced PMN activation occurs independently of endosomal 
acidification. PMN were pre-incubated in the absence (Medium) or presence of polymyxin 
B (PB), ammonium chloride (AC), chloroquine (CQ), PB and AC, PB and CQ. Cells were 
then incubated for 16 h with purified nucleosomes or other stimuli and PMN activation was 
estimated by flow cytometry for CD11b expression (A) and by ELISA to estimate cytokine 
secretion (B). Data are representative of at least five independent experiments. See figure 
2 for abbreviations. 
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Nucleosome-induced CD11b up-regulation (medium control) was not inhibited in the 
presence of PB, AC, CQ, PB with AC or PB with CQ (Fig. 3A). PMN activation with 
CpG-ODN and R848 was abolished in the presence of AC or CQ. As a control, LPS 
was inhibited by PB and GpC-ODN did not activate. Importantly, all the stimuli except 
nucleosomes were inhibited by PB with AC and PB with CQ, indicating that 
nucleosome-induced PMN activation did not require endosomal acidification. Those 
results were confirmed by measuring cytokine secretion upon activation. Nucleosomes 
induced IL-8 secretion by PMN (medium control), which was not decreased by PB or 
inhibitors of endosomal acidification, in combination or not with PB (Fig. 3B, right). In 
contrast, activation with CpG-ODN or R848 was completely inhibited by AC or CQ. 
Likewise, LPS was completely inhibited by PB. Again, all the stimuli except 
nucleosomes were inhibited by AC plus PB or CQ plus PB, confirming that endosomal 
acidification was not required for nucleosome-induced activation. Similar results were 
obtained when IL-6 secretion was measured (Fig. 3B, left). Cell activation with R848, 
but not with nucleosomes, was completely inhibited in the presence of AC or CQ. 
 
 
TLR9 is not required for nucleosome-induced PMN activation 
 
To confirm the existence of a TLR9-independent pathway in nucleosome-induced PMN 
activation, neutrophils were isolated by positive selection from the BM of WT or TLR9-
KO mice and compared. The online supplemental figure S2 shows the yield of 
enrichment, a typical flow cytometry analysis and a representative activation of WT 
PMN. Cell activation was estimated by CD11b expression (by Ly-6GhighSSChigh cells, 
i.e. PMN) and MIP-2 secretion. Nucleosomes as well as LPS induced CD11b up-
regulation and MIP-2 secretion in both WT and TLR9-deficient PMN (Fig. 4). On the 
contrary, CpG-ODN only activated WT PMN, confirming that nucleosome-induced PMN 
activation occurs in a TLR9-independent manner and that nucleosomes and CpG-ODN 
trigger different pathways in PMN. The fact that TLR9 is not required in nucleosome-
induced PMN activation was confirmed in a human system using 293T cells transfected 
with a vector coding for human TLR9. 293T-TLR9 transfectants were activated by 
CpG-ODN 2006 but not by nucleosomes, whereas 293T-mock transfectants were 
unresponsive to stimulation (Fig. S3, left panel and data not shown). As a control, 
mouse DC were activated using the same nucleosome preparation, as estimated by  
IL-12 secretion (Fig. S3, right panel). 
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Figure 4. TLR9 is not required for 
nucleosome-induced PMN activation. BM 
neutrophils were prepared from WT and TLR9-
KO mice and their sensitivity towards activation 
with purified nucleosomes or TLR ligands was 
compared. PMN activation was estimated by 
flow cytometry (CD11b expression, upper 
panel) and ELISA (MIP-2 secretion, lower 
panel). Two mice were pooled per group and 
per experiment. Data are from four 
independent experiments. See figure 2 for 
abbreviations. LPS was from Escherichia coli. 
The CpG-ODN 1826 was used. 
 
 
PMN activation with nucleosomes induces TLR9 up-regulation in part of 
the donors 
 
Although TLR9 was not required in PMN for nucleosome-mediated activation, we 
analyzed whether nucleosomes may modulate TLR9 expression upon cell activation. 
PMN were isolated from healthy donors and untouched cells were stained for CD66b 
and CD11b to estimate the quality of the preparation by flow cytometry. Figure 5A 
(upper panel) shows the phenotype of PMN. All the cells gated according to FSC/SSC 
parameters were homogeneously and strongly CD66b-positive, excluding the presence 
of contaminating cells, and expressed moderate CD11b levels, confirming that the 
gated cells were non-activated PMN. Cells were then incubated with different stimuli, 
stained for CD11b surface expression and intracellular TLR9 expression and analyzed 
by flow cytometry. PMN cultured in medium alone express TLR9 (Fig. 5A, middle 
panel) and TLR9 was up-regulated upon activation by CpG-ODN as well as 
nucleosomes, cell activation being confirmed by the concomitant CD11b up-regulation 
(Fig. 5A, lower panel). Activation with LPS or R848 also led to TLR9 up-regulation, 
confirming that non-TLR9 ligands may also modulate TLR9 expression (Fig. 5B). As 
expected, TLR9 up-regulation was not observed in the presence of GpC-ODN. We 
then analyzed TLR9 expression by PMN from several healthy donors upon activation 
by nucleosomes in more detail. Interestingly, some donors up-regulated TLR9 in a 
dose-dependent manner upon nucleosome-induced activation (Fig. 5C, upper panel), 
whereas in a second group of donors nucleosome-induced PMN activation did not lead 
to TLR9 modulation (Fig. 5C, lower panel). 
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Figure 5. Nucleosome-activated PMN up-regulate TLR9. (A) Freshly isolated normal 
PMN were first analyzed by flow cytometry for CD66b and CD11b expression to exclude 
the presence of contaminating cells (upper panel). Cells were then cultured for 16 h in 
medium alone (middle panel) or medium supplemented with CpG-ODN or purified 
nucleosomes (lower panel). PMN were harvested, stained for surface CD11b and 
intracellular TLR9 expression with specific mAb or the corresponding isotype controls and 
analyzed by flow cytometry. (B) PMN were cultured with different TLR ligands and 
analyzed by flow cytometry for intracellular TLR9 expression as described in (A). (C) PMN 
were isolated from several healthy donors, activated with purified nucleosomes and 
analyzed as described in (A). Intracellular TLR9 expression was normalized to TLR9 
expression by non-stimulated cells (Gdt) in order to show the TLR9 up-regulation (fold 
increase) upon activation. The upper and lower panels present two groups of donors whose 
PMN up-regulate TLR9 or not, respectively. Each line represents an independent donor      
(n = 12). Data are representative of at least six independent experiments. See figure 1 and 
2 for abbreviations. 
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Free nucleosomes accumulate in the cytoplasm of PMN upon endocytosis 
 
We have previously shown that circulating nucleosomes are endocytosed by PMN [29]. 
To gain more insight we first compared different human leukocyte populations for their 
ability to bind or endocytose free nucleosomes. Cells were incubated on ice (to detect 
cell surface binding) or at 37 °C (to measure binding and endocytosis) in the 
presence/absence of FITC-nucleosomes and cells were analyzed by flow cytometry 
with or without trypan blue in order to quench the extracellular FITC fluorescence. As a 
control, cells were stained with FITC-conjugated mAb specific for surface markers. 
Nucleosomes slightly bind to the cell surface of PMN or DC (Fig. 6A). Nevertheless, 
PMN and DC strongly endocytose nucleosomes as demonstrated by the signal 
observed at 37 °C, which was not inhibited by trypan blue (in contrast to the control Ab 
staining on ice). Likewise, monocytes strongly engulf nucleosomes. However, in 
contrast to previous cell types, nucleosomes also strongly bind to the monocyte cell 
surface. On the contrary, lymphocytes only slightly bind and do not endocytose 
nucleosomes. Interestingly, only PMN and DC but not monocytes or lymphocytes are 
activated by free nucleosomes [15, 29]. We then analyzed whether macropinocytosis 
was involved in nucleosome endocytosis. Cells were incubated with FITC-nucleosomes 
in the presence of Alexa Fluor 647-conjugated dextran and analyzed by confocal 
microscopy. In contrast to DC, PMN do not endocytose dextran, whereas FITC-
Nucleosomes were taken up by both cell types (Fig. 6B). Even in DC, engulfed 
nucleosomes do not co-localize with dextran, indicating that free nucleosomes are not 
ingested via macropinocytosis in PMN or DC. We also investigated whether 
nucleosome endocytosis occurred in PMN via phagocytosis by using FITC-
nucleosomes and fluorescent microspheres. Microspheres and nucleosomes were 
rapidly taken up by PMN but did not co-localize inside cells (Fig. 6C), suggesting that 
nucleosomes are not internalized via phagocytosis in PMN. Nevertheless, because 
primary PMN are sensitive and short-lived cells, we did not gain more and 
unambiguous insight regarding the endocytic pathway (clathrin-mediated or caveolae-
mediated endocytosis) and the intracellular destination of nucleosomes using confocal 
microscopy. Such studies are actually often performed with cell lines in order to 
achieve optimal conditions for confocal microscopy. However, using FITC-
nucleosomes and the DNA dye TO-PRO-3, we could observe that free nucleosomes 
are not translocated into the nucleus of PMN upon endocytosis (Fig. 6D). 
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Figure 6. Endocytosed circulating nucleosomes accumulate in the cytoplasm of 
PMN. (A) PMN, DC, monocytes and lymphocytes were incubated on ice or at 37 °C with 
PBS or FITC-nucleosomes in the presence/absence of trypan blue (TB) to quench the 
extracellular FITC fluorescence. The different cell types were analyzed by flow cytometry to 
compare their ability to bind and endocytose nucleosomes. As a control, cells were stained 
for cell surface molecules with FITC-conjugated mAb to verify the activity of TB. (B-D) 
Endocytosis of FITC-nucleosomes (green) by PMN and DC was investigated by confocal 
microscopy. (B) Macropinocytosis by DC (left panel) or PMN (right panel) was analyzed 
using Alexa Fluor 647-conjugated dextran (red). (C) Phagocytosis of FITC-nucleosomes by 
PMN was estimated using fluorescent microspheres (red). (D) The translocation of FITC-
nucleosomes into the nucleus (red) of PMN upon endocytosis was followed in the presence 
of the DNA dye TO-PRO-3. Confocal images show individual fluorescence channels for 
FITC-nucleosomes or the endocytic markers (right) and the corresponding overlays (left 
pictures). A.U., arbitrary units (only for Ab staining of PMN); Ab-FITC, FITC-conjugated 
mAb specific for cell surface molecules; TB, trypan blue. The data are from three 
independent experiments using cells isolated from independent donors. Bars in B-D, 5 µm. 
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Discussion 
 
We have clearly shown that in the absence of autoAb free nucleosomes activate PMN 
independently of CpG motifs, endosomal acidification and TLR9, leading to the 
secretion of pro-inflammatory cytokines. The pathway involved in the recognition of 
circulating nucleosomes is therefore different from the classical pathway involved in the 
recognition of CpG-ODN. Importantly, similar results were obtained when we activated 
normal PMN with SLE plasma whereas nucleosome-depleted plasmas were not 
stimulatory, showing that the activation was specifically mediated by circulating 
nucleosomes. The elevated concentrations of circulating nucleosomes observed in part 
of the patients may be responsible for the PMN activation reported in SLE. Our results 
highlight the influence of the innate immunity and TLR9-independent pathways in SLE 
development. Those observations do not rule out that TLR9 might be required in other 
processes. TLR9 might be differently required during nucleosome-induced PMN 
activation and Ag-specific stimulation of nucleosome-specific autoreactive B 
lymphocytes. Our results are in agreement with an in vivo role of circulating 
nucleosomes in PMN activation, even if other factors might contribute to this process. 
Continuous exposure to nucleosomes in vivo may favor PMN exhaustion and may 
partly explain the low PMN counts and the inflammatory status observed in patients. It 
may also explain the apparent low activity of lupus PMN reported in other studies, 
although lupus PMN might also have an endogenous alteration rendering them less 
sensitive to activation. The role of TLR9 in SLE development is still a matter of debate. 
The involvement of TLR9 in nucleosome recognition has often been analyzed using 
chromatin-containing IC and not free nucleosomes, or upon enforced uptake of free 
mammalian DNA, and not nucleosomes, upon transfection. However, DNA is not 
circulating as a free molecule in SLE patients but in the form of nucleosomes [1]. In the 
latter system, intracellular mammalian DNA stimulates myeloid DC to produce type I 
IFN through a TLR9-independent pathway [33]. Likewise, vertebrate and even 
mammalian DNA trigger TLR9-independent pathways [17, 26]. Consistently, non-CpG 
dsDNA (phosphodiester) aggravates the disease in a TLR-independent manner in 
lupus mice [34]. All those results support a TLR9-independent mechanism in 
nucleosome-induced PMN activation. Other receptors have been suggested to 
recognize DNA and/or nucleosomes. A nucleosome-specific receptor might be 
expressed at the cell surface [35]. Oligonucleosomes bind to glomerular mesangial 
cells in a receptor-mediated fashion [36]. Recently, cytosolic receptors able to 
recognize different types of DNA have been reported, leading to type I IFN production 
[37], innate immune responses [38, 39], or activation of the inflammasome and cell 
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death [40-43]. Nevertheless, it is unknown whether those pathways are triggered by 
free nucleosomes. We have observed that circulating nucleosomes are endocytosed in 
PMN as well as in DC and monocytes. In PMN, nucleosomes slightly bind to the cell 
surface and are not translocated to the nucleus upon endocytosis, which could have 
been expected for a nuclear autoAg. Our results suggest that nucleosomes are not 
taken up via macropinocytosis or phagocytosis in PMN. Unfortunately, we could not 
identify the endocytic pathway (clathrin-mediated or caveolae-mediated endocytosis) 
used. Nevertheless, such experiments are usually performed with cell lines for 
technical reasons, whereas we focused on primary short-lived cells. Likewise, using 
FITC-nucleosomes together with a fluorescent lysosome/endosome dye, we could not 
determine by confocal microscopy whether nucleosomes reach the lysosome upon 
endocytosis. However, we could clearly show that lysosomal acidification is not 
required to activate PMN with nucleosomes, suggesting that if nucleosomes reach the 
lysosome to activate a receptor, nucleosome denaturation is not required. Our results 
also indicate that if nucleosomes are transported to lysosomes, TLR9 is not triggered 
since nucleosome-induced activation is TLR9-independent in PMN. Interestingly, we 
observed that nucleosome-induced PMN activation leads to TLR9 up-regulation in part 
of the donors. Nucleosomes may thus pre-activate PMN in SLE, leading to TLR9 up-
regulation and render them more sensitive to a concomitant or a further activation with 
TLR9 ligands. TLR9 up-regulation due to circulating nucleosomes in patients with 
bacterial infection might lead to a synergistic response, leading to an uncontrolled 
inflammatory response which may favor SLE development. Indeed, PMN link innate 
and adaptive immunity, which may lead in part of the patients to the break of peripheral 
tolerance and anti-nucleosome autoimmunity upon continuous exposure to circulating 
nucleosomes. Since TLR9 has been reported to be protective against lupus, the fact 
that the innate immunity stimulated by the nucleosome, a major lupus autoAg, occurs 
in a TLR9-independent manner supports the major role of this autoAg in disease 
development. Nucleosomes are pro-inflammatory and trigger innate immune 
responses. Now SLE is an inflammatory disorder. Nucleosomes are thus not only 
passive targets for autoAb but may play an active role in lupus pathogenesis. 
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Supplemental material  
 
 
 
 
Figure S1. We analyzed whether prednisolone (Pred) or hydroxychloroquine (HCQ), two 
drugs used to treat SLE patients and having anti-inflammatory and anti-malarial activity, 
respectively, may influence IL-8 induction. We observed a negative correlation between the 
doses of therapeutic agents applied in SLE patients (n = 10) and the capacity of the SLE 
plasmas to induce IL-8 secretion in normal PMN (R = -0.62 and p = 0.048 for Pred;             
R = -0.80 and p = 0.0038 for HCQ). R, Spearman correlation coefficient; p, probability; 
each dot represents an independent lupus patient. 
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Figure S2. Characteristics of neutrophils isolated from WT or TLR9-KO mice. BM 
neutrophils were enriched by positive selection using Ly-6G magnetic beads. Cells were 
first analyzed by flow cytometry for Ly-6G and CD11b expression before and after 
enrichment gating on large and granular cells according to FSC/SSC parameters. As 
shown in figure S2A, the percentage of neutrophils (defined as Ly-6GhighCD11b+ cells) was 
strongly increased upon positive selection as compared to BM cells analyzed ex vivo, 
yielding one homogenous cell population. Neutrophils isolated from WT and TLR9-deficient 
mice had the same phenotype and the cell populations showed similar purity, as 
determined by flow cytometry (Fig. S2B; percentages are shown). We first tested whether 
neutrophils isolated from WT mice were also sensitive to nucleosome-induced activation by 
measuring CD11b up-regulation on Ly-6GhighSSChigh cells (also defined as neutrophils) 
using flow cytometry. A representative flow cytometry analysis of WT neutrophils showing 
the gating strategy and CD11b expression upon activation is depicted. Cells incubated in 
medium alone showed a moderate CD11b expression which was clearly up-regulated in 
the presence of nucleosomes or LPS (Fig. S2C). 
 
 
 
 
Figure S3 shows that TLR9 is not required in nucleosome-induced activation of 293T cells 
transfected with a vector coding for human TLR9 and a vector coding for a NF-B 
luciferase reporter. Cell lysis and measurement of luciferase activity in extracts were 
performed with the Luciferase Assay System Kit from Promega according to manufacturer’s 
recommendations. 293T-TLR9 transfectants were activated by CpG-ODN 2006 (CpG) but 
not by nucleosomes (Nuc; left panel; A.U., arbitrary units). 293T-mock transfectants were 
unresponsive to stimulation. As a control, the same nucleosome preparation was able to 
activate mouse BM-derived DC (BMDC, obtained after a 7 day culture with Granulocyte 
macrophage colony-stimulating factor, as shown by an enhanced IL-12 secretion after 
stimulation with nucleosomes (Nuc, right panel). Gradient is the buffer used for the 
nucleosome purification and serves as a negative control. LPS was used as a positive 
control. Numbers indicate the concentrations of stimuli. This experiment was performed 
only once. 
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Table 1. SLE patient characteristics.  
 
Patient Gender Age SLEDAI PRED AZA CSA HCQ MMF MTX 
    yr   mg/day mg/day mg/day mg/day g/day mg/day 
1 W 43 n.k. n.k. n.k. n.k. n.k. n.k. n.k. 
2 W 30 8 5 - 150 - - - 
3 W 32 2 7.5 - 230 400 - - 
4 W 26 0 - - - - - - 
5 M 50 2 5 - - 400 - - 
6 W 25 2 10 20 - - - - 
7 W 26 0 - - - - - - 
8 W 42 4 10 - - - 2 15 
9 W 63 2 7.5 - - 400 - - 
10 W 61 2 3.5 50 - - - - 
11 M 57 6 - - - - - - 
 
 
PRED, prednisolone; AZA, azathioprine; CSA, cyclosporine A; HCQ, hydroxychloroquine; 
MMF, mycophenolate mofetil; MTX, methotrexate; n.k., not known; SLEDAI, SLE disease 
activity scores; yr, year.  
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Chapter VI 
 
 
 
Primary blood neutrophils express a functional 
cell surface Toll-like receptor 9 
 
 
 
 
This chapter is derived from an article submitted for publication by Dennis Lindau, 
Britta Janina Wagner, Viktoria Rönnefarth, Ivan Jelcic, Hans-Georg Rammensee and 
Patrice Decker. 
 
 
 
 
The author of this thesis was involved in all experiments except the one leading to 
figure 4. Furthermore, he wrote the manuscript together with HGR and PD. 
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Abstract 
 
PMN represent one of the first lines of defense against pathogens. TLR9 is normally 
expressed in endosomes/lysosomes where it is activated by pathogen-derived DNA. 
Here we show by flow cytometry and confocal microscopy that human and mouse 
neutrophils express TLR9 at the cell surface. The signal is TLR9-specific since it is only 
observed with neutrophils isolated from WT but not TLR9-KO mice. Moreover, surface 
TLR9 expression is up-regulated upon activation of neutrophils with different stimuli 
and not only TLR9 ligands. Importantly, surface TLR9 is active and functional. TLR9 
ligands, ODN with unmethylated CpG motifs (CpG-ODN), indeed bind to human 
surface TLR9 and binding was only observed at the cell surface of WT but not TLR9-
deficient mouse neutrophils. Finally, CpG-ODN cross-linked onto a solid phase and 
having no access to intracellular TLR9 induces neutrophil activation, leading to IL-8 
secretion. As a control, only WT and not TLR9-deficient mouse neutrophils are 
activated by CpG-ODN. This is the first demonstration of a functional TLR9 expressed 
at the cell surface of human primary cells. This pathway may be triggered when 
pathogen-derived TLR9 ligands can not reach the endosome, offering a rescue 
mechanism for PMN activation. 
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Introduction 
 
PMN are the first cells recruited at inflammation sites. They play a central role in host 
defense and their accumulation into sites of acute infection or tissue injury is a critical 
component of inflammation [1]. Activated PMN are directly mobilized to drive pro-
inflammatory reactions and to eradicate pathogens. However, upon inappropriate 
activation, PMN-derived products may induce tissue damages and may alter self-Ag, 
transforming a harmless self-Ag in a potent autoAg. Importantly, PMN have been 
suggested to link innate and adaptive immunity [2-4] by influencing e.g. DC. PMN 
activation may thus favor adaptive immunity but may represent double-edged swords 
leading to tissue injury or autoimmunity. TLR9 is activated in endosomal/lysosomal 
compartments by unmethylated CpG motifs present in pathogen-derived DNA [5] as 
well as in synthetic ODN. Nevertheless, vertebrate DNA can also trigger TLR9 under 
certain circumstances although TLR9-independent pathways are triggered in addition 
[6]. Moreover, natural phosphodiester ODN lacking CpG motifs activate TLR9 upon 
enforced endosomal translocation [7]. All those results refer however to intracellular 
TLR9. Since nucleic acids have to be released from microbial particles, concentrated or 
modified in endosomal-lysosomal compartments [8, 9] before receptor-ligand 
interactions can take place with cleaved TLR9 [10, 11] an emerging paradigm in innate 
immunity is the intracellular expression of TLR9 [12]. It has been suggested that TLR9 
is sequestered intracellularly to exclude recognition of extracellular host-derived nucleic 
acids, thus preventing autoimmune responses [13]. Endosomal compartmentalization 
of TLR9 may thus reflect an evolutionary strategy to avoid TLR9 activation by self-DNA 
and localization of the nucleic acid-sensing TLR is critical in discriminating between self 
and non-self nucleic acid. PMN recognize PAMP on foreign organisms by expressing 
TLR1-10, except TLR3 [14]. Particularly, PMN express TLR9 and respond to TLR9 
ligands, leading to cytokine secretion and CD11b up-regulation, although the 
subcellular localization of TLR9 in PMN has not been investigated. A few studies have 
demonstrated that specialized human primary immune cells such as B lymphocytes 
[15-18], tonsil cells [19] and monocytes [20] as well as intestinal epithelial cells [21], 
might express TLR9 at the cell surface although the functionality of the human surface 
TLR9 was not demonstrated. APC represent therefore the major cell populations 
expressing cell surface TLR9. Nevertheless, human primary PMN have not been 
studied so far. Only studies using engineered cell lines and expressing a chimeric cell 
surface TLR9 could clearly show that surface TLR9 responds to its ligand and even to 
mammalian DNA [13]. Such a demonstration is not available for primary cells. 
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We therefore investigated whether human and mouse primary PMN express a cell 
surface TLR9 and whether this receptor can trigger an activation signal upon binding 
and recognition of its ligand in the extracellular milieu. Using an approach combining 
different immunological and microscopic techniques, we investigated the cellular 
distribution of TLR9 in lymphoid and myeloid cell types. We demonstrate that surface 
TLR9 interacts with CpG-ODN, leading to the activation of human PMN, and that 
surface expression of TLR9 is enhanced upon PMN activation. 
 
 
Material and methods 
 
Mice. TLR9-KO mice [5] on a C57BL/6 genetic background were obtained from Prof. 
H. Wagner (Munich, Germany). WT C57BL/6 control mice were purchased from 
Charles River. Experiments were approved by the local animal ethics committee 
(Regierungspräsidium Tübingen, § 4 Abs. 3). 
 
Human samples. Heparin-blood from random, healthy individuals was used. Human 
experiments were approved by the local ethics committee (reference 386/2006V). 
 
Nucleosome purification. Mononucleosomes (major lupus autoAg known to induce 
PMN activation [22]) were purified from calf thymus under sterile conditions by 
ultracentrifugation onto sucrose gradients as described previously [23]. As a control, an 
empty gradient (not loaded with chromatin) was prepared. DNA and protein contents 
were verified. The preparations contain low endotoxin levels (10-50 IU/mg nucleosome) 
as determined using a Limulus Amebocyte Lysate assay (BioWhittaker). A similar 
concentration (in IU/ml) was measured in purified nucleosomes and in the purification 
buffer (Gdt) which was used as a negative control. Moreover, nucleosome preparations 
were always first tested using PMN cultured with and without the LPS inhibitor PB 
(Fluka) and only preparations which activate PMN without being inhibited by PB were 
used. 
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Cell isolation, culture and activation. Human PBMC and PMN were isolated from 
heparinized peripheral blood by density centrifugation as described previously [22]. 
Contaminating red blood cells were lysed using a hypotonic buffer. Mouse neutrophils 
were isolated from BM cells obtained from adult WT and TLR9-KO mice (sex-and age-
matched, 8-12 weeks old). Neutrophils were enriched by positive selection for Ly-6G+ 
cells using magnetic beads (Miltenyi Biotec) according to the manufacturer’s 
recommendations. Contaminating red blood cells were lysed. Human (defined as CD3-, 
CD19-, CD56-, CD11b+, CD66b+ cells, purity > 85 %) and  mouse PMN (defined as 
F4/80-, CD3-, B220-, CD11b+, Ly-6Ghigh cells, purity > 90 %) were cultured in RPMI 
1640 medium (BioWhittaker) supplemented with 10 % FCS (PAA), 100 U/ml penicillin, 
100 mg/ml streptomycin (both from Gibco) and 50 µM β-mercaptoethanol (Roth). For 
cell activation studies, human and mouse PMN were plated onto 96-well plates at a 
density of 1 or 1.5 x 106 cells/ml, respectively. Granulocyte colony-stimulating factor (50 
ng/ml, ImmunoTools) was added to mouse PMN. Cells were either incubated in 
medium alone or activated with purified nucleosomes, the purification buffer as 
negative control (Gdt), R848 (Alexis), LPS (from Salmonella typhimurium or 
Escherichia coli, Sigma), CpG-ODN (2006 and 1826, Metabion), GpC-ODN (2006, 
Metabion) and FITC-CpG-ODN (2006, Invivogen). All CpG-ODN and the GpC-ODN 
were phosphorothioate ODN. Experiments were conducted in the presence/absence of 
PB (25 µg/ml) or a TLR9 antagonist (an ODN containing a G5 motif (G-ODN), 4 µM, 
Metabion). After 16 h, cell culture supernatants were harvested and cells were 
analyzed by flow cytometry. 
 
Antibodies and flow cytometry. All Ab were purchased from BD Biosciences, if not 
stated otherwise. The following mAb conjugated with different fluorochromes were 
used: anti-human CD3-PerCP (clone SK7), CD11b-PE (ICRF44), CD19-APC (HIB19), 
CD56-PE (B159), CD66b-FITC (G10F5), anti-human/mouse TLR9-FITC (5G5, Abcam) 
and anti-mouse CD11b-PE (M1/70), Ly-6G-FITC (1A8), F4/80-APC (BM8, 
eBioscience), CD3-FITC (145-2C11, SouthernBiotech), B220-PE (RA3-6B2). Human 
PMN and PMBC were first incubated with PBS/5 % heat-inactivated human serum, 
whereas PBS/2 % heat-inactivated autologous mouse serum was used for mouse 
PMN. After washing, cells were incubated with the indicated mAb or the corresponding 
isotype controls in PBS/0.01 % sodium azide to reduce the unspecific uptake of mAb. 
For surface TLR9 staining, cells were  incubated with FITC-CpG-ODN 2006 or 
additionally washed and incubated with anti-TLR9-FITC (or the corresponding isotype 
control) and then with anti-FITC-Alexa Fluor 488 (Invitrogen). For intracellular staining, 
cells were first stained for surface markers, permeabilized with Cytofix/Cytoperm (BD 
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Biosciences) and incubated with anti-TLR9-FITC (or the corresponding isotype control), 
washed and then with anti-FITC-Alexa Fluor 488 or directly incubated with FITC-CpG-
ODN 2006 in PBS/0.1 % Saponin (Sigma). All incubations were carried out at 4 °C for 
30 min. Cells were finally fixed with 1 % paraformaldehyde and analyzed on a four-
color FACSCalibur apparatus (Becton Dickinson). Data were evaluated with 
CELLQuest software (Becton Dickinson). 
 
Confocal microscopy. To demonstrate the cell surface expression of TLR9 in mouse 
and human PMN, cells were incubated with FITC-CpG-ODN 2006 or were 
consecutively incubated with anti-TLR9-FITC (or the corresponding isotype control) 
followed by anti-FITC-Alexa Fluor 488 in PBS/0.01 % sodium azide to reduce the 
unspecific uptake of fluorochrome-conjugated molecules (30 min, 4 °C for all steps). To 
stain the cell surface, cells were incubated with Alexa Fluor 555-conjugated cholera 
toxin subunit B (CTB, 20 µg/ml, Molecular Probes) and fixed. For intracellular TLR9 
staining, cells were permeabilized and incubated with anti-TLR9-FITC (or the 
corresponding isotype control) and then with anti-FITC-Alexa Fluor 488 or directly 
incubated with FITC-CpG-ODN 2006. To stain the nucleus, cells were then incubated 
with TO-PRO-3 (1/1,000, Molecular Probes). Finally, cells were mounted on Lab-Tek 
Chambered 1.0 borosilicate coverglass systems (Nunc) and kept in the dark at 4 °C. 
Confocal microscopy was conducted using an inverted LSM510 confocal laser 
scanning microscope (Carl Zeiss) fitted with a Plan-Apochromat 63 x/1.4 OIL DIC 
objectives, and the pinhole was set to scan layers of 1 µm. FITC and Alexa 488 were 
excited at 488 nm with an argon-ion laser. Alexa 555 and TO-PRO-3 were excited at 
543 and 633 nm, respectively, with helium-neon lasers. Images were acquired by 
single-track measurement and scales are indicated. 
 
ELISA. Detection of IL-8 and MIP-2 secretion by human and mouse PMN was 
analyzed by sandwich ELISA using OptEIA set or mAb pairs and streptavidin-
peroxidase conjugate from BD Biosciences or R&D Systems, respectively, and 
according to the manufacturer’s instructions. Cytokine concentrations in cell culture 
supernatants are depicted as mean ± standard deviation of triplicates. 
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Cell surface TLR9 functional assay. Nitrocellulose plates (Millipore, MSHA S4510) 
were activated by UV irradiation at 254 nm (UV Stratalinker 1800, Stratagene, 20J/cm2) 
and coated with PBS or FITC-CpG-ODN 2006 in PBS (1.5-2.5 µM) for 4 h at RT. The 
presence of the FITC-CpG-ODN 2006 was confirmed by measuring the FITC 
fluorescence using a SPECTRA Fluor fluorometer (TECAN). Plates were then washed 
three times with PBS and the last wash was measured with the fluorometer to confirm 
the absence or free (unbound) FITC-CpG-ODN. The plate was filled with PBS and the 
FITC fluorescence was measured in order to estimate the CpG-ODN binding efficiency. 
Plates were then emptied and used for cell culture using human PMN (1.5 x 106 
cells/ml). LPS and free FITC-CpG-ODN 2006 were used as controls. After 16 h, the 
FITC fluorescence in the plate was measured. Cell culture supernatants were then 
transferred, the FITC fluorescence was measured and the IL-8 secretion was estimated 
by ELISA. Simultaneously, PMN were harvested and analyzed by flow cytometry for 
the FITC fluorescence. 
 
Statistical analysis. The mean FITC fluorescences measured by flow cytometry in the 
presence/absence of ammonium chloride (10 mM, Roth) were compared using a 
Student’s t-test or a Mann-Whitney rank sum test. The mean IL-8 concentrations 
induced in PMN by either the medium alone or the coated CpG-ODN were compared 
using a Student’s t-test after normalization of the different experiments to the actual 
concentration of the coated CpG-ODN. The SigmaStat software was used and a p 
value < 0.05 was considered significant. 
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Results 
 
 
Human PMN spontaneously express TLR9 at the cell surface 
 
To investigate the ex-vivo expression of TLR9 at the surface of non-stimulated cells, 
we first analyzed simultaneously all the human leukocyte populations in several 
independent healthy donors. Cells were prepared by dextran centrifugation and the two 
layers containing PBMC or PMN were harvested and mixed, yielding a leukocyte 
population depleted from erythrocytes and platelets. Cells were then analyzed by 
polychromatic flow cytometry in the presence of sodium azide to reduce the uptake of 
fluorochrome-conjugated Ab and thus to minimize unspecific staining. As shown in 
figure 1, the R1 gate contained only PMN (CD66b-positive cells), whereas the R2 gate 
contained essentially T lymphocytes, B lymphocytes, NK/NKT cells and a few 
monocytes. Cells were then stained for cell surface or intracellular TLR9 using a 
specific mAb recognizing both human and mouse TLR9. Focusing on gate R1, we 
identified cell surface expression of TLR9 on PMN (Fig. 1B), all the cells being double-
positive for CD66b and CD11b. Gating on R2, and as already reported, B lymphocytes 
also express TLR9 at the cell surface (Fig. 1C, middle panel). Likewise, gating on CD3-
CD19- cells, we confirmed that part of the monocytes also express cell surface TLR9 
(Fig. 1C, lower panel). Interestingly, no cell surface TLR9 was detected on T 
lymphocytes (Fig. 1C, upper panel), NK cells or NKT cells (Fig. 1D, lower and upper 
panels, respectively). However, all the cell types analyzed expressed TLR9 
intracellularly and expression was stronger than surface expression. No binding of the 
isotype control was observed, indicating that the staining was TLR9-specific. The 
specificity of the TLR9 staining was confirmed by comparing BM cells prepared from 
WT and TLR9-KO mice. Indeed, the 5G5 anti-TLR9 mAb used in the present study 
recognizes both human and mouse TLR9 [8]. We gated on Ly-6Ghigh cells (most of 
them are CD11b+ cells and thus granulocytes) which are known to express intracellular 
TLR9. WT PMN express intracellular TLR9 whereas no expression was observed in 
TLR9-KO PMN, as expected (Fig. 1E). Those results indicate that the signal measured 
at the surface of human PMN corresponds to TLR9. More importantly, only the cells 
expressing TLR9 at the cell surface (namely PMN, B lymphocytes and monocytes) also 
bind the TLR9 ligand (FITC-CpG-ODN 2006) at the cell surface (Fig. 1B-C), whereas 
all the cell types were stained positively with that ligand upon fixation/permeabilization, 
suggesting that the CpG-ODN also binds to its intracellular receptor.  
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This observation confirms the presence of TLR9 at the cell surface and the specific 
interaction with its ligand suggests that the surface TLR9 is active. 
 
 
 
 
Figure 1. Human primary PMN express TLR9 at the cell surface. PBMC and PMN were 
freshly isolated from the peripheral blood of healthy individuals by dextran centrifugation 
and mixed. Upon Ab staining, cells were analyzed by multicolor flow cytometry using 
different gates. (A) Cells contained in gates R1 and R2 were characterized using anti-
human (CD3, CD11b, CD19, CD56, CD66b) mAb. The percentages of gated cells positive 
for the marker of interest are indicated. (B) Cells from gate R1, which are PMN according to 
the staining for CD66b and CD11b (left), were stained for cell surface (without 
permeabilization) and intracellular (after permeabilization) TLR9 using an anti-TLR9-FITC 
mAb in combination with an anti-FITC-Alexa Fluor 488 Ab. Alternatively, cells were stained 
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with a FITC-CpG-ODN (a TLR9 ligand). (C, D) Cells from gate R2 were stained for CD3 
and CD19 (C) or CD3 and CD56 (D) and analyzed for surface and intracellular TLR9 
expression as in (B). Cells were also stained with the FITC-CpG-ODN as described in (B). 
(E) BM cells were isolated from WT and TLR9-KO mice and stained for Ly-6G and CD11b 
or the corresponding isotype controls. Ly-6G-positive cells were then analyzed for 
intracellular TLR9 expression as in (B). Ab, antibody; CpG, FITC-CpG-ODN 2006. 
 
 
To confirm those results, human PMN were isolated from fresh blood and analyzed by 
confocal microscopy. We used from now on highly purified PMN, yielding only the cell 
population corresponding to gate R1 and PMN were not mixed with PBMC. Cells were 
stained for TLR9 expression (green) at 4 °C in the presence of CTB (red) to stain the 
cell surface. As shown in figure 2A, a TLR9-specific signal was observed at the cell 
surface of PMN, as demonstrated by the merged signal with CTB staining. The 
histogram depicting the intensity of both signals (measured along the white bar) nicely 
shows that both signals overlay along the cell membrane. PMN were then incubated 
with FITC-CpG-ODN 2006 (green) in the presence of CTB and analyzed (Fig. 2B). The 
TLR9-ligand bound to the cell surface of PMN (merged signal), in line with the cell 
surface expression of TLR9. When analyzing both signals across the cells (white bar), 
we only detected the FITC-CpG-ODN at the cell surface, as depicted by the overlay in 
the histogram showing the intensity of both signals. The binding of the CpG-ODN at the 
cell surface suggests that TLR9 expressed at the surface of PMN is active. 
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Figure 2. Human primary PMN express a cell surface TLR9 and bind to TLR9 ligands. 
PMN were purified from fresh blood and analyzed by confocal microscopy in the absence 
of PBMC. (A) PMN were stained consecutively with anti-TLR9-FITC and anti-FITC-Alexa 
Fluor 488 (without permeabilization) at 4 °C in the presence of Alexa Fluor 555-CTB. The 
individual fluorescence channels and the merged signal are shown (right). The intensity of 
both signals (measured along the white bar) is also depicted. (B) PMN were then incubated 
with FITC-CpG-ODN 2006 at 4 °C in the presence of Alexa Fluor 555-CTB and analyzed. 
The individual channels, the merged signal (arrows) and the intensity of both signals across 
the cells (white bar) are depicted. All incubations were performed in PBS/0.01 % sodium 
azide. Confocal microscopy was conducted using an inverted LSM510 confocal laser 
scanning microscope (Carl Zeiss) fitted with a Plan-Apochromat 63 x/1.4 OIL DIC 
objectives, and the pinhole was set to scan layers of 1 µm. The scale in (A) and (B) 
represents 10 µm. CpG, FITC-CpG-ODN 2006; AFU, arbitrary fluorescence units. 
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To confirm the specificity of the TLR9 staining and to show that the CpG-ODN 
specifically binds to the cell surface TLR9 and not to an as yet unknown DNA sensor 
as proposed [24], PMN were isolated from WT and TLR9-KO mice by magnetic cell 
sorting. Mouse PMN were stained in the presence of CTB and analyzed by confocal 
microscopy. WT PMN showed a nice cell surface TLR9 signal upon staining with the 
5G5 mAb, as demonstrated by the co-localization with the CTB signal depicted in the 
histogram, which was not detected upon staining with the corresponding isotype control 
(Fig. 3A). More importantly, the TLR9 staining was not observed with TLR9-KO PMN, 
indicating that the cell surface signal measured with WT PMN was TLR9-specific. 
Likewise, the TLR9-ligand CpG-ODN only bound to the cell surface of WT PMN, 
whereas no binding was detected with TLR9-KO PMN, confirming that the binding of 
the CpG-ODN to the cell surface of PMN is mediated by TLR9. The same experiment 
was then reproduced with fixed and permabilized cells (Fig. 3B). Cells were stained 
with the DNA dye TO-PRO-3 instead of CTB in order to stain the nucleus. Only WT, but 
not TLR9-KO, PMN showed a TLR9 signal, whereas no signal was observed upon 
staining with the isotype control, confirming that the mAb used was TLR9-specific and 
that the control mice used where TLR9-KO. Similarly, the CpG-ODN only bound to the 
intracellular TLR9 present in WT PMN. The surface expression of TLR9 by those 
purified PMN was confirmed by flow cytometry. Non-permeabilized PMN were stained 
at 4 °C in the presence of sodium azide. WT PMN show a strong expression of surface 
TLR9, which was not observed with TLR9-deficient PMN (Fig. 3C). To confirm that the 
FITC-CpG-ODN 2006 used is an active TLR9 ligand for mouse PMN, cells were 
cultured with different stimuli and cell activation was estimated. Indeed, CpG-ODN are 
often cell type-specific and the conjugation to a FITC molecule may interfere with cell 
activation. WT PMN were equally activated by CpG-ODN 2006 and FITC-CpG-ODN 
2006, as shown by CD11b up-regulation and MIP-2 secretion (Fig. 3D), whereas 
activation was not observed with TLR9-deficient PMN. Likewise, only WT PMN were 
activated by the mouse-optimized CpG-ODN 1826. As a control, WT and TLR9-
deficient PMN were activated by LPS, indicating that all the CpG-ODN used 
(conjugated to FITC or not) are TLR9 ligands and are not contaminated by endotoxins 
(which is an important control for the functional assay of surface TLR9 described 
below). All those results confirmed the specificity of the TLR9 staining and the 
presence of TLR9 at the cell surface of PMN. The binding of the CpG-ODN at the cell 
surface of WT but not KO PMN suggests that the surface TLR9 recognizes its ligand. 
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Figure 3. Mouse PMN express also a surface TLR9 and the staining is specific. PMN 
were purified by Ly-6G positive selection from the BM of WT and TLR9-KO mice. (A) Cells 
were stained consecutively with anti-TLR9-FITC (upper panel) or the corresponding isotype 
control (middle panel) and anti-FITC-Alexa Fluor 488 or were directly incubated with FITC-
CpG-ODN 2006 (lower panel) at 4 °C in the presence of Alexa Fluor 555-CTB (without 
permeabilization). PMN were then analyzed by confocal microscopy as described in figure 
2. The individual channels, the merged signal and the intensity of both signals across the 
cells are depicted. The scale in (A) and (B) represents 5 µm. (B) The same staining was 
performed using permeabilized cells to detect intracellular TLR9 expression and CpG-FITC 
binding, except that PMN were stained with TO-PRO-3 instead of CTB. (C) Purified PMN 
isolated from WT and TLR9-KO mice were analyzed by flow cytometry. The phenotype of 
the isolated cells was verified by Ly-6G and CD11b staining. Non-permeabilized Ly-6G-
positive cells (all of them are CD11b-positive) were analyzed for cell surface TLR9 
expression as described in figure 1. (D) The mouse PMN isolated in (C) were cultured with 
LPS, CpG-ODN 2006, FITC-CpG-ODN 2006 or CpG-ODN 1826 (right histograms) for 16 h. 
Cell activation was then estimated by measuring CD11b up-regulation (flow cytometry) and 
MIP-2 secretion (ELISA). CpG, FITC-CpG-ODN 2006; AFU, arbitrary fluorescence units; 
Med, cell culture medium. 
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TLR9 expressed at the cell surface of primary neutrophils is functional 
 
The results described above clearly show that the TLR9 ligand binds to the cell surface 
of primary PMN and that the binding is specifically mediated by TLR9. It therefore 
indicates that this receptor is at least partially functional since it recognizes this ligand. 
We then analyzed whether ligation of FITC-CpG-ODN 2006 to the cell surface TLR9 
triggers activation of primary human PMN. In order to specifically stimulate the cell 
surface TLR9, the FITC-CpG-ODN 2006 was cross-linked by UV irradiation onto a 
sterile nitrocellulose filter-containing cell culture plate. The efficacy was verified by 
measuring the FITC fluorescence using a fluorometer. Wells incubated with the FITC-
ODN displayed a strong fluorescence, as expected (Fig. 4A, upper part, “coating”). The 
plate was washed three times to eliminate unbound CpG-ODN and the fluorescence in 
the last wash was measured. No FITC fluorescence was detected in the last wash (Fig. 
4A, upper part), confirming that all free CpG-ODN were removed. The empty plate was 
then measured to estimate the amount of CpG-ODN remaining in the wells (Fig. 4A, 
upper part), showing that the ODN was covalently bound to the wells. Nevertheless, 
only 25.6 ± 9.8 % of the incubated ODN was efficiently cross-linked to the plate. 
Freshly isolated PMN were then cultured in the CpG-ODN-coated plate. As negative 
and positive controls, PMN were cultured in medium alone or supplemented with LPS, 
respectively. As a comparison, PMN were cultured with the FITC-CpG-ODN 2006 free 
in solution at a sub-optimal concentration. The concentration of the free ODN used was 
either the same than that of the cross-linked ODN (as estimated by measuring the 
FITC fluorescence) or slightly higher. Indeed, UV irradiation did not allow the cross-
linking of an optimal amount of ODN. After overnight cell culture, the cross-linked ODN 
was still detectable (Fig. 4A, lower part, “in plate”) and the fluorescence was much 
stronger in the presence of the free ODN, indicating that the latter was present at a 
higher concentration. The cell culture supernatants were then harvested and 
measured. Only a slight signal was detected for the cross-linked ODN (Fig. 4A, lower 
part), suggesting that only part of the ODN is released and that most of it is 
nitrocellulose-bound. A stronger signal was detected for the free ODN, indicating that 
part of it was still in solution. Importantly, the cross-linked ODN induced the activation 
of PMN, as shown by the IL-8 secretion (Fig. 4B), indicating that the cell surface TLR9 
is functional. The activation was even stronger than the activation measured with the 
same ODN in solution, whereas the latter was used at a stronger concentration.  
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Figure 4. Human primary PMN express a functional surface TLR9. (A) UV-treated 
nitrocellulose plates were incubated with PBS or FITC-CpG-ODN 2006 in PBS (upper 
panel, before cell culture). The efficiency of the ODN cross-linking was verified by 
measuring the FITC fluorescence in the plate (coating), in the last wash and in the empty 
plate after washing using a fluorometer. Human PMN were isolated from healthy individuals 
and cultured in the cross-linked plate (lower panel, after cell culture) for 16 h. As a control, 
cells were activated with free (non-cross-linked) FITC-CpG-ODN 2006 or LPS (5 ng/ml). 
The FITC fluorescence was measured in the plate and in the cell culture supernatants. The 
fluorescence background was the same in medium and in medium supplemented with LPS 
(data not shown). The actual concentrations were 0.48 and 1 µM for the cross-linked and 
the free ODN, respectively. Shown is one representative experiment. (B) The level of PMN 
activation was estimated by measuring IL-8 secretion by ELISA. (C) Cultured PMN were 
also analyzed by flow cytometry for the FITC fluorescence in the absence (upper panel) or 
presence (lower panel) of AC (NH4Cl). The impact of AC on the FITC fluorescence was 
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estimated; * p = 0.029, ** p < 0.001. MFI, mean fluorescence intensity (mean ± standard 
deviation). (D) PMN were isolated from six independent healthy individuals. The capacity of 
the cross-linked ODN to trigger surface TLR9-mediated cell activation was tested in six 
independent experiments. IL-8 secretion was determined by ELISA. The cumulative results 
are shown and the probability is indicated. Experiments were normalized to the actual 
concentration of the cross-linked ODN. 
 
 
Upon cell culture, the FITC fluorescence was also measured by flow cytometry. As 
expected, a strong signal was detected in PMN incubated with the free FITC-ODN (Fig. 
4C, upper panel). Surprisingly, PMN incubated with the cross-linked ODN showed an 
intermediate signal, suggesting that PMN are able to detach part of the FITC molecules 
or part of the cross-linked ODN from the nitrocellulose filter. To determine whether the 
signal corresponds to a cell surface signal only, the same cells were measured in the 
presence of AC, an inhibitor of endosomal acidification. The FITC fluorescence is 
indeed inhibited at low pH values and AC protects the endosomal FITC fluorescence. 
As shown in figure 4C (lower panel), whereas the FITC fluorescence of the free ODN 
was significantly increased in the presence of ammonium chloride (p < 0.001), the 
fluorescence of the cross-linked ODN was slightly but significantly decreased               
(p = 0.029), indicating that the ODN has different properties when cross-linked. 
Compared to the expected behavior of the free ODN, the results confirm that the cross-
linked ODN bound only to the PMN surface (i.e. is cell-bound but remains external) and 
did not reach the endosomal TLR9. The activation observed with the cross-linked ODN 
is therefore triggered by the cell surface TLR9. Primary PMN were then isolated from 
six independent healthy donors and cell activation by the cross-linked ODN was 
determined in six independent experiments. The coated ODN induced a significant IL-8 
secretion (p = 0.014), showing clearly that the TLR9 expressed at the cell surface of 
PMN recognized its ligand and is functional (Fig. 4D). 
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TLR9 surface expression is up-regulated in response to some stimuli 
 
We next investigated whether the expression of the cell surface TLR9 is modulated 
upon PMN activation. Cells from healthy individuals were incubated with different TLR 
ligands or purified nucleosomes, an autoAg which activates PMN in a TLR9-
independent manner (see chapter V). Interestingly, CpG-ODN-mediated PMN 
activation led to an up-regulation of the cell surface TLR9 in part of the donors, which 
correlated to either the down-regulation or the up-regulation of the intracellular TLR9 
(Fig. 5A). As expected, no significant effect was observed when PMN were cultured 
with the control GpC-ODN. Activation with R848, a TLR7/8 ligand in humans, also led 
to surface TLR9 up-regulation in some donors, whereas the TLR4 ligand LPS did not 
induce up-regulation of TLR9 at the cell surface but rather intracellularly, suggesting 
that PMN activation with TLR4 ligands is associated with the up-regulation of 
endosomal TLR9. Importantly, nucleosome-induced PMN activation was associated 
with a concentration-dependent up-regulation of the cell surface TLR9 in most of the 
donors (Fig. 5A), which correlated to a down-regulation of the intracellular TLR9. 
Modulation of the TLR9 expression is therefore not restricted to TLR9 ligands. PMN 
activation was verified by measuring the CD11b up-regulation (Fig. 5B) and IL-8 
secretion (Fig. 5C). Nucleosomes trigger a concentration-dependent PMN activation 
which was not inhibited by the LPS inhibitor PB or the TLR9 antagonist G-ODN. As a 
control, LPS and CpG induced also PMN activation but were inhibited by PB or G-
ODN, respectively, whereas GpC-ODN did not activate. R848 activated PMN and was 
not inhibited by PB or G-ODN. Thus, all the potential stimuli led to PMN activation, 
indicating that the modulation of endosomal/cell surface TLR9 expression is correlated 
to cell activation. Only LPS-induced PMN activation did not lead to a significant surface 
TLR9 up-regulation. The results indicate also that the nucleosome-mediated PMN 
activation and the surface TLR9 up-regulation occurred independently of TLR9 
triggering and are not influenced by endotoxins. 
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Figure 5. The surface TLR9 is up-regulated in human PMN upon cell activation. PMN 
were isolated from seven independent healthy donors and cultured with different 
concentrations of nucleosomes, LPS (5 ng/ml), R848 (0.5 µg/ml), CpG-ODN (2 µM) or 
GpC-ODN (2 µM). (A) After 16 h, cells were stained for surface and intracellular TLR9 and 
analyzed by flow cytometry as described in figure 1. The specific fluorescence indexes 
(SFI, ratios between the specific TLR9 staining and the isotype control staining) were 
determined and normalized to that of the gradient or medium controls in order to visualize 
the modulation (fold increase) of TLR9 expression induced by either nucleosomes or the 
TLR ligands, respectively. Shown are all the donors tested; each line represents a donor. 
The level of PMN activation was verified by measuring the CD11b up-regulation by flow 
cytometry (B) and IL-8 secretion by ELISA (C). Shown is one representative donor. PB, 
polymyxin B; G-ODN, TLR9 antagonist; Med, medium; Gdt, nucleosome purification buffer; 
Nuc, nucleosomes. 
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Discussion 
 
We have shown for the first time that primary human and mouse PMN express TLR9 at 
the cell surface. This is also the first demonstration that a functional TLR9 is expressed 
at the cell surface of human primary cells. Previous studies have already reported that 
monocytes and B lymphocytes express a cell surface TLR9 [15-18, 20] but PMN have 
not been described. Moreover, the functionality of the cell surface TLR9 has not been 
addressed so far. Recently, bacterial DNA has been shown to bind to the cell surface 
of human PMN but the role of TLR9 in this process has not been analyzed [24]. 
Although activation by the cross-linked ODN was relatively low, IL-8 secretion was 
significantly increased. It therefore suggests that the surface TLR9 is less efficient than 
the endosomal TLR9. Nevertheless, other causes, essentially technical reasons, may 
explain the apparent low activity of the surface TLR9. We observed that the 
nitrocellulose plates used are less adequate for PMN activation. Thus, when PMN were 
cultured with CpG-ODN 2006 in solution in classical cell culture plates and 
nitrocellulose plates in parallel, cell activation was much stronger in classical plates 
(data not shown). Moreover, UV irradiation only allowed the cross-linking of low 
amounts of CpG-ODN (0.51 ± 0.20 µM, final concentration in nitrocellulose plates) 
whereas we found that 2 µM of the same ODN is required for optimal PMN activation in 
classical plates. We can also not exclude that UV irradiation (and the induced ODN 
alterations) partially affects the capacity of the ODN to activate PMN. Likewise it is 
possible that ODN free in solution are simply more efficient in activating PMN than 
cross-linked ODN. By measuring the FITC fluorescence at all steps of the cross-linking 
procedure, we have clearly shown that the cross-linked ODN did not reach the 
endosomal TLR9. Activation could therefore only be achieved through the triggering of 
surface TLR9. Similarly to what we explained above, nitrocellulose and classical cell 
culture plates gave slightly different fluorescence values when measured with the 
fluorometer, explaining why values in the cell cultures and in the wash/supernatants 
are not perfectly additive. However, this approach evidenced that the cross-linked ODN 
was not taken up by PMN. The flow cytometric analysis of the FITC fluorescence 
confirmed that the free CpG-ODN reached the endosome, as evidenced by the 
increased signal intensity in the presence of ammonium chloride. On the contrary, a 
decrease in signal intensity was observed with the cross-linked ODN in the presence of 
ammonium chloride, indicating that this ODN only bound to the cell surface. Altogether, 
we have confirmed that the CpG-ODN used in the present study triggers only TLR9 
and that this cross-linked ODN is cell-bound. Therefore, the signal triggered at the cell 
surface of human PMN by the cross-linked ODN is TLR9-mediated. 
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We observed that intracellular TLR9 is up-regulated in some donors upon activation. 
TLR9 up-regulation occurred not only in PMN activated with CpG-ODN but also in the 
presence of LPS or R848. Consistently, previous studies have reported that 
intracellular TLR9 is up-regulated at the messenger RNA and protein expression levels 
in activated human immune cells [25] and in LPS-activated mouse MΦ [26]. On the 
contrary, nucleosome-stimulated PMN rather down-regulated intracellular TLR9. We 
also found that cell surface TLR9 was up-regulated in PMN activated with CpG-ODN or 
R848, although not in all donors. Up-regulation of cell surface TLR9 was less 
pronounced in LPS-activated PMN and was only observed in a few donors. In contrast, 
nucleosomes were the best inducers of surface TLR9 up-regulation. At 20 µg/ml 
nucleosomes, PMN strongly up-regulated surface TLR9 in most of the donors, which 
was associated with intracellular TLR9 down-regulation. Moreover, when surface TLR9 
was not up-regulated, intracellular TLR9 was not down-regulated. Those results 
suggest that upon PMN activation, especially with nucleosomes, intracellular TLR9 
may be translocated to the cell surface. In conclusion, CpG-ODN do not need to be 
accumulated in subcellular compartments for TLR9 binding and signaling in PMN. We 
suggest that surface TLR9 expression works as a rescue mechanism for PMN 
activation when pathogen-derived TLR9 ligands have no access to endosomal TLR9, 
e.g. when the ligand is membrane-bound and the pathogen can not be endocytosed, or 
when intracellular TLR9 is not activable. Alternatively, surface TLR9 may also be 
involved in the transport of extracellular TLR9 ligands to endosomes. Finally, the cell 
surface TLR9 may recognize ligands that normally do not activate intracellular TLR9 as 
previously reported for transfected cell lines [13]. Increased cell surface expression of 
TLR9 may be a pro-inflammatory activation marker during infectious or autoimmune 
diseases. Thus, identification of TLR9 cell surface expression in PMN is critical for our 
further understanding of the triggering and the regulation of inflammation, and might 
lead to the discovery of so far unknown TLR9 ligands specific for the cell surface 
receptor. 
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Chapter VII 
 
 
 
PD-1 expression is not sufficient to induce 
exhaustion of dendritic-like microglia in models 
of protein misfolding diseases 
 
 
 
 
This chapter is derived from an article submitted for publication by Christian Thetard, 
Jens Schittenhelm, Dennis Lindau, Tasuku Honjo, Phillip Kahle, Thomas Gasser and 
Lars Stoltze. 
 
 
 
 
The author of this thesis generated BM chimera leading to figure 3. He performed pilot 
experiments on the isolation of immune cells from the CNS and initiated the 
collaboration with the Neuropathology, Institute for Brain Research at the University of 
Tübingen. At the end he contributed to finalize the manuscript. 
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Abstract 
 
Microglia cells are thought to play a pivotal role in cellular inflammation of protein 
misfolding diseases such as Alzheimer’s and Parkinson’s disease. Close examination 
of microglia subtypes during the development of α-synuclein (α-syn) as well as Aβ 
protein deposits revealed the parallel appearance of a dendritic-like microglia 
population, characterized by CD11c expression in mouse and human CNS. This cell 
type surrounds amyloid deposits and is also found at neighboring neurons containing 
α-syn, tau or transactive response DNA binding protein (TDP)-43 deposits. 
Furthermore, cells were characterized by expression of several regulatory molecules 
and the exclusive expression of PD-1 in the parenchymal microglia/MΦ CNS 
population. Regulatory surface molecules have been shown to control cellular 
inflammatory responses with PD-1 as major regulator for T cell responses in chronic 
infections. The emergence of such molecules on a protein misfolding-specific microglia 
population, suggests a tight regulation of inflammation in response to aggregation. 
Manipulating such regulation would be a promising target to influence these diseases. 
However, the single elimination of PD-1 in mice, as prime suspect for regulation, did 
not result in obvious changes of inflammation or dendritic-like microglia function. Thus, 
multiple regulatory molecules control the response of this protein misfolding-specific 
inflammatory cell type. 
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Introduction 
 
Cellular inflammatory responses are usually stringently regulated to avoid overreaction, 
which may result in bystander damage or autoimmunity. Especially surface molecules 
reacting with specific ligands have been shown to regulate a cellular response by 
inhibitory or activating signals. Regulating signals may result from an active interaction 
or from the lack of this interaction between receptor and ligand [1]. In some instances 
activating and inhibiting signals balance the response of a certain cell type and may 
combine from several receptors, such that the cellular reaction depends on the relative 
strength of various signals. Classical examples for regulation by these mechanisms are 
NK or T cells, which are regulated by many different molecules [2, 3] and regulatory 
receptors include surface molecules containing intracellular ITIM (Immunoreceptor 
Tyrosine-based Inhibitory Motifs). One such ITIM-bearing molecule is PD-1, for which 
expression has been described on T cells, B cells, monocytes and DC in humans and 
T, B and stem cells in mice [4]. PD-1 interaction with its ligands PD-L1 and PD-L2 is 
highly important to maintain peripheral tolerance [5] and PD-1 expression during 
persistence of foreign antigens leads to immune exhaustion in T cells [6, 7]. This has 
been observed in many chronic viral infections such as HIV (Human immunodeficiency 
virus) and hepatitis C in humans [8, 9] or LCMV (Lymphocytic Choriomeningitis Virus) 
in mice [10]. The extent of cellular exhaustion may however, depend on the expression 
of further inhibitory molecules [11]. CNS immunity is more stringently regulated than in 
other organs to prevent damage to the sensitive environment, which is described as 
immune-privileged [12]. Still, in many CNS diseases inflammation is an important part 
in the course of disease. For example, CNS parenchymal protein misfolding leads to 
protein deposition and neuronal impairment. In most cases this aggregation is a slow 
progressive process with increasing pathology over years and neuroinflammation is 
associated with disease progression. This inflammation during neurodegeneration is 
characterized by strong microglia activation as well as astrocytosis [13]. The cause and 
effects of this inflammatory reaction is still under debate [14]. In the case of externally 
triggered immune responses in different animal models of various protein misfolding 
diseases, microglia and other immune effector mechanism showed effects against 
CNS-localized protein aggregation [15-18]. On the other hand, other data support the 
view that microglia and associated immune mechanisms contribute to 
neurodegeneration [19-21]. Due to the slow progression of CNS-protein misfolding the 
immune system might be challenged in a similar constant way as with chronic infection 
by foreign pathogens. To address the issue of microglia immune status during protein 
misfolding we characterized their reaction in mouse models to Aβ peptide and α-syn 
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aggregation, the most common misfolded proteins in AD and PD, respectively. This 
resulted in the identification of a new microglia subtype, appearing in parallel to the 
development of protein aggregate pathology, which expressed several regulatory 
molecules including the inhibitory regulator PD-1. The newly appearing microglia 
subtype was verified in four different human CNS-protein misfolding diseases, 
underlining the importance of the cell type. The effect of deleting the inhibitory PD-1 
molecule was subsequently analyzed in a mouse model of Aβ aggregation. 
 
 
Materials and methods 
 
Mice. All animals used were housed in the animal facility of the Hertie-Institute for 
Clinical Brain Research under SPF conditions and experiments approved by the 
Regierungspräsidium Tübingen. Tg6799 [22], enhanced cyan fluorescent protein 
(eCFP)-tg [23] and C57BL/6 mice were obtained from The Jackson Laboratory, Bar 
Harbor, USA. (thy1)-h[A30P]SYN (i.e. the amplified human (WT)α-SYN-coding 
sequence with A30P mutation under control of a neuron specific Thy 1 promoter 
element) mice [24] were bread in-house and C57BL/6-PD-1-/- mice [25] were kindly 
provided by Tasuku Honjo (Kyoto University, Kyoto, Japan) and obtained from the 
RIKEN BioResource Center (Koyadai, Japan). Tg6799 mice were backcrossed to 
C57BL/6 mice, at N3 intercrossed with C57BL/6-PD-1-/- and analyzed at N5. Mice were 
genotyped by tail biopsy and polymerase chain reaction.  
 
Patients. Human autopsy brains from histopathologically confirmed AD, PD, multiple 
system atrophy (MSA) and Frontotemporal lobar degeneration (FTLD) as well as age-
related controls were obtained from the archives of the Neuropathology at the 
University Hospital Tübingen, which serves as local BrainBank Center for the German 
BrainNet. Use of the tissue specimen was approved by the local ethics committee. 
Autopsy was performed in a standardized fashion for relevant CNS structures 
according to the BrainNet Europe protocol for neurodegenerative diseases [26]. 
Detailed clinicopathological data of the cases are given in supplemental table S1. 
 
Antibodies. All Ab used for flow cytometry and immunohistology are listed in table S2. 
Matthias Mack (University of Regensburg, Regensburg, Germany) and Howard Katz 
(Harvard Medical School, Boston, USA) kindly provided the Ab recognizing chemokine 
(C-C motif) receptor 2 (CCR2) and gp49B1 respectively. Anti-CCR2 was FITC 
(Molecular Probes) labeled by standard procedure. 
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CNS cell preparation and flow cytometry. CNS-cells were purified as previously 
described [27] with the following modifications. Mice were anesthetized by a mixture of 
Ketamin/Xylazin and perfused with ice-cold PBS. Removed tissue was mechanically 
dissociated by a razor blade, digested by collagenase/DNase and a single cell 
suspension generated by a 40 µm cell strainer (BD Bioscience). Immune cells were 
separated by Percoll purification and analyzed by flow cytometry in FCS/2 % BSA 
(bovine serum albumin). For flow cytometry Ethidium monoazide (EMA) (Invitrogen) 
was used for dead cell exclusion and blocking of FcR as well as Ab staining followed at 
4 °C. Cells were measured on a CyAn™ ADP (Dako) and analyzed with Summit 4.4 
software. 
 
Immunohistochemistry. Methanol/2 % paraformaldehyde fixed 10 µm cryoconserved 
mouse tissue slices were incubated with primary Ab overnight at 4 °C in PBS/10 % 
FBS. After washing with Tween20 slices were incubated with secondary Ab for 90 min 
at 4 °C and developed with Vectastain ABC kits and Vector SG (Vector Laboratories) 
according to manufacturer’s instruction. Congo red and Methyl Green staining was 
performed according to standard practice using 10 % (w/v) filtered Congo red dye 
cleared with alkaline alcohol or 0.5 % (w/v) Methyl Green dye dehydrated with ethanol. 
For double staining of human tissue formalin-fixed, paraffin-embedded tissue was 
immunostained with the Benchmark immunohistochemistry system (Ventana, Tucson, 
AZ) using a standardized protocol with slight optimizations for each Ab pair. In short, 
after heat pre-treatment and blocking of endogenous peroxidase, slides were incubated 
with rabbit anti-CD11c for 30 min, washed and stained by secondary swine anti-rabbit 
Ab (DakoCytomation). For visualization in brown, sections were incubated with I-View 
Streptavidin-horseradish peroxidase followed by I-View diaminobenzidine (Ventana). 
Slides were then again heat-pretreated, incubated with the second primary Ab (anti-
Aβ(DR-1), anti-α-syn (KM51), 30 min; rabbit anti-tau, 20 min, rabbit anti-TDP-43, 20 
min and methanol pre-treatment), washed and stained by a standard secondary Ab kit 
(Ventana). After signal amplification slides were developed with the FastRed staining 
kit (Ventana) according to manufacturers’ recommendations before counterstaining 
with hemalaun. 
 
Proteinase K (PK)-digested paraffin-embedded tissue (PET) blot. PK-PET-Blots 
were performed as previously described [24]. Briefly, 5-μm paraffin-embedded tissue 
sections were dried onto nitrocellulose membrane (Bio-Rad Laboratories Inc.), 
deparaffinized with xylol, 1:1 xylol/2-propanol and rehydrated in descending 2- 
propanol. Membranes were wetted in 0.1 % Tween-20/H20 and digested with 50 μg/ml 
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PK (Roche, Germany). After Tris-buffered saline Tween-20) TBS-T (10 mM Tris-HCl, 
pH 7.8; 100 mM NaCl; 0.1 % Tween-20) wash and denaturation with 4 M guanidine 
isothiocyanate, membranes were blocked (0.2 % casein in TBS-T) and PK-resistant    
α-syn detected by 15G7 incubation o/n at 4 °C. 15G7 was detected by bridging rabbit 
anti-rat-IgG and affinity purified goat anti-rabbit-IgG for 1 h each at RT and signals 
developed by NTM/BCIP reaction (Roche). Membranes were embedded in Sylgard 184 
Silicone Elastomer and evaluated by light microscope. 
 
BM reconstitution. Newborn mice were conditioned with sub lethal (2 x 2 Gy) whole-
body irradiation. Intrahepatic reconstitution with eCFP-tg BM in 25 µl PBS followed 2 h 
after last irradiation with a 30G syringe (Hamilton; Switzerland). Reconstitution in 
individual mice ranged from 26 to 70 %. 
 
Ex vivo assays. FITC-β-Ala-Aβ (1-42) (Bachem, Switzerland) was aliquoted on ice to 
400 µM in 0.1 % ammonium hydroxide, relyophilised and stored at -20 °C. For pre-
aggregation one aliquot was diluted to 200 µM and incubate under shacking at 37 °C 
for 24 h (fAβ). For soluble Aβ one aliquot was thawed and dissolved prior to cell 
addition (sAβ). For Aβ uptake Percoll-purified cells from one hemisphere were EMA-
stained and plated in a 24 well plate for 1.5 h in RPMI 1640 (2 % FCS, 1 % glutamine, 
1 % penicillin/streptomycin) at 37 °C and from the second hemisphere for 1 h at 37 °C 
and pre-cooled for 30 min on ice. fAβ and sAβ were added at 1 µM and incubated for 
20 min. The reaction was terminated by addition of ice-cold RPMI 1640 and directly 
centrifuged at 4 °C in 7 times the volume ice-cold RPMI 1640. Cells were transferred to 
96 well plates, washed twice with PBS/2 % FBS and stained for flow cytometry. TNF 
production was determined with Percoll-purified cells from one hemisphere. Cells were 
incubated for 5 h in RPMI 1640 (10 % FBS, 1 % glutamine, 1 % Pen/Strep, 50 μM      
β-mercaptoethanol) at 37 °C in the presence of 3 μg/ml Brefeldin A. Cells were stained 
for surface molecules and permeabilized with fix/perm-buffer (eBioscience) for 1 h        
4 °C. After washing and blocking with 2 % rat serum, cells were incubated with rat anti-
TNF Ab and analyzed by flow cytometry. The second hemisphere was used for isotype 
staining. 
 
Statistics. P values were calculated by the nonparametric Mann-Whitney-U-Test using 
GraphPad Prism5 software. 
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Results 
 
Protein misfolding induces dendritic-like microglia 
 
Tg6799 mice, which express APP with three FAD mutations (Swedish, Florida and 
London) and PS1 with two FAD mutations (M146L and L286V), develop an age-
dependent gliosis which parallels Aβ deposition [22]. Detailed analysis of marker 
expression by flow cytometry (for gating scheme see figure S1) revealed a new 
appearing microglia type, which paralleled aggregate deposition (Fig. 1A-C). This 
population is characterized by being CD11b/CD11c double positive (Fig. 1A). CD45 
expression is only intermediate on these cells (CD45int), allowing further differentiation 
from standard MΦ (CD45high) and conventional microglia (CD45low) (Fig. 1B). Due to 
their expression of CD11c, a peripheral pan-DC marker, we termed this subpopulation 
dendritic-like microglia. When amyloid deposition has reached later stages 
CD11c+CD45int dendritic-like microglia represent more then 20 % of the parenchymal 
microglia/macrophage CNS population (defined as CD45+CD11b+) and is only 
marginally present in non-tg (ntg) controls (Fig. 1B). The appearance of dendritic-like 
microglia is not restricted to Aβ aggregation but is also found in the CNS of (thy1)-
h[A30P]SYN mice (Fig. 1D), an established model for α-syn protein aggregation [24]. 
Similar to the tg6799 mice, dendritic-like microglia showed intermediate CD45 
expression and increasing numbers in parallel to α-syn aggregation (Fig. 1E, F). After 
development of prominent pathology the increase in dendritic-like microglia was highly 
significant in both aggregation models for all mice analyzed (Fig. 1G, H). 
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Figure 1. The appearance of dendritic-like microglia parallels protein aggregation. 
CNS-derived cells of the left brain hemisphere from 10, 17 and 23 week-old tg6799 and ntg 
littermate controls were analyzed for dendritic-like microglia. (A) The percentage within 
CD45+CD11b+ cells was determined for CD11b+CD11c+ cells and (B) CD45intCD11b+ 
CD11c+ cells. Arrows indicate conventional microglia and MΦ. (C) In parallel the increasing 
Aβ aggregation was analyzed by DR-1 staining in the right brain hemisphere of the tg 
animals. CNS-derived cells of the left brain hemisphere from (thy1)-h[A30P]SYN mice and 
age-matched C57BL/6 mice were analyzed with increasing α-syn pathology for dendritic-
like microglia. (D) The percentage within CD45+CD11b+ cells was determined for 
CD11b+CD11c+ cells and (E) CD45intCD11b+CD11c+ cells, in comparison to (F) α-syn 
pathology determined in the inferior colliculs of the right brain hemisphere by PK-PET blot 
of the tg animals. One representative experiment of 3 (tg6799) and 2 (α-syn) time series is 
shown. (G) For 23 week-old tg6799 mice dendritic-like microglia increased highly 
significantly in comparison to ntg littermates for all mice analyzed. 10 week-old mice, n = 4 
each and 23 week-old mice, n = 8 ntg and n = 10 for tg6799 mice. (H) All phenotypic (thy1)-
h[A30P]SYN mice analyzed revealed also significantly more dendritic-like microglia 
compared to C57BL/6 age-matched controls. Both groups n = 4. Solid lines in G, H 
represent mean values, ** P < 0.01, * P < 0.05. 
 
 
Dendritic-like microglia surround amyloid deposits  
and are CNS- derived 
 
To obtain a first functional indication for dendritic-like microglia in protein misfolding, we 
determined their localization in the CNS parenchyma of tg6799 mice by 
immunohistochemistry (Fig. 2). CD11c+ cells were only found in areas with amyloid 
deposition (Fig. 2A, B). Thereby, most if not all CD11c+ cells were attached to deposits, 
but not all deposits had attached CD11c+ cells (Fig. 2B). Thus, dendritic-like microglia 
seem to be attracted by CNS protein aggregates and they attempt to surround or shield 
these aggregates (Fig. 2C). Ntg mice and isotype controls showed no detectable signal 
for CD11c (data not shown).  
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Figure 2. Enclosure of Aβ deposits by dendritic-like microglia. (A) Aβ aggregates were 
visualized by DR-1 staining on cryoconserved slices of a 23 week-old tg6799 mouse. (B) 
The adjacent slice depicts CD11c staining (black) and Congo red-stained amyloid, with cell 
nuclei counterstained by Methyl Green. Filled arrows indicate aggregates without CD11c 
staining and open arrows CD11c cells attached to aggregates. (C) An enlargement from B 
highlights CD11c cells surrounding a Congo red-stained aggregate. One representative 
mouse of 4 is shown. 
 
 
Since MΦ/microglia from the periphery have been implicated in the removal of Aβ 
deposits [28], we addressed the issue of peripheral origin for the dendritic-like microglia 
by eCFP-tg BM transfer in newborn tg6799 mice. Our protocol of intrahepatic 
engraftment resulted in 19 week-old mice in a reconstitution level of 70 % for PBMC 
(Fig. 3A). CD8+ T cells found in the CNS parenchyma showed the identical percentage 
of reconstitution with eCFP+ cells (Fig. 3B) and the majority (at least 50 %) of the MΦ 
present in the CNS was of peripheral origin (Fig. 3C, D). As expected, conventional 
microglia remained eCFP negative and the dendritic-like microglia population entirely 
lacked eCFP expression in all mice investigated (Fig. 3E, F). Therefore, most if not all 
dendritic-like microglia are CNS-derived and not recruited from the periphery. 
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Figure 3. Dendritic-like microglia are not recruited from the periphery. Newborn 
tg6799 mice were sub lethally irradiated and intrahepatically reconstituted with eCFP-tg 
BM. 19 week-old mice were analyzed and depicted are the percentage of eCFP+ cells for 
(A) PBMC, (B) CNS-derived CD8+ T cells as well as CD11b+ cells which were (C) CD45high 
CD11c- MΦ, (D) CD45highCD11c+ MΦ/DC, (E) CD45lowCD11c- conventional microglia and 
(F) CD45intCD11c+ dendritic-like microglia. Data are from one representative mouse. The 
experiment was performed twice independently with similar results per tg mouse and two 
litters, each with total n = 14 and 17. 
 
 
Dendritic-like microglia are present in human protein 
misfolding diseases 
 
To verify the relevance of dendritic-like microglia in human protein misfolding diseases, 
we analyzed CD11c expression in post-mortem human CNS tissue from four different 
neurodegenerative diseases (Fig. 4). For Alzheimer’s patients, identical results were 
obtained as in the mouse model. All dendritic-like microglia in the neocortex were 
attached to Aβ deposits but not all deposits were surrounded by dendritic-like microglia 
(Fig. 4A, B). In humans infiltration of Aβ deposits by CD11c expressing cells was even 
more prominent than in mice (Fig. 4B). No Aβ staining and only occasionally single 
CD11c+ cells were visible in neocortex of age related controls (Fig. 4C). Staining for tau 
protein and CD11c also revealed co-localization as well as tau positive NFT without the 
presence of CD11c+ cells (Fig. 4D). CD11c+ dendritic-like microglia were also visible in 
the substantia nigra of Parkinson’s patients in close proximity to Lewy bodies (Fig. 4E), 
but absent in the substantia nigra of controls (Fig. 4F). However, co-localization of       
α-syn positive Lewy bodies and CD11c was not evident. CD11c appearance in the 
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neocortex and especially cerebellum of MSA patients was more prominent than in PD 
(Fig. 4G, H). CD11c staining was always in close proximity of α-syn staining and direct 
contact was seen more often than in Parkinson but less than in Alzheimer patients. In 
FTLD a large number of CD11c+ cells appeared in close vicinity of TDP-43 positive 
inclusions in the hippocampus (Fig. 4I). In cases with associated motor neuron 
affection (FTLD-MND), CD11c+ cells directly contacted motor neurons with TDP-43 
positive inclusions (Fig. 4J). 
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Figure 4. Dendritic-like microglia frequently exist in human protein misfolding 
diseases. Immunohistological staining of paraffin embedded human tissue identified 
CD11c+ cells (brown) in four different neurodegenerative diseases. (A) In the cortex of 
Alzheimer’s patients, amyloid deposits (red) without CD11c cells exist (filled arrows) but 
nearly all CD11c cells were attached to amyloid deposits (open arrows). (B) Infiltration of 
amyloid by CD11c cells was highly prominent in Alzheimer’s patients. (C) In control cortex 
only few cells with faint CD11c signals could be detected (open arrows). (D) CD11c+ cells 
were also found close to tau aggregates (red) in the cortex of Alzheimer’s patients (open 
arrow). (E) α-syn positive Lewy bodies (red, open arrow) in the substantia nigra of 
Parkinson patients had CD11c+ cells in their vicinity but rarely directly attached. (F) Control 
substantia nigra tissue revealed no CD11c positive cells in or around dopaminergic 
neurons (arrow). (G) The cortex and (H) cerebellum of MSA patients showed many CD11c+ 
cells, in close proximity or directly attached to numerous α-syn positive glial inclusions 
(red). (I) In the granule cell layer of the dentate gyrus in the hippocampus of FTLD patients 
the majority of neurons with cytoplasmic TDP-43 positive inclusions (red) had CD11c+ cells 
in close vicinity but not directly attached (open arrows). (J) A FTLD patient with additional 
motor neuron degeneration in the spinal cord (FTLD-MND) showed direct contact of 
CD11c+ cells to the degenerated motor neuron with TDP-43 positive inclusions (open 
arrow). Tissue from representative cases are shown and similar results were obtained for     
n = 6 control, n = 10 Alzheimer, n = 5 Parkinson, n = 6 MSA, n = 3 FTLD patients. 
 
 
Dendritic-like microglia exhibit high activity despite expression 
of multiple inhibitory surface markers 
 
Phenotypical analysis of dendritic-like microglia in tg6799 mice revealed a more 
activated state compared to conventional microglia (Fig. 5). MHC class I and TLR2 
were markedly increased, whereas CD86 and CCR2 (more pronounced in             
(thy1)-h[A30P]SYN mice, Fig. S2A) showed only a small increase in expression (Fig. 
5A). No significant change was seen for CD80. MHC class II, Dec205 and CD40 were 
neither expressed on dendritic-like microglia nor conventional microglia. Because of 
their localization and reports of positive effects from CD11c+ cells in models of protein 
misfolding [29, 30], we assumed that the dendritic-like microglia try to prevent 
aggregate growth. Obviously clearance is not sufficiently achieved and we 
hypothesized a restrained activation state for dendritic-like microglia. To verify this 
hypothesis the expression of several regulatory receptors with inhibitory potential for 
cellular immune responses was measured [31-35]. No signal on either cell type was 
obtained for CTLA-4 (Cytotoxic T-Lymphocyte Ag-4), BTLA (B and T lymphocyte 
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attenuator), 2B4 or SiglecE (Fig. 5B). Expression of Tim-3 (T-cell immunoglobulin 
domain and mucin domain-3) increased on dendritic-like microglia and gp49, more 
specifically the inhibitory gp49B1, was only expressed on dendritic-like microglia (more 
pronounced in (thy1)-h[A30P]SYN mice, Fig. S2B). Most remarkable was the high 
expression of PD-1, which was completely absent on all other cell types analyzed (for 
phenotype of MΦ/DC populations see Fig. S3). Expression of PD-1 appeared to be 
constitutive with only a small proportion PD-1 negative at the beginning of dendritic-like 
microglia appearance. This constellation did not change over the time frame of 
aggregate development (Fig. S4). PD-1 appearance was further complemented by the 
expression of its ligand PD-L1 on half of the dendritic-like microglia (Fig. 5C, D) and 
some MΦ/DC (Fig. S3C), whereas all cell types were negative for PD-L2. Dendritic-like 
microglia induced by α-syn aggregation in (thy1)-h[A30P]SYN mice revealed an 
identical phenotype (Fig. S2). The expression of three receptors with inhibitory potential 
on dendritic-like microglia strengthened the notion of tightly regulated activity. 
Therefore, their ability to endocytose different aggregation states of FITC-labeled Aβ 
was tested in ex vivo assays. Surprisingly they were much more efficient than 
conventional microglia in the uptake of pre-aggregated Aβ at 37 °C in comparison to no 
internalization at 4 °C (Fig. 6A). In line with previously published data a freshly 
prepared solution of soluble Aβ was less efficiently internalized than pre-aggregated Aβ 
[36] but dendritic-like microglia again had a higher internalization rate compared to 
conventional microglia (Fig. 6A, B). Cytokine production was likewise more pronounced 
in dendritic-like microglia compared to conventional microglia as determined by TNF ex 
vivo staining (Fig. 6C). Again no difference was seen for dendritic-like microglia from 
(thy1)-h[A30P]SYN mice (data not shown). 
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Figure 5.  Activated phenotype and inhibitory markers on dendritic-like microglia. 
CD11b+ CNS-derived cells of tg6799 mice were analyzed as CD45lowCD11c- conventional 
microglia and CD45intCD11c+ dendritic-like microglia. (A) Expression of indicated functional 
and (B) inhibitory surface marker, as well as (C) ligands for PD-1 and (D) the distribution of 
PD-L1 on CD45intCD11c+PD-1+ dendritic-like microglia were examined. Numbers in A-C 
represent ∆ (delta) MFI of isotype (gray area) and test signal (open area). Markers were 
measured at least twice. 
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Figure 6. High activity of dendritic-like microglia. Aβ uptake and cytokine production 
activity was tested ex vivo on CD11b+ CNS-derived cells of tg6799 mice. Depicted are data 
for CD45lowCD11c- conventional microglia and CD45intCD11c+ dendritic-like microglia. (A) 
Uptake of FITC-labeled Aβ was measured for soluble (sAβ) and preaggregated fibrillar 
(fAβ) material. Numbers represent ∆ MFI of 4 °C control (gray area) and uptake signal at     
37 °C (open area). (B) Identical results were obtained in three independent experiments for 
sAβ and fAβ each. Solid lines indicate mean values. (C) Ex vivo TNF production was also 
higher in dendritic-like microglia compared to conventional microglia. Numbers represent ∆ 
MFI of isotype (gray area) and TNF signal (open area). One representative mouse is shown 
from two independent experiments with similar results. 
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The sole elimination of PD-1 expression does not influence 
dendritic-like microglia function 
 
Since PD-1 was the inhibitory marker expressed exclusively and very strongly by 
dendritic-like microglia, the effect of PD-1 deficiency on their functionality was 
analyzed. Tg6799 mice were crossed to PD-1-deficient mice and corresponding 
littermates analyzed. PD-1-deficient mice showed a clear increase in CNS-localized 
CD8+ T cells, which was further enhanced by the presence of aggregating Aβ (Fig. 7A). 
All CD8+ cells were exclusively CD3+ (data not shown). In spite of this expected effect 
on T cells, the lack of PD-1 influenced neither the percentage nor the localization of 
dendritic-like microglia (Fig. 7B, C). 
 
 
 
 
Figure 7. Dendritic-like microglia in PD-1-deficient mice. Tg6799 mice were 
intercrossed to PD-1-deficient mice and 23 week-old littermates analyzed. (A) CNS 
localized CD8+ T cells increased in PD-1-deficient mice. This effect was further enhanced 
in tg6799xPD-1-/- mice. The percentage of CD45+ cells is shown. (B) PD-1 deficiency did 
not influence dendritic-like microglia numbers in tg6799 mice. The percentage of 
CD45low/intCD11b+ cells is shown. (C) Their location around amyloid deposits in 
immunohistological staining was also not influenced. Black: CD11c staining, red: Congo 
red-stained Aβ. 
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The kinetics and total amount of amyloid deposit development was also not obviously 
changed (Fig. 8A). This is in line with the observation that in terms of uptake for pre-
aggregated Aβ or the production of TNF their functional activity was equally unaffected 
by lack of PD-1 (Fig. 8, B - D). Pre-aggregated Aβ uptake was independent of PD-1 
genotype and was again much higher in dendritic-like microglia (Fig. 8C). TNF 
production was similarly more intense compared to conventional microglia (Fig. 8D). 
 
 
 
 
Figure 8. Activity of dendritic-like microglia in PD-1 deficient mice. Tg6799 mice were 
bred to PD-1 deficient mice and 23 week-old littermates analyzed. (A) The amount of DR-1-
stained amyloid in the cortex and hippocampus of tg6799 mice was independent of PD-1 
genotype status. (B) The percentage of dendritic-like microglia internalizing FITC-labeled 
fAβ in ex vivo assays was similar in tg6799 mice with different PD-1 genotypes. (C) 
Dendritic-like microglia (CD45intCD11c+) internalized also in tg6799xPD-1-/- mice more fAβ 
and (D) produce more ex vivo measured TNF compared to conventional microglia 
(CD45lowCD11c-). Values in C and numbers in D represent ∆ MFI of 4 °C control/isotype 
(gray area) and test signal (open area). 
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Discussion 
 
Immune responses and inflammatory reactions are tightly regulated to avoid unspecific 
side effects on the organism. On the downside inhibitory regulative signals may leave 
existing immune effector mechanisms unable to attack and lead to the persistence of 
chronic infections [7, 37, 38] or prevent efficient cancer immunity [39]. Protein 
misfolding diseases of the CNS are slowly progressing in terms of pathology and 
inflammation development. Permanent exposure of new structures (aggregates) as 
well as self-Ag (cell damage) to immune cells shows similarity to chronic infection. The 
accompanying CNS-inflammation has demonstrated beneficial effects by external 
modification [15-18], which argues for a restrained state of the existing spontaneous 
immune response. These circumstances lead to the induction of the here described 
new microglia subtype, which expresses CD11c and several regulatory immune 
receptors. CD11c positive cells in the CNS have been described in mice and humans 
in response to infection, autoimmunity, injury or degeneration [40]. CNS-localized 
CD11c+ cells have been primarily attributed to peripheral origin [28, 30, 41]. This is in 
line with the observation, that in a model of multiple sclerosis (EAE) only minor 
numbers of the here described dendritic-like microglia (CD11c+CD45int) were found, 
with the majority of CD11c+ cells being CD45high (data not shown). In contrast the 
dendritic-like microglia described here are clearly CNS-derived similar to CD11c+ 
microglia in a drug induced demyelination model [42]. This suggests that these cells 
develop either from CNS-resident microglia, which have the potential to up-regulate 
dendritic cell markers [43-45] or from a CD11c parenchymal CNS population, which is 
in normal adult mice difficult to detect [46, 47] and is present only in low numbers in 
normal aged human brain. The emergence and upregulation of dendritic-like microglia 
may contribute to protein profile changes of the total CNS CD11b population in Aβ 
accumulating mice [48], but appears to be a response to general protein misfolding. 
The aggregating protein or its anatomic location in the CNS seems to be of minor 
importance, because pathology in α-syn-transgenic mice starts in the spinal cord and 
spreads further to the brain stem and midbrain, whereas in tg6799 mice protein 
aggregates are predominantly found in the hippocampus and the cortical areas. In 
previous studies CD11c+ cells were undetectable in untreated/unmodified Aβ 
accumulating mice [29, 30], which might be due to the use of different mouse models. 
In spite of this, the identification of CD11c+ dendritic-like microglia in four human CNS-
protein misfolding diseases and two different mouse models underlines the important 
relevance of these cells. Especially, these cells appear in response to different protein 
aggregates (Aβ, α-syn, tau or TDP-43) in diversely affected CNS regions. Dendritic-like 
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microglia were always located in close proximity to protein aggregates suggesting 
direct attraction by aggregates or their local effects on neighboring cells. Their extent of 
direct aggregate penetration depends on the aggregating protein, which is very strong 
for Aβ but less frequent for more intracellular aggregating α-syn, tau or TDP-43. Here 
the cellular location of aggregates or their poly- or oligomeric state might be of 
importance for the dendritic-like microglia response. The functional state and number of 
CD11c+ cells strongly influences CNS-inflammation [49-52]. According to their surface 
marker profile, dendritic-like microglia represent a more activated state compared to 
conventional microglia. MHC class I and CD86 can be used to communicate with CNS-
infiltrating CTL, which increase later in pathology of tg6799 and (thy1)-h[A30P]SYN 
mice (data not shown) and which has also been suggested for CD11c+ cells in a model 
of amyotrophic lateral sclerosis (ALS) [53]. CCR2 deficiency has been shown to affect 
amyloid pathology due to cellular mobilization impairment [54] and the slight increase 
of CCR2 on dendritic-like microglia may indicate movement to surround existing 
amyloid. MΦ seem to rely more on CCR2 (Fig. S3A), which is in agreement with their 
migratory behavior from the periphery. Likewise, it has been shown that TLR2 
deficiency affects Aβ levels in mice, because TLR2 seems to be a receptor for Aβ 
clearance or Aβ-mediated microglia activation [55-58]. The high TLR2 level on 
dendritic-like microglia may thus account for their increased capability of Aβ uptake. 
CD40 ligand influences amyloidosis as well [59] but here all microglia appeared CD40-
negative arguing for a different molecular or cellular target for CD40L. The high activity 
of dendritic-like microglia in terms of endocytosis and cytokine production stands in 
contrast to the expression of at least three inhibitory receptors. Especially PD-1 with its 
exclusive expression on dendritic-like microglia was expected to induce a negative 
signal. This was anticipated, because prolonged PD-1 expression induces functional T 
cells exhaustion [60, 61] prevents naïve T cell priming [62] and inhibits B cell signaling 
[63]. However, PD-1 deficiency seems not to affect dendritic-like microglia or the 
phenotype of tg6799 mice. Even though we have to restrict this conclusion to the 
activities and pathologic markers tested, several explanations exist for this observation. 
A first possibility would be no function at all for PD-1 on dendritic-like microglia. Due to 
the specific and rare expression of PD-1 described up to now, this seems to be highly 
unlikely. A second option could be that activating signals overcome the negative PD-1 
signal, which would result in no phenotype for PD-1 deficiency. This situation would 
resemble the PD-1 expression on acute effector T cells [61] but one has to consider 
that dendritic-like microglia never down-regulate PD-1. A third option would be a 
defective signaling in the WT situation, so that a lack of PD-1 changes actually nothing. 
A fourth possibility takes into account the additional influence of other cell types 
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affected by PD-1 deficiency, such as CD8+ T cells. Their increasing numbers may 
directly affect dendritic-like microglia, due to their high MHC class I expression. We 
have also to consider that the model of tg6799 mice represents a very fast kinetic for 
amyloid development. Diminishing inhibitory signals for dendritic-like microglia may still 
not be sufficient to cope with this aggressive model. With the current knowledge of 
immune regulation, we favor the notion of complex control for dendritic-like microglia 
activation due to the additional expression of Tim-3 and gp49B1. Complex activity 
regulation represents an additional cellular control mechanism and exhausted T cells 
for example, for which PD-1 has a strong effect, express at least one or more additional 
regulatory molecules allowing for different exhaustion stages [11, 64]. Activating 
signals by TLR2 and other surface molecules may outbalance dendritic-like cell 
activation with regulatory signals of PD-1, Tim-3, gp49B1 and further here not tested 
molecules [65-67]. Tim-3 has been described as marker for exhausted T cells [68] and 
terminator of T cell immunity [69], trigger of MΦ [70] and DC [69] and implicated to 
mediate phagocytosis [71]. Whether Tim-3 contributes to TLR2 signaling on dendritic-
like microglia or to restrained activity will be interesting to see. On the other hand the 
ITIM-containing gp49B1 (also termed Leukocyte Ig-like receptor B4 (LILRB4) or Ig-like 
transcript 3 (ILT3)) has been shown to negatively regulate the cytokine response of NK 
and T cells [72] as well as DC function [73]. The human counterpart is predominantly 
expressed on APC [74], decreases pro-inflammatory cytokine production in DC [75] 
and renders human monocytes and DC tolerogenic through CD8+ T cells [76]. Thus, it 
may act more synergistically with PD-1. Furthermore, a complexly regulated, restrained 
activation state of dendritic-like microglia would be in line with the observation, that 
microglia reduction has no obvious pathology-changing effect in another mouse model 
of Aβ aggregation [77]. Therefore, only the first steps have been initiated in 
understanding the complex regulatory mechanisms behind inflammation in protein 
misfolding diseases [30, 78] and more experiments are clearly necessary. Regulating 
such mechanisms, in either beneficial or detrimental function, will be an interesting 
objective for therapeutic intervention with the newly identified dendritic-like microglia as 
an attractive cellular target for protein misfolding diseases. 
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Figure S1. Flow cytometry gating scheme. CNS-derived and Percoll-purified cells were 
gated on living cells by excluding EMA+ cells (G1). Appropriate Forward and Side scatter 
were chosen (G2) and doublets excluded (G3). CD45+ cells were chosen to select for 
hematopoietic origin (G4). The expression of CD11b and CD11c defined three distinct 
populations. G5 (CD11b-CD11c-) contained by majority CD8+ T cells (G8), G6 
(CD11b+CD11c-) contained CD45low conventional microglia (G10) and CD45high MΦ (G9) 
and G7 (CD11b+CD11c+) CD45int dendritic-like microglia (G12) and CD45high MΦ/DC 
(G11). This scheme was used for all experiments. 
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Figure S2. Activated phenotype and inhibitory markers on dendritic-like microglia. 
CD11b+ CNS-derived cells of (thy1)-h[A30P]SYN mice were analyzed as CD45lowCD11c- 
conventional microglia and CD45intCD11c+ dendritic-like microglia. (A) The expressions of 
indicated functional and (B) inhibitory surface marker, as well as (C) ligands for PD-1 were 
examined. Numbers represent ∆ MFI of isotype (gray area) and test signal (open area),       
n. t. = not tested. Markers were measured at least twice. 
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Figure S3. Phenotype of CNS MΦ/DC. CD11b+ CNS-derived cells of tg6799 mice were 
analyzed as CD45highCD11c- MΦ and CD45highCD11c+ activated MΦ or DC. (A) The 
expressions of indicated functional and (B) inhibitory surface marker, as well as (C) ligands 
for PD-1 were examined. Numbers represent ∆ MFI of isotype (gray area) and test signal 
(open area). Markers were measured at least twice. 
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Figure S4. Constant PD-1 expression on dendritic-like microglia. The PD-1 expression 
kinetics on dendritic-like microglia of tg6799 mice was determined for 10, 17 and 23 week-
old mice. The majority of cells stained PD-1+ with constant levels over the indicated time 
frame. Gray area marks isotype controls. Data are from individual mice and the experiment 
was repeated three times with similar results. 
 
 
Table S1. Characteristics of patients involved in the study. The nomenclature of 
frontotemporal lobar degeneration (FTLD)-patients follows reference [26]. MND = motor 
neuron degeneration, n = number of cases tested. 
 
 
Disease    n  Age 
 
Control  6 38 -100 
Alzheimer    10  47 - 94 
(Protein: Aβ, tau) 
Parkinson 5  67 - 79 
(Protein: α-syn) 
Multiple system atrophy (MSA) 6  58 - 80 
(Protein: α-syn) 
FTLD-TDP43 (type 1 and 3, type 2 with MND) 3  60 - 77 
(Protein: TDP-43) 
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Table S2. Ab used for flow cytometry and immunohistology are listed. 
 
Ag  Species  Label  Supplier  Clone 
 
Anti-mouse 
 
CD8a  Rat  Pacific Orange  Caltag  5H10 
CD11b  Rat  Pacific Blue  Caltag  M1/70.15 
CD11c Hamster  PE-Cy7  Biolegend  N418 
  Hamster  FITC  Biolegend  N418 
  Hamster  -  eBioscience  N418 
CD16/CD32   Rat  -  eBioscience  93 
CD40   Rat  PE  eBioscience  1C10 
CD45   Rat  APC  Caltag  30-F11 
CD80   Hamster  PE  eBioscience  16-10A1 
CD85 (gp49)   Hamster  PE  eBioscience  H1.1 
CD85k (gp49B1)   Rat  -  Howard Katz  B23.1 
CD86   Rat  FITC  eBioscience  GL1 
CD152 (CTLA-4)   Hamster  PE  Biolegend  UC10-4B9 
CD170 (Siglec-E)   Rat  FITC  Biozol  8D2 
CD244.2 (2B4)   Rat  FITC  eBioscience  eBio244F4 
CD272 (BTLA)   Mouse  PE  eBioscience  8F4 
CD273 (PD-L2)  Rat  PE  eBioscience  122 
CD274 PD-L1)   Rat  PE  eBioscience  MIH5 
CD279 (PD-1)   Rat  PE  eBioscience  RMP1-30 
CD282 (TLR2)   Rat  PE  eBioscience  6C2 
CCR2   Rat FITC  Matthias Mack  MC-21 
Tim-3   Rat  PE  Biolegend  RMT3-23 
H-2Kb / H-2Db   Mouse  PE  Biolegend  28-8 6 
I-Ab   Mouse  PE  Biolegend  AF6-120.1 
TNF   Rat  Alexa Flour 488  eBioscience  MP6-XT22 
 
 
Anti-human 
 
CD11c   Rabbit  -  Abcam  EP1347Y 
Aβ   Rabbit  -  Innovagen AB  DR1-Polyclonal 
  Mouse  -  Covance  6E10 
tau   Rabbit  -  Dako  Polyclonal 
α-syn  Mouse  -  Novocastra  KM51 
  Rabbit -  In house  15G7 
TDP-43   Rabbit  -  Proteintech  Polyclonal 
 
 
Secondary Ab 
 
Hamster IgG   Goat  Biotin  Vector Laboratories  Polyclonal 
Rabbit IgG   Goat  Biotin  Vector Laboratories  Polyclonal 
Mouse IgG   Goat  Biotin  Ventana  Polyclonal 
Rabbit IgG  Goat  AP  Dako  Polyclonal 
Rat IgG  Rabbit  -  Dako  Polyclonal 
Rat IgG   Swine  Biotin  Dako  Polyclonal 
Rat IgM   Mouse  PE  eBioscience  HIS40 
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Conclusions 
 
Chronic disorders have major medical, social and economical consequences. It has 
been estimated that they account for 60 % of all deaths per annum worldwide and in 
regions with a Western lifestyle, such as Europe, this figure is as high as 86 % [1]. In 
addition to personal suffering of those affected, the economic impact of chronic 
diseases is truly staggering. The annual impact on the American economy of the most 
common chronic diseases is calculated to be more than US$ 1 trillion, and this is 
expected to escalate to nearly US$ 6 trillion by the middle of the century [2]. SLE and 
AD are described as chronic disorders associated with abiding inflammation and tissue 
damage, caused by several different autoAg. Discrimination of self and non-self is 
based on both structural features of the autoAg as well as on the context in which it is 
encountered. Unraveling the intricate relationships between the effectors of immunity 
and autoAg by immunological research continues to be a serious scientific challenge 
paving the way for the development of new disease-modifying strategies and 
therapeutic interventions. These novel research avenues require the integration and 
evaluation of comparative in detail analyses in well defined experimental systems as 
well as translational approaches to human disorders. These latter points were the 
common aim of this PhD thesis. It sheds new light on important aspects of 
inflammation: significance of immune receptors, autoAg-induced activation of immune 
cells and tissue-specific autoimmunity in the context of SLE and AD. 
 
In SLE, the nucleosome composed of DNA and histone proteins, has been suggested 
to play a key role as a major autoAg in disease development [3]. Indeed, levels of 
circulating nucleosomes correlate with the SLEDAI and increased concentrations are 
associated with the development of central and peripheral nervous manifestations [4]. 
Nucleosome-restricted autoAb are observed in patients suffering from SLE and 
strongly correlate with SLEDAI scores (reviewed in [5]). We have previously shown that 
nucleosomes activate PMN in vivo and in vitro in an HMGB1-independent manner but 
the triggering pathway involved is unknown [6]. Both normal PMN and PMN from SLE 
patients were sensitive to nucleosome-induced activation. Whereas most studies 
analyzed the effects of chromatin-containing IC, we focused on free nucleosomes. 
Since nucleosomes are partly composed of DNA, we have investigated whether TLR9 
was required for nucleosome-induced PMN activation. Whether TLR9 is involved or not 
is of prime importance since the role of TLR9 in SLE development is still controversial.  
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We show that circulating nucleosomes from SLE plasmas trigger innate immunity 
independently of TLR9, leading to the secretion of pro-inflammatory cytokines by PMN 
and CD11b up-regulation. Indeed, nucleosomes activate human PMN independently of 
the presence of unmethylated CpG-motifs in nucleosomal DNA and activation does not 
require endosomal acidification and in not impaired in the presence of a TLR9 inhibitor. 
Moreover, both PMN isolated from WT and TLR9-KO mice were activated by 
nucleosomes. Although TLR9 is not required for nucleosome-mediated PMN activation, 
nucleosomes induce the up-regulation of TLR9 in some donors. Finally, nucleosomes 
are endocytosed by PMN and accumulate in the cytoplasm but are not translocated to 
the nucleus. Importantly, nucleosomes act as free complexes without the need for IC 
formation. The role played by TLR9 during SLE development is still not elucidated. 
TLR9 has been shown to be activated by unmethylated CpG-motifs present in 
pathogen-derived DNA. Nevertheless, natural phosphodiester ODN lacking CpG-motifs 
and even vertebrate or mammalian DNA can trigger TLR9 under certain 
circumstances, although TLR9-independent pathways are also triggered in addition. 
Whereas TLR9 is required for anti-nucleosomal autoAb production, TLR9 was also 
suggested to protect against SLE. However, other receptors than TLR9 have been 
found to recognize DNA and/or nucleosomes and cytosolic receptors able to recognize 
DNA have been reported [7]. Therefore it will be of interest determine the role of AIM-2 
or DAI (ZBP-1) in PMN towards the innate response to nucleosomes. New functions 
have been attributed to autoAg, such as activation of chemokine receptors on 
immature DC. Likewise, increasing efforts are concentrating on the involvement of the 
innate immune system in SLE development. PMN play an important role in innate 
immunity and are the first cells recruited at inflammation sites [8]. They have been 
suggested to link innate and adaptive immunity by influencing DC and PMN activation 
may favor adaptive immunity. Nucleosome-induced PMN activation may thus partly 
explain why the peripheral tolerance is broken in SLE patients. Our results support the 
key role of nucleosomes in SLE and suggest that nucleosomes are not only passive 
targets for autoAb but may play an active role in SLE pathogenesis. TLR9 may thus be 
differently required in the triggering of nucleosome-induced innate immunity and anti-
nucleosome B cell autoimmunity. So far, most studies investigated autoAb secretion 
against this autoAg and disease development but did not analyze nucleosomes as a 
potential trigger of innate immune responses. The induction of a pro-inflammatory 
context by nucleosomes had not been explored as yet. Preliminary results in our group 
indicate that the nucleosome belongs to the group of IFN-α-inducing factors in SLE. At 
present, these factors are described as small IC with anti-DNA specificity and DNA as 
essential components [9]. Thus, we have identified for the first time that nucleosomes 
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without the need for IC-formation have the capacity to induce IFN-α secretion in PMN. 
Therefore it is not surprising that the interest in these immune cells emerges. NET 
formation by PMN and its immunological activity is currently an interesting issue to be 
investigated in disease treatment [10] and chronic autoinflammatory conditions [11]. In 
addition, we report the startling finding that primary PMN express functional TLR9 at 
the cell surface. This discovery generates new clues to the TLR9 biology since 
scientists had long thought that this PRR only resides in endolysosomal compartments. 
This mechanism may predispose PMN critically to activation in the presence of 
microbial products making them more susceptible to aberrant reactions turning onto 
self. Cell surface TLR9 may recognize different ligands as its intracellular counterpart 
responsible for the induction of SLE. Interestingly, the intracellular localization of 
nucleic-acid sensing TLR does not seem to apply for all cell types equally. For 
example, TLR3 is predominantly expressed on the cell surface of astrocytes [12], but 
intracellularly in DC [13]. This suggests that the innate immune response is not 
homogeneous but rather tailored according to cell type and the environmental signal.  
 
The leading hypothesis in AD is that an imbalance between the production and 
clearance of Aβ leads to its accumulation in senile plaques, which in turn promotes 
disease progression. However, this theory has not yet given rise to effective drugs [14]. 
Recent clinical trials have produced disappointing results to the treatment of AD, and 
have given rise to the sobering realization that the majority of vaccines currently under 
development are unlikely to provide a truly effective cure [15, 16]. Hence, there is now 
a broad consensus that the field needs to return to some fundamentals. Bridging the 
physiological and pathological role of Aβ, and its interaction with the immune system is 
of most interest [17]. It is has recently be suggested that Aβ serves the physiological 
function of fighting off microbes as part of the body’s innate immune system [18]. In 
addition studies concentrating into the role of CNS-resident microglia and peripheral 
MΦ receive much attention in AD. Certainly the understanding of neurodegeneration 
would have been limited without the creation of mouse models, but research in APP-tg 
mice can also be controversial and is largely depending on the mutant used. Worthy of 
note is that an obscure list of molecules, ranging from cholesterol drugs and painkillers 
to blueberries and curry spice, has been shown to reduce pathology in APP-tg mice 
[19-24]. Thus, the rumors become louder and were already summarized by the editors 
of Nature Medicine that investigations in the causes and treatment of AD yield one 
culprit time and time again using rodents [25, 26]. Most of the currently used mouse 
models never exhibit the extent of neurodegeneration seen in people afflicted with AD. 
Because these mice are based on FAD mutations, it may be that they only model the 
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rare form of the disease and not the more common SAD [26]. More importantly, these 
mice have never shed much light on the mechanisms involved in the disease, such as 
the relationship between Aβ and tau [25, 26]. Evidence now supports the idea that both 
protein species actually define, but do not fully represent the disease process [27]. 
Maybe there has been too much focus on early events of the amyloid cascade [14, 26], 
exaggerating research novelty and boosting apparent significance [27], e.g. prion-like 
mechanisms in AD nowadays. Modern tools of genetic approaches may indicate that 
microglia do not play a role in Aβ clearance in mice [28] but at a time of self-criticism 
one should remember that research dating back to the 1990s already implicating that 
microglia in vivo cannot phagocytose Aβ in humans [29]. Progressive AD further 
involves CNS inflammation, neuronal, axonal and synaptic loss as well as dysfunction, 
which are modeled inadequately in APP-tg mice [30]. The AN1792 trial has best 
illustrated that many scientists run risk of overlooking aspects of human immunology 
that do not manifest, or cannot be replicated, in APP-tg mice [14-16]. The differences 
between mouse and human immunology should always be kept in mind when using 
mice as preclinical model of human disease as 65 million years of evolution might 
suggest [31, 32]. One may also criticize if an immunologically humanized AD mouse 
model would be the correct choice to get off these limits [33]. Encounters with Ag 
activate T cells in these mice [34], but questions remain as to the consequences of 
these interactions, in particular, whether these lymphocytes are selected and restricted 
to mouse or human MHC. This is an important issue, as obvious future applications of 
humanized animal models might include screening of candidate vaccines [35]. To 
provoke new lines of discussion novel techniques and experimental strategies have to 
be implemented in AD research. The existing AD mice begin to allow investigations of 
human pathology in a small animal model, but the current system is not ideal. The 
extreme overexpression of mutated transgenes forces aberrant reactions likely to be 
misinterpreted in comparison to the real life situation. For example there is compelling 
evidence that one consequence of FAD mutations is dependent upon microglia, since 
when these cells express mutant forms of PS1 they alter the fate of neural progenitor 
cells [36]. Senile plaques are only one hallmark of AD, thus further investigations into 
the cascade of upcoming events, synergistic effects of Aβ and tau, different synaptic 
protein isoforms and mitochondrial impairment are of major interest. And while we are 
struggling for new ideas, simply taking an extra pot of coffee [37] after a nap [38] and 
calling our friends using the mobile phone [39] could already help to reduce the Aβ 
plaque load and the cognitive impairment seen in AD. But again, since most of these 
results were obtained in APP-tg mice, it may be difficult to extrapolate these findings to 
human beings.  
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For all that better models of AD are needed that are evolutionary closer to humans. It is 
unnecessary to mention that disorders of higher brain functions are especially 
challenging to model. Consequently non-human primates might offer an alternative to 
kick AD research into a new direction [40-44].  
 
Yang et al. have already established a genetically mutated non-human primate model 
of a neurodegenerative disease [41]. Furthermore cerebral amyloid-β protein develops 
upon aging in ntg monkeys [42] and their usage is highly discussed [43].  
 
Meanwhile the disadvantages of long-lived non-human primates are disabled because 
advanced technologies become available to generate small monkeys that pass a 
transgene on to their offspring [40]. These monkeys are short-lived and show genetic 
homogeneity which makes them a powerful tool to study neurodegenerative diseases. 
In this light current research already indicates an important role of vervet monkeys in    
a series of novel therapeutic strategies [44], showing that naturally occurring autoAb 
specific for known amyloidogenic species can protect primary neurons from Aβ toxicity. 
 
Thus, helping to gain true knowledge is of major interest rather than pretending that 
primates are not used in AD research. Surely, it should be possible to do better than 
that and some scientists do so by providing alternatives which avoid ethical constraints. 
Induced pluripotent stem (iPS) may offer a more sophisticated strategy for modeling 
AD. Recent studies have reported the derivation and differentiation of patient-specific 
iPS cells. Disease-related phenotypes, the ability to model neuropathology and its 
treatment in iPS cells have been shown [45]. Creating human iPS cells gets easier [46] 
and patient-specific iPS cells are currently established to study AD, PD and ALS 
[Harald Neumann, University of Bonn, personal communication]. This may represent 
an even more powerful and elegant model system than animals, and an approach to 
produce first relevant functional assays for the identification of candidate drugs. Human 
disease experimentation suffers necessarily from bioethical restrictions and from the 
lack of appropriate predictive model systems. To this end, mice will continue to be one 
model of AD up to a certain degree but with patent defects. Nevertheless, experiments 
with mice may gain refreshment from time to time when they show a clear convergence 
between animal models and human data. We were luckily able to tell such a story by 
showing that a new phenotype of CNS-resident microglia is present in several human 
proteopathies, suggesting a tight regulation of inflammation in response to aggregation 
(Fig. 1). Multiple regulatory molecules control the response of this protein misfolding-
specific inflammatory cell type and manipulating such regulation would be a promising 
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target to influence these diseases. Indeed, inflammatory events may help CNS-resident 
phagocytes to clear aggregates in humans and APP-tg mice [47]. While these innate 
immune responses receive much interest in AD reserach, the relevance of invading T 
cells into the CNS is largely unknown. To this end future directions will not only 
concentrate on further regulatory functions of CNS-phagocytes but also on the 
involvement of adaptive immunity in AD. Identifying the role of T cells in a beneficial 
versus detrimental dialogue during the course of AD would be of special interest in 
humans. If these immune cells are playing any active role in any neurodegenerative 
disease then enhancing favorable behaviors or suppressing harmful ones may be 
capable of slowing the progression of the disease. Even if the immune response 
cannot be manipulated by a therapeutic intervention, its derangements could perhaps 
be used as markers of diagnosis or disease progression [48]. 
 
 
 
Figure 1. Immune cells present in the proteopathic CNS. Different hematopoietic cells 
were identified within the CNS of Aβ and α-syn depositing mice. Besides infiltrating CTL, 
peripheral MΦ and conventional microglia, a new subtype of microglia which we termed 
dendritic-like microglia was identified. These cells were even more pronounced in human 
cases of AD and most interestingly also found in other proteopathies. Highly activated 
dendritic-like microglia cells accumulated together with CTL upon aging and increasing 
pathology in the CNS. Enhanced expression of MHC class I, CD80 and CD86 on these 
cells suggests the possibility of communication with CNS-infiltrating CTL, but this 
assumption needs further proof. Although the dendritic-like microglia showed a very high 
activity of phagocytosing Aβ ex vivo, this ability could not be restored by deleting the 
expression of the inhibitory PD-1 gene, which suggests a more complex situation in vivo.  
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Future directions 
 
 
Nucleosome-activated PMN represent a new 
source of IFN-α 
 
IFN-α has received particular attention for its disease-promoting role in SLE, although 
the triggering stimulus in its secretion has not been explored [1]. In a first series of 
experiments we have induced IFN-α secretion by PMN, pDC and monocytes cultured 
with nucleosomes, which represents a previously unknown pathway of innate immunity 
(Fig. 1A-C). It is anticipated to confirm these results and to evaluate the mechanism. 
 
 
 
 
Figure 1. Nucleosome induces IFN-α secretion. (A) Myeloid and lymphoid cells were 
stimulated simultaneously with nucleosomes or different TLR-ligands. Intracellular cytokine 
staining revealed IFN-α secretion in neutrophils (CD66b+), pDC (CD123+) and monocytes 
(CD14+). (B) IFN-α secretion was most strongly up-regulated by neutrophils (CD14-CD16+) 
as compared to conventional (CD14+CD16-) and pro-inflammatory (CD14+CD16+) 
monocytes. (C) In all cells tested the nucleosome was together with CpG-ODN the most 
potent inducer of IFN-α. Data is representative from four independent experiments. 
Gradient (Gdt) is the nucleosome purification buffer. 
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Ag-specificity of CNS-infiltrating CTL 
 
We were clearly able to demonstrate an accumulating effect of cytotoxic T cells in the 
CNS of aging ntg and tg animal models of neurodegenerative disorders. Massive 
infiltrates of CTL have been demonstrated in AD patients [2, 3] and as initial approach 
we have further established the HLA tetramer technology to identify Aβ-specific CTL 
(Fig. 2, Lindau et al. unpublished). Thus, the logical consequence would be to imply in 
situ tetramer staining on frozen brain material of HLA-A2+ AD patients to determine the 
Ag-specificity of CNS-infiltrating CTL in AD [4]. 
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Figure 2. Ex vivo detection and recall of Aβ-specific CTL. (A) PBMC from HLA-A*0201+ 
healthy young and elderly controls as well as AD patients were analyzed by 10-color flow 
cytometry. Dead cells were excluded and lymphocytes gated according to forward/side 
scatter, excluding CD4+CD14+CD32+ cells from the analysis. Depicted is the % of CD28+ 
cells within the total CD8 population. Comparing either the young group (CY, p < 0.001) or 
the AD group (p = 0.0058) with the elderly group (CO) revealed a highly significant 
difference in CD28 expression (Student’s t test). CY, n = 13; CO, n = 14; AD, n = 16. (B) 
HLA class I tetramers were produced essentially as described and loaded with predicted 
Aβ-specific epitopes [5]. Histograms represent CD8 expression and HLA-A2 PE-tetramer 
staining on gated CD3+ cells. This revealed the existence of directly visible Aβ-specific CTL 
in some but not all individuals tested in comparison to staining for HIV (RT476-484)-specific 
CTL. Representative data from an Aβ-specific negative-stained young donor (CY16) and an 
Aβ30-39 positive stained individual with AD are shown. These results were independent from 
the presence of CMV (pp65495-503)-specific CTL in the donors. (C) Some individuals allowed 
detection of all three Aβ-specific CTL types as depicted for an elderly control (CO19). 
Histograms represent HLA-A2 PE-tetramer (Aβ30-39, Aβ33-41, RT476-484) against APC-
tetramer staining (Aβ34-42, pp65495-503, RT476-484) on gated CD3+CD8+ cells. Numbers in all 
histograms represent % of tetramer-positive cells within the CD8+ population. (D) Human 
Aβ-specific CTL were expanded from PBMC of AD patients and young as well as elderly 
unaffected controls with depicted peptide-HLA monomer-loaded artificial APC as well as   
IL-2 and IL-12. After 22 days, cultures were stained with the relevant PE-labeled Aβ-
specific tetramer and anti-CD8 Ab as published [6]. Cells were analyzed by flow cytometry 
and depicted histograms show individual cultures for the given peptides gated on living 
lymphocytes as determined by forward/side scatter. Numbers indicate % tetramer+ cells of 
the CD8+ population. Aβ histograms are from one single donor and for comparison a 
histogram of a pp65495-503-expanded culture of a CMV serum-positive donor is shown.  
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Generation of mAb against Aβ-peptide loaded 
HLA class I molecules 
 
Based on the identification of immunodominant Aβ42-derived CTL epitopes this project 
was started by Katja Grgur during her diploma thesis [7]. My contribution involved 
technical assistance in the generation of Aβ-loaded HLA-A2 class I complexes which 
were used by Katja to generate and select specific mAb reactive with these structures. 
Furthermore I generated HLA-A2+ APP-KO and APP-WT transfectants. When used in 
immunofluorescent staining reactions, the anti-Aβ-HLA-A2 mAb produced by Katja 
specifically stained these transfectants in a peptide-dependent manner. It is desirable 
to continue with this study because anti-Aβ-HLA-A2 mAb could be used in various 
approaches such as flow cytometry, immunoprecipitation, blotting and intracellular 
immunofluorescence to detect specific Aβ-peptide-HLA class I molecules formed by 
either peptide exposure or natural processing of Aβ42. Other issues, especially for in 
vivo tracking of specific ligand-bearing APC using two-photon microscopy, will be 
useful to determine where CNS-Ag presentation takes place.  
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α alpha 
β beta 
γ gamma 
Δ delta 
ζ zeta 
κ kappa 
µ my 
Φ phi 
Ω omega 
α-syn alpha-synuclein 
aa amino acids 
autoAb autoantibody 
autoAg  autoantigen 
Ab antibody 
Aβ amyloid-beta 
AC ammonium chloride  
AD Alzheimer’s disease 
AD  anno domini 
ADAM a disentegrin and metalloproteinase 
AFU arbitrary fluorescence units 
Ag antigen 
AICD antigen induced cell death 
AK Alzheimer-Krankheit 
ALS Amyotrophic lateral sclerosis 
AIM-2 absent in melanoma-2 
ANA anti-nuclear AAb 
APC antigen presenting cells 
APC allophycocyanin 
APP amyloid precursor protein 
APPsα N-terminus of APP after α-secretase 
 cleavage 
APPsβ N-terminus of APP after β-secretase 
 cleavage 
Apoe4 apolipoprotein E4 
AU arbitrary units 
AZA azathioprine 
BBB blood-brain barrier 
BCR B cell receptor 
BM bone marrow 
bp base pairs 
BSA bovine serum albumin 
BTLA B and T lymphocyte attenuator 
C1q complement component 1q 
CAA cerebral amyloid angiopathy 
CCR2 chemokine (C-C motif) receptor 2 
CD cluster of differentiation 
CMV Cytomegalovirus 
CNS central nervous system 
CpG cytosine-phosphate-guanine 
CRP C-reactive protein 
CTB cholera toxin subunit B 
CTL cytotoxic T cell 
CTLA-4 Cytotoxic T-Lymphocyte Antigen-4 
CO old control 
CQ chloroquine 
CSA cyclosporine 
CY young control 
DAI DNA-dependent activator of IRF 
DC dendritic cell 
ds double stranded 
DNA deoxyribonucleic acid 
DNase deoxyribonuclease 
EAE experimental autoimmune encephalitis 
eCFP enhanced Cyan Fluorescent Protein 
EDTA ethylenediaminetetraacetic acid 
ELISA enzyme linked immunosorbent assay 
EM electron microscopy 
EMA ethidium monoazide 
ER endoplasmatic reticulum 
fAβ pre-aggregated Aβ 
FACS fluorescent activated cell sorting 
FAD familiar Alzheimer’s disease 
FcR Fc-receptor 
FCS fetal calf serum 
FITC fluorescein isothiocyanate 
FTLD Frontotemporal lobar degeneration 
FTLD-MND FTLD with motor neuron disease 
GA glatiramer acetate (Copaxone) 
Gdt. gradient 
GFAP glial fibrillary acidic protein 
GN glomerulonephritis 
h hour 
HC healthy control 
HCQ hydroxychloroquine 
HIV Human immunodeficiency virus 
HLA human leukocyte antigen 
HMGB-1 high motility group box-1 
Iba-1 ionized calcium binding adaptor molecule-1 
IC immune complex 
IFN interferon 
Ig immunoglobulin 
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IL interleukin 
IRF IFN regulatory factor 
IPS cells induced pluripotent stem cells 
ITIM Immunoreceptor Tyrosine-based Inhibitory 
 Motif 
KO knockout 
LCMV Lymphocytic Choriomeningitis Virus 
LPS lipopolysaccharide 
MΦ macrophage 
mAb monoclonal antibody 
MACS magnetically activated cell sorting 
MBL mannose-binding-lectin 
MFGE8 milk fat globule EGF-factor 8 
MFI  mean fluorescence intensity 
MHC major histocompatibility complex 
min minutes 
MIP macrophage-inflammatory protein 
MMF mycophenolate mofetil 
MRL Murphy Roths Large 
MS Multiple sclerosis 
MSA multiple system atrophy 
MTX methotrexate 
MyD88 Myeloid differentiation primary response 
 gene 88 
n number 
N number of backcross generations 
NALP  NACHT-, LRR- and pyrin domain-
 containing protein 
Nct nicastrin 
NET neutrophil extracellular traps 
NFT neuropfibrillary tangles 
NF-κB nuclear factor kappa-light-chain-enhancer 
 of activated B cells 
NK natural killer 
n. k. not known 
n. t. not tested 
ntg non-transgenic 
Nuc  nucleosome 
ODN oligodeoxynucleotide 
P probability  
PAMP pathogen-associated molecular patterns 
PB polymyxin B 
PBS phosphate buffered saline 
PBMC peripheral blood mononuclear cell 
PD Parkinson’s disease 
PD-1 Programmed Death-1 
PD-L Ligand of PD-1 
pDC plasmacytoid dendritic cell 
PE phycoerythrin 
PercP Peridinin Chlorophyll Protein Complex 
PK proteinase K 
PK-PET PK-digested paraffin-embedded tissue 
PMN polymorphonuclear leukocytes 
Pred prednisolone 
PrP prion protein 
PrPC PrP cellular 
PrPSc PrP Scrapie 
PRR pattern recognition receptors 
PS presenilin 
PTX Pentraxin 
R Spearman correlation coefficient 
R848 resiquimod 
RAGE receptor for advanced glycation 
 endproducts 
RIP regulated intramembrane proteolysis 
RNA ribonucleic acid 
ROS reactive oxygen species 
RPMI Roswell Park Memorial Institute 
RT room temperature 
sAβ soluble Aβ 
SAD sporadic Alzheimer’s disease 
SAP serum amyloid P 
SFI specific fluorescence index 
Sigirr single Ig IL-1R-related molecule  
SLE Systemic lupus erythematosus 
SLEDAI SLE disease activity score 
SLPI secretory leukocyte protease inhibitor 
ss single stranded 
TB trypan blue 
TBS-T Tris-Buffered Saline Tween-20 
TDP-43 transactive response DNA binding protein 
 DNA binding protein-43 
tg transgenic 
TGF transforming growth factor 
TH T helper cell 
Thy 1 Thymocyte antigen 1 (CD90) 
TICAM Toll-like receptor adaptor molecule 
TIR Toll/interleukin-1 receptor 
TIRAP TIR domain containing adaptor protein 
TIM-3 T-cell immunoglobulin domain and mucin 
 domain 3 
TLR Toll-like receptor 
TM transmembrane 
TNF tumor necrosis factor 
TRAM TIR-containing adaptor molecule 
TRIF TIR-domain-containing adapter-inducing  
 IFN-β 
TREG regulatory T cell 
UV ultraviolet 
WT wildtype 
yr year 
ZBP-1 Z-DNA binding protein-1 
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